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Acute lymphoblastic leukemia 
The incidence of malignant neoplasms per year per 100,000 children under 15 year 
of age was 14 for 1986-1987 in the United States [1], 15.0 for Dutch males and 11.9 for 
Dutch females for 1989-1992 [2]. Acute lymphoblastic leukemia (ALL) accounts for 
approximately one fourth of all childhood malignancies [2,3]. In the Netherlands ALL 
incidence rates per year per 100,000 children under 15 year of age were 3.2 for males and 
2.9 for females over the period 1989-1992 [2]. International treatment protocols for ALL 
include multidrug regimens with chemotherapeutic agents. The duration of treatment is 
commonly two to three years and starts with a remission induction therapy, generally a 
combination of at least a glucocorticoid, vincristine and L-asparaginase. Complete 
remission is reached in 94-99% of patients [4-15]. Treatment for the prevention of central 
nervous system relapses consists of cranial irradiation or intrathecal therapy. Cranial 
irradiation is predominantly reserved for high-risk patients and for patients with central 
nervous system involvement of the disease. Intrathecal therapy consists of age adjusted 
doses of methotrexate (MTX), alone or in combination with hydrocortisone and cytosine 
arabi nos ide. Intrathecal therapy is often given in combination with MTX infusions and oral 
or intravenous 6-mercaptopurine (6MP). These regimens, also called consolidation therapy, 
generally do not give severe acute or long-term side-effects [4-6,11,15,16]. The efficacy of 
high-dose MTX infusions has been well established [4,5,11,16]. Recently it became 
apparent that low-dose oral MTX in combination with high-dose intravenous 6MP was less 
effective in the prevention of relapses [6]. Most international treatment protocols include a 
third phase which has no uniform name: reinduction or intensification treatment. This is 
given immediately or shortly after remission induction. The benefit of this treatment has 
been demonstrated, even in low risk patients [4,8,11]. In this phase the same drugs are 
used as in the induction phase but at higher concentrations or new agents with minimal 
cross-resistance are administered [3]. The last phase of the treatment of ALL is the 
maintenance or continuation therapy. Then, oral 6MP is administered daily and oral MTX 
weekly during 1.5 to 2 years. 
The treatment of ALL has improved dramatically over the past four decades 
[7,8,15,17]. With current treatment regimens and adequate supportive care, event-free 
survival ranges now between 57 and 73% in several international studies 
[3,5,7,8,11,15,17,18]. With increasing numbers of patients surviving ALL late sequelae of 
the treatment become apparent. The most severe ones are second malignancies (epipodo-
phylotoxins) [19] and cardiomyopathy (anthracyclines) [20]. Antimetabolites, such as MTX 
and 6MP give in general few long-term side effects [3,6,16]. Patients with hyperdiploidy 
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(>50 chromosomes in lymphoblasts) have a favorable prognosis [4,8,21,22]. For these 
patients an antimetabolite-based therapy, avoiding the use of anthracyclines and 
epipodophylotoxins, probably is sufficient [21]. Many prognostic factors have been 
described, predicting treatment outcome. Among these there are only a few consistently 
found in multivariate analysis in several trials, regardless of treatment improvement during 
successive protocols. Early response to the treatment during the First two weeks 
[3,8,11,18,22] and hyperdiploidy [4,8,21,22] have favorable prognosis. Age (<1 or >10 
years) [8,11,18,21,22], white blood cell count at diagnosis (>100.10f/L) [4,8,11,14,18,21, 
22], poor response to prednison therapy during the first week of treatment [11], and 
chromosomal abnormalities as t(9;22)(q34;qll) and t(4;ll)(q21;q23) [23] have worse 
prognosis. Based on these risk factors and others (hepatosplenomegaly, mediastinal mass, 
central nervous system involvement, immunophenotype, cytogenetics) patients are stratified 
in risk groups and treated accordingly. Nevertheless, the treatment is still not successful in 
about 30% of children with ALL who never reach remission or who relapse. 
Improvement of survival for these patients may be achieved along different 
pathways. Molecular genetic and cytogenetic techniques are more sensitive to detect 
minimal residual disease, but it has to be estimated whether detection and treatment of 
minimal residual disease at an earlier stage will improve treatment outcome. Drug 
resistance testing in lymphoblasts at diagnosis has prognostic significance [24-26], which 
may become a valuable tool in risk-group stratification. Improvement of supportive care 
may allow further treatment intensification, but the benefit of intensification of the current 
treatment is not yet clear. Development of new anticancer drugs, which have modes of 
action different from the existing drugs, may result in cell kill of lymphoblasts resistant to 
present chemotherapy. Finally, the action of existing anticancer drugs may be improved in 
patients poorly responding to them. For example, there is a wide interpatient variability in 
the bioavailability of MTX and 6MP [27,28] and the systemic clearance of MTX [29-32], 
which account for differences in toxicity and therapeutic efficacy [28,30,31,33]. 
Pharmacokinetic, pharmacodynamic and biochemical studies may reveal the causes of these 
interpatient variabilities. Furthermore, the therapeutic efficacy of existing drugs may be 
enhanced when they are administered in combination which demonstrates synergism in the 
cytotoxic action in vitro. As a consequence of the synergism of MTX and 6MP which was 
found in ALL cell lines, the present clinical trial was designed. The studies described in 
this thesis were performed to investigate whether the administration of 6MP, in 
combination with MTX, could be optimized. 
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Synergism between MTX and 6MP 
Incubations of several ALL cell lines with combinations of MTX and 6-thioguanine 
[34] or of MTX and 6MP [35] have shown a synergism in the cytotoxic action of these 
drugs. MTX and 6MP showed a dose-, time- and sequence dependent synergistic effect on 
cell growth and viability [36] and enhanced incorporation of thioguanine nucleotides, 
produced from 6MP, into newly synthesized DNA and RNA [35]. The biochemical basis of 
this synergism is the effect of MTX on purine metabolism. MTX is an inhibitor of two 
folate dependent enzymes in purine de novo synthesis, glycinamide ribonucleotide 
transformylase and 5-aminoimidazole carboxamide ribonucleotide transformylase [37,38]. 
Inhibition of purine de novo synthesis causes an increase of 5-phosphoribosylpyrophosphate 
(PRRP), the first product in this pathway [35,39]. To exert cytotoxicity 6MP has to be 
converted first into its nucleotide, thioinosine monophosphate (tIMP), for which reaction 
PRPP is an essential cofactor. Thus the increased availability of PRPP is the basis of the 
enhanced cytotoxic effect of 6MP after pretreatment with MTX. 
Oral combination treatment of MTX and 6MP has been used since many years in 
the treatment of ALL and these drugs are the cornerstones of maintenance treatment. In 
1961 it has been demonstrated that combination therapy with oral MTX and 6MP improved 
the treatment outcome in ALL, compared to monotherapy of each drug [40]. A clinical trial 
in ALL with intermediate-dose intravenous MTX (1 g/m2 in 24 h) followed by high-dose 
intravenous 6MP (1 g/m2 in 8 h) showed high event-free survival with few side effects 
[5,16]. However, a recent pilot study showed that replacement of intermediate-dose 
intravenous MTX by low-dose oral MTX (30 mg/m2 every 6 h for 5 doses) in the 
intensification treatment resulted in less effective prevention of relapses [6]. In a phase 1 
study patients with hematologic malignancies or solid tumors were treated with low-dose 
intravenous MTX (30 mg/m2 in 24 h) followed by escalating doses of intravenous 6-
thioguanine (150-375 mg/m2 in 2 h). The therapeutic responses were encouraging for the 
patients with lymphoma. The PRPP levels in lymphoblasts and peripheral blood 
mononuclear cells increased twofold to threefold after 24 h low dose intravenous MTX 
treatment, indicating that the desired biochemical modulation by MTX can be achieved in 
vivo [41]. 
Thiopurine metabolism 
6MP was synthesized by Elion and Hitchings in the early fifties and its clinical 
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effect in leukemia was first reported in 1953 [42]. 6MP is an analogue of hypoxanthine, the 
only difference being a mercapto group (SH, thiogroup) on carbon atom 6 of the purine 
ring instead of a hydroxy group (OH) (Figure 1). 6MP is metabolized by similar enzymes 
as hypoxanthine, but the metabolism is not exactly the same (Figure 2). With respect to the 
catabolic pathway both compounds are oxidized by xanthine oxidase into the 2,8-dihy-
droxylated form (uric acid or thiouric acid). Hypoxanthine is in vitro first oxidized on 
carbon atom 2 into xanthine, whereas oxidation of 6MP occurs preferentially first on 
carbon atom 8 into 6-mercapto-8-hydroxypurine (M80HP) [43]. Oxidation of 6MP via 
carbon atom 2 into thioxanthine occurs as well [43]. Xanthine oxidase is the rate-limiting 
enzyme in nucleic acid degradation [13,44,45]. It converts 6MP irreversibly into inactive 
metabolites, since thiouric acid, thioxanthine and M80HP are not substrates for the 
anabolic pathway. 
6MP is a prodrug and has to be converted in the anabolic pathway into active 
metabolites before it can exert cytotoxicity. The first step in the anabolic pathway is the 
conversion of 6MP into tIMP by the purine salvage enzyme hypoxanthine guanine 
phosphoribosyltransferase (HGPRT) with PRPP as essential cosubstrate [46]. tIMP can be 
either converted into thioguanosine monophosphate (tGMP), in which reaction inosine 
monophosphate dehydrogenase (IMPDH) is the rate-limiting enzyme [44,45], or it can be 
O H S H 
I I 
с с 
Ni б С Ν N С Ν 
ι ιι Ί ι ι ιι ιι 
HC2 4C ее H НС с сн 
N N Ν Ν Ν 
Η Η 
hypoxanthine 6-mercaptopurine 
Figure 1 Structural formula of hypoxanthine and its analogue 6-mercaptopurine. 
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Figure 2 Metabolism of 6-mercaptopurine. 
Metabolites: 
(6MP) 6-mercaptopurine; (M80HP) 6-mercapto-8-hydroxypurine; (MeMP) 6-methylmer-
captopurine; (MeMPR) 6-methylmercaptopurine riboside; (MetIMP (MetlDP, MetlTP)) 6-
methylthioinosine mono- (di-, tri-) phosphate; (PRPP) 5-phosphoribosylpyrophosphate; (tGMP 
(tGDP, tGTP) thioguanosine mono- (di-, tri-) phosphate. 
Enzymes: 
(1) thiopurine methyltransferase (TPMT EC 2.1.1.67); (2) hypoxanthine guanine phosphoribosyltr-
ansferase (HGPRT EC 2.4.2.8); (3) xanthine oxidase (EC 1.2.3.2); (4) purine nucleoside Phosphor­
ylase (EC 2.4.2.1); (5) purine 5'-nucleotidase (EC З.1.З.5.); (6) adenosine kinase (EC 2.1.7.20); 
(7) inosine monophosphate dehydrogenase (EC 1.2.1.14); (8) guanosine monophosphate synthetase 
(EC 6.3.5.2); (9) guanosine monophosphate reductase (EC 1.6.6.8). 
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methylated by thiopurine methyltransferase (TPMT) into methylthioinosine monophosphate 
(MetIMP) [47]. Thioguanine nucleotides (TGN) are incorporated into DNA and RNA 
[48,49]. Incorporation of TGN into DNA is responsible for the delayed cytotoxic action of 
6MP in the L5178 mouse lymphoma cell line [49,50] and causes DNA damage such as 
protein cross links, interstrand cross links and single strand breaks [51-53]. MetIMP is an 
inhibitor of PRPP amidotransferasse, the second step in the purine de novo synthesis [54]. 
This causes an increase of PRPP [10,48], a depletion of adenine and guanine nucleotides 
and subsequently an inhibition of DNA and RNA synthesis [48]. 
TPMT catalyzes the methylation of tIMP, but also of 6MP, 6-mercaptopurine 
riboside and M80HP [55]. Methylation occurs on the sulfur group which is attached to 
carbon atom 6 of the purine ring. 6-Methylmercaptopurine riboside (MeMPR) can be 
converted by adenosine kinase into MetIMP [56,57], but is not a substrate for purine 
nucleoside Phosphorylase [56]. 6-Methylmercaptopurine (MeMP) is produced by direct 
methylation of 6MP and, as shown until now, this compound cannot be converted into an 
anabolic metabolite. TPMT activity is controlled by a genetic polymorphism [58]. The 
activity in red blood cells correlates with that in lymphoblasts, lymphocytes, trombocytes, 
liver and kidney [9,59-61]. There is a wide variation in TPMT activity in the population, 
88.6% of the subjects displaying high activity, 11.1% intermediate activity and 0.3% 
undetectable activity [58]. The clinical implications of the interpatient variability in TPMT 
activity for the treatment of ALL was the topic of many clinical studies [28,62-68]. 
Purpose of the present study 
Based on our in vitro studies demonstrating a synergistic effect of MTX and 6MP 
on cellular cytotoxicity [35,36,39], we started in 1992 in cooperation with the Dutch 
Childhood Leukemia Study Group (DCLSG) a randomized clinical trial in ALL (DCLSG-
ALL-8), which is very similar to the Berlin-Frankfurt-Münster (BFM)-90 trial (BFM-86 is 
reported in [11]). During the consolidation treatment all patients received high-dose MTX 
infusions (5 g/m2 in 24 h, four courses in eight weeks). In addition, the patients were 
randomized by the DCLSG for either oral administration of 6MP (the common regimen 
with daily 25 mg/m2 6MP orally during eight weeks) or for intravenous administration of 
6MP (the experimental treatment with 1300 mg/m2 in 24 h immediately after the MTX 
infusion, four courses in eight weeks). The cumulative dose in eight weeks was 1400 
mg/m2 in the oral group and 5200 mg/m2 in the intravenous group. The oral 6MP dose was 
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the same as used in previous studies of the BFM group [11]. The intravenous dose in our 
study was the one recommended in the phase 1 study of Zimm [69]. 
The purpose of this thesis was to investigate the metabolism of 6MP and the 
pharmacokinetics and intracellular pharmacology of 6MP and its metabolites during high-
dose 6MP infusions. The toxicity of high-dose MTX infusions in combination with low-
dose oral 6MP or high-dose intravenous 6MP was studied as well. In chapter 2 the 
methods which were used for the determination of 6MP and its intracellular and 
extracellular metabolites are described. Our study focussed mainly on the randomized 
DCLSG-ALL-8 study, especially on the patients treated with intravenous MTX and 6MP. 
Since we intended to compare the 6MP metabolism in this group with that in patients who 
were not pretreated with MTX, we investigated the metabolism of 6MP in 10 patients with 
non-Hodgkin lymphoma who were treated with one high-dose 6MP infusion in a therapeu-
tic window phase at diagnosis. These results are described in chapter 3 and 4. In chapter 3 
the effects of the xanthine oxidase inhibitor allopurinol on the metabolism of high-dose 
intravenous 6MP are described. Co-administration of allopurinol results not only in a 
decreased catabolism of 6MP, but surprisingly also in a decreased anabolism. In chapter 4 
a relatively low activity of the anabolic pathway of 6MP has been demonstrated in a patient 
with a tumor lysis syndrome compared to patients without this syndrome. This suggests that 
competition between hypoxanthine and 6MP occurs not only in vitro [70], but also in vivo. 
TPMT plays an important role in the metabolism of 6MP and is involved in both the 
cytotoxic action and the elimination of 6MP. In chapter 5 the genetic polymorphism of 
TPMT and its contribution to the cytotoxic action of 6MP in the treatment of ALL is 
reviewed and the results of a clinical pilot study on TPMT induction during the consolida-
tion treatment are described. In chapter 6 the detection and identification of a major, 
hitherto unknown metabolite of 6MP in plasma, 6-methylmercapto-8-hydroxypurine 
(MeM80HP), is described and the possible pathways leading to formation of this 
compound are discussed. In chapter 7 the metabolism, pharmacokinetics in plasma and 
renal excretion of high-dose intravenous 6MP during the consolidation treatment of ALL 
are described. In chapter 8 the intracellular metabolism of orally and intravenously 
administered 6MP during the consolidation treatment of ALL in peripheral blood 
mononuclear cells and in red blood cells is described. We demonstrated in the present study 
that during and after high-dose intravenous 6MP large amounts of 6MP and its metabolites 
are methylated. S-adenosyl-L-methionine, a universal methyldonor for many methyltrans-
ferase reactions [71], is used in these reactions. Incubations of Molt-F4 ALL cells with 
6MP have demonstrated a decrease of S-adenosyl-L-methionine. In chapter 9 we describe 
the effects of MTX and 6MP infusions on S-adenosyl-L-methionine and other 
Introduction 17 
transmethylation metabolites. Finally, the clinical toxicity of a consolidation treatment with 
MTX infusions in combination with low-dose daily oral 6MP or with high-dose 6MP 
infusions is described in chapter 10. Survival analysis in the two groups has to be 
investigated by the DCLSG in a later stage of the ALL-8 study. 
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Abstract 
The thiopurine antimetabolites 6-thioguanine and 6-mercaptopurine are important 
chemotherapeutic drugs in the treatment of childhood acute lymphoblastic leukemia. 
Measurement of metabolites of these thiopurines is important because correlations exist 
between levels of these metabolites and the prognosis in childhood acute lymphoblastic 
leukemia. The reversed phase method for the determination of extracellular thiopurine 
nucleosides and bases was previously developed and has been modified, that methyl-thi-
opurine nucleosides, bases, thioxanthine and thiouric acid can be measured also. The anion-
exchange method enables the determination of intracellular mono-, di- and triphosphate 
(methyl)thiopurine nucleotides in one run. Extraction on ice with perchloric acid and 
dipotassium hydrogen phosphate results in good recoveries for (methyl)thiopurine 
nucleotides in lymphoblasts and peripheral mononuclear cells and for methylthioinosine 
nucleotides in red blood cells. Measurement of the low concentrations of mono-, di- and 
triphosphate thioguanine nucleotides in red blood cells (detection limit 20 pmol/109 cells) is 
possible after extraction with methanol and methylene chloride, followed by oxidation of 
thioguanine nucleotides with permanganate and fluorescence detection. 
Introduction 
Purines and pyrimidines play an essential role in human cell metabolism. The 
thiopurine antimetabolites 6-thioguanine (6TG) and 6-mercaptopurine (6MP) are important 
chemotherapeutic drugs in the treatment of childhood acute lymphoblastic leukemia (ALL). 
Since 1953 6MP and 6TG have been administered orally in childhood ALL and other 
leukemias. Recently the administration of high-dose 6MP infusions has started in clinical 
trials [1]. 
Several studies showed correlations between levels of extracellular and intracellular 
metabolites of low dose oral 6MP and prognosis of childhood ALL [2,3]. Because 6MP 
and 6TG are prodrugs and exhibit their cytotoxic effects by various intracellular metabolic 
routes, it is important to develop methods by which extracellular as well as intracellular 
metabolites can be measured as nucleosides and nucleobases and as mono-, di- and 
triphosphate nucleotides. 
The metabolism of 6TG and 6MP is indicated in Scheme 1. Thioguanine nucleo-
tides (TGN), which cause a delayed cytotoxic reaction after incorporation into DNA and 
RNA, and methylthioinosine monophosphate (MetIMP), which is an inhibitor of the purine 
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Scheme 1 Thiopurine metabolism 
(Methyl)thiopurine nucleotides tGM(D,T)P = 6-thioguanosine mono (di-,tn) phosphate, 
MetIM(D,T)P = 6-methylthioinosme mono (di-,tn-) phosphate, tIMP = 6-thioinosine mono­
phosphate (Methyl)thiopunne nucleosides TGR = 6-thioguanme riboside, MPR = 6-mercapto-
punne riboside, MeMPR = 6-methylmercaptopunne riboside (Methyl)thiopurme bases 6TG = 
6-thioguanine, 6MP = 6-mercaptopunne, MeMP = 6-methylmercaptopunne 
de novo synthesis, are responsible for the cytotoxic action of thiopunnes in vitro [4-6] 
Conflicting data exist about the relative importance of each cytotoxic pathway in vivo 
Because thiopunne methyltransferase, an important enzyme involved in the metabolism of 
thiopunnes and the formation of MetIMP, shows a genetic polymorphism [7], it is 
important to elucidate the intracellular cytotoxic pathways in vivo in order to select patients 
at risk for high toxicity or for undertreatment 
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Previously, we published HPLC methods for the detection of purine and pyrimidine 
nucleotides [8], nucleosides and bases [9] and thiopurine nucleosides and bases [10,11]. In 
the present article we describe two HPLC methods, one for measurement of 
methylthiopurine and thiopurine nucleosides and bases and another for measurement of 
(methyl)thiopurine nucleotides. Both methods are used in the clinical randomized ALL-8 
trial of the Dutch Childhood Leukemia Study Group. 
Several methods have been described for the measurement of (methyl)thiopurine 
nucleotides in red blood cells (RBC) [12-18] and in lymphoid cells [19-21]. Many of these 
methods [13-16,19] measure these nucleotides only indirectly after hydrolysis to their base 
and thus require an extra measurement of (methyl)thiopurine nucleosides and bases before 
hydrolysis to establish which part of the base originates from the hydrolyzed nucleotides. 
Moreover, no distinction can be made between the concentrations of mono-, di- and 
triphosphate nucleotides. An ion-pairing HPLC assay enables the measurement of 
thioguanosine monophosphate (tGMP) and thioinosine monophosphate (tIMP) [20] and an 
anion-exchange fluorimetrie method detects tGMP, tGDP and tGTP [21] in human 
neoplastic cells. Extraction of tGMP, tGDP and tGTP from RBC was performed with 
mercurial cellulose resin and mercaptoethanol, which procedure shows extraction 
efficiencies of 75-90% [17]. A less laborious procedure for extraction of TGN from RBC 
has recently been developed by Rabel et al [18]. RBC are deproteinized and TGN extracted 
with methanol and methylene chloride. After this TGN are oxidized with permanganate 
[18,21], separated by capillary electrophoresis and detected with laser induced fluorescence 
[22]. This procedure results in extraction efficiencies of 86-95% [18] and in attomole 
detection limits [22]. 
The anion-exchange HPLC method we describe in this article enables the detection 
in one run of separate (methyl)thiopurine nucleotides in lymphoblasts and peripheral 
mononuclear cells. Detection of methylthioinosine nucleotides (MeTIN) and TGN in RBC 
still has to be done by two separate runs in our system. 
Experimental 
Chemicab 
(Methyl)thiopurine nucleosides and bases, thioinosine monophosphate (tIMP), dithi-
othreitol, 5-phosphorylribose-l-pyrophosphate, bovine serum albumin, xanthine oxidase and 
hypoxanthine guanine phosphoribosyltransferase were obtained from Sigma (St. Louis, 
MA, USA). Thioinosinetriphosphate (tlTP) was from Pharmacia/LKB (Woerden, The 
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Netherlands). All other chemicals were obtained from E. Merck (Darmstadt, Germany). 
Water used for all buffers was purified in a Milli-Q System (Millipore, Bedford, MA, 
USA). 
Enzymatic preparation of thiouric acid 
Thiouric acid was produced by enzymatic oxidation of thioxanthine with xanthine 
oxidase, according to the procedure described by the manufacturer of the enzyme. The 
conversion into thiouric acid was 100% as determined by HPLC. 
Preparation of TGN 
tGMP was prepared by enzymatic conversion of 6TG with hypoxanthine guanine 
phosphoribosyltransferase in the presence of 5-phosphorylribose-l-pyrophosphate (PRPP). 
The reaction was performed at 37°C overnight with 500 μΐ 0.4 μΜ 6TG, 500 μΐ 8 mM 
PRPP, 480 ¿il Tris-MgCl2 buffer (0.5 M Tris + 0.05 M Tris-MgCl2, pH 7.4), 20 μ\ hypo­
xanthine guanine phosphoribosyltransferase (250 units in 500 μ\) in Tris-MgCl2 buffer and 
50 μΙ Triton-X-100 10 %. The conversion into tGMP was 100% as determined by HPLC. 
Thioguanosinediphosphate (tGDP) and thioguanosinetriphosphate (tGTP) were 
obtained by incubating Molt-F4 lymphoblasts with 6-thioguanine and separating the TGN 
by HPLC from the cell free extracts. 
Preparation ofMeTIN 
MetIMP was synthesized by methylation of tIMP: 0.026 mmol of tIMP was 
dissolved in 500 μ\ 2 M ammonia, 5 μ] 0.40 mM methyliodide was added and the mixture 
was mixed immediately and incubated at room temperature for 2 h. The suspension was 
flushed with N2 for 10 minutes in order to remove the excess of ammonia, frozen and 
lyophilized. 
The same procedure was used to synthesize methylthioinosinetriphosphate (MetlTP) 
and methylthioinosinediphosphate (MetlDP) from a mixture of tITP and thioinosinedi-
phosphate (tIDP). With this procedure the methylation of thioinosine nucleotides was 100 
% as determined by HPLC. 
Stock solutions 
Stock solutions of the (methyl)thiopurine nucleosides and bases were prepared as 
described before [10]. The exact concentrations were determined spectrophotometrically. 
Extinction coefficients were used at pH 4.6 as described [23]. 
Stock solutions of tIMP and tITP were prepared by dilution of 10 mg nucleotide in 
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10 ml distilled water. Exact concentrations were calculated at pH 4.6 with: e
max
=27.6 mM" 
'.cm
1
 at λ
ιηω
=322 nm. TGN and MeTIN were prepared as described above and the 
concentrations were measured spectrophotometrically at pH 4.6 with ^ = 2 6 . 7 mM'.cm' 
at \
n M=342 nm for TGN and £„„,= 18.9 mM'.cm-' at XmM=291 nm for MeTIN [23]. 
Extraction of (methyl)thiopurine nucleosides and bases 
Extraction of plasma was performed with 1/20 volume of ice cold 8 M perchloric 
acid (PCA). The suspension was mixed and kept on ice for 10 minutes. After centrifugation 
at 10,000 g for 5 min the supernatant was adjusted to pH 6-7 with 1/10 volume of ice cold 
4 M dipotassium hydrogen phosphate, and kept on ice for another 10 min. The precipitated 
potassium Perchlorate was removed by centrifugation at 10,000 g for 5 minutes and the 
supernatant was stored at -20°C until measurement. 
Extraction of (methyl)thiopurine nucleotides 
Peripheral mononuclear cells were separated from defibrinated blood by a ficoll 
isolation procedure. Contaminating RBC were removed by a NH4Cl-shock [24]. Lympho-
blasts of the MoIt-F4 T-ALL cell line were cultured as described [5]. Cell pellets of 
peripheral mononuclear cells or Molt-F4 cells were resuspended in 100 μ\ phosphate 
buffered saline with 1% (w/v) bovine serum albumin and 5% (w/v) dithiothreitol. 
Extraction was performed on ice with 50 μ\ of 1.2 M PCA and the supernatant was 
adjusted to pH 6-7 with 25 μί of 4 M dipotassium hydrogen phosphate. 
RBC were isolated from heparinized blood and washed thrice with 0.9% saline. One 
volume of RBC was resuspended in approximately 2 volumes 0.9% saline with 1% (w/v) 
dithiothreitol. Extraction of MeTIN was performed with PCA as described above with 1/20 
volume of 8 M PCA and 1/10 volume of 4 M dipotassium hydrogen phosphate. 
Extraction of TGN from 100 μ\ RBC was performed with 150 μ\ 55 mM EDTA (pH 10.5), 
100 μ\ methanol and 500 μ\ methylene chloride as described by Rabel et al [18]. All cell 
extracts were stored at -80°C until measurement. 
Oxidation of TGN in RBC 
Oxidation of TGN was performed with 100 μ\ RBC extract, 10 μί 1 M sodium 
carbonate (pH 10.1), 100 μί 0.24% potassium permanganate and 10 μί hydrogen peroxide 
as described by Rabel et al. [22]. 
HPLC apparatus 
Measurements were performed with a Thermo Separation Products HPLC system, 
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which consists of a ternary HPLC pump (SP 8800), an automatic sampler (SP 8880) and a 
variable ultraviolet/visible absorbance detector (SpectraFocus 2000 HR system), set at three 
wavelengths (290 nm, 320 nm and 342 nm). Fluorescent detection was performed with a 
Japan Spectroscopic Co fluorescent detector (model 821-FP). For measurement of TGN 
\,
x
=329 nm and XOT= 410 nm [17]. Measurements were performed at room temperature 
and during elution all solutions were deareated with helium. Injection volumes were 100 μΐ. 
Chromatography of (methyl)thiopurine nucleosides and bases 
Separation of (methyl)thiopurine nucleosides and bases was performed in one hour 
runs on a reversed phase column (Supelcosil LC-18-DB, 250x4.6 mm I.D., particle size 5 
μηι, Supelco INC., Bellefonte, PA, USA). Chromatography was carried out as presented in 
Table 1. 
Table 1 
Mobile phase sequence : used for 
separation of (methyl)thiopurine 
nucleosides and bases. 
Time 
(min) 
0 
5 
8 
10 
20 
22 
25 
45 
48 
60 
A В 
(%v/v) 
98 
% 
85 
80 
40 
40 
20 
20 
98 
98 
2 
4 
15 
20 
60 
60 
80 
80 
2 
2 
Table 2 
Mobile phase sequence used for separation 
(methyl)thiopurine nucleotides 
Time 
(min) 
0 
6 
8 
14 
30 
68 
69 
90 
A В 
(%v/v) 
10 
20 
44 
40 
10 
10 
10 
10 
90 
80 
44 
40 
10 
10 
90 
90 
С 
0 
0 
12 
20 
80 
80 
0 
0 
A: 0.025 M КН2Р04 
В: 0.05 M КН2Р04 
25 % (v/v) methanol. 
Flow rate 1.25 ml/min. 
A: 0.05 M KH2P04, 3% acetonitrile, adjusted to 
pH 3.25 with phosphoric acid; B: 3% acetonitrile; 
C: 0.5 M KH2P04 1.5% acetonitrile, adjusted to pH 
5.25 with KOH. Flow rate 1.30 ml/min. 
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Chromatography of (methyl)thiopurine nucleotides 
Separation of (methyl)thiopurine nucleotides was performed on an anion-exchange 
column (Partisil-10-SAX, 250x4.6 mm I.D., particle size 10 μπι, Whatman, Clifton, New 
Jersey, UK). Chromatography was carried out with a minor modification of the method 
described earlier [8]. The gradient, indicated in Table 2, allows a reduced runtime as 
compared to the method described before [8] without loss of resolution. 
Recovery of (methyl)thiopurine nucleosides, bases and nucleotides 
Dithiothreitol was added in a concentration of 60 mg/1 [10] to plasma, RBC and 
suspensions of peripheral mononuclear cells or Molt-F4 lymphoblasts, an ALL cell line 
used for the study of thiopurine metabolism [5]. Standards of (methyl)thiopurines were 
added in various concentrations and extractions were performed immediately as described 
above. 
Results 
Chromatogratns 
Retention times of standards of the (methyl)thiopurines are indicated in Table 3. 
Chromatograms of these compounds, measured in plasma, urine and RBC of patients 
treated with a 6MP infusion (1300 mg/m2.24 h) are shown in Figures 1 and 2. 
Calibration 
Concentrations of thiouric acid were calculated from the amount of thioxanthine 
from which it was prepared. Since MetlDP and MetlTP were prepared from tIDP and tITP 
their concentrations were calculated from the areas under the peaks. Absorbance of 
MetIMP, determined spectrophotometrically under chromatographic conditions of MetlDP 
and MetlTP, did not differ from these two compounds. 
Detection limits for the (methyl)thiopurine nucleosides and bases were between 20-
50 nM, except for thiouric acid (100 nM). Detection limits measured during absorption 
were 110 nM for tIMP, 380 nM for tGMP and 130 nM for MetIMP (11, 38 and 13 pmol 
per 100 μΐ injection). The detection limits measured during fluorescence were 15-35 nM 
for tGMP, tGDP and tGTP (1.5-3.5 pmol per injection). 
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Table 3 Retention times of (methyl)thiopurines. 
Nucleosides and bases: 
thiouric acid 
thioguanine 
6-mercaptopurine 
thioxanthine 
thioguanine riboside 
mercaptopurine riboside 
methylthioguanine 
methyl mercaptopurine 
methylmercaptopurine riboside 
Nucleotides: 
MetIMP, MetlDP, MetlTP 
tIMP, «DP, tITP 
tGMP, tGDP, tGTP 
oxidized tGMP, tGDP, tGTP 
Retention time 
(min) 
5 
10 
11 
13 
17 
18 
28 
33 
42 
12, 23, 35 A 
13, 26, 39 
15, 30, 50 
12, 23, 34 A 
Optimal wavelength 
(290, 320 or 342 nm) 
342 
342 
320 
342 
342 
320 
320 
290 
290 
290 
320 
342 
\ x 329 nm 
K, 410 nm 
After the oxidation procedure for TGN, MeTIN are not detectable with fluorescent detection. 
Reproducibility 
The within-day (n=5) and the day-to-day (n=3) coefficients of variation for 6TG, 
6MP, TGR and MPR were in similar ranges as described previously (1.4-12.5%) [10]. 
These coefficients of variation were also determined for thioxanthine, MeMP and MeMPR. 
The within-day variation for these three compounds was in the range of 0.4-2.7% for 
concentrations above 150 nM and 5.6-11.2% for concentrations below 150 nM. The day-
to-day variations were 0.1-2.7% for concentrations above 150 nM and 6.5-14.7% for 
concentrations below this level. MeTG was not detectable at levels below 150 nM and 
coefficients of variation at levels above 150 nM were 4-8.5% for within-day variation and 
5.9-6.0% for day-to-day variation. 
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Figure 1 Chromatograms of (methyl)thiopurine 
nucleosides and bases in plasma (1A and IB) and 
urine (1С) of patients with ALL treated with a 24 h 
infusion of methotrexate (5 g/m2.24 h) followed by a 
24 h infusion of 6MP (1300 mg/m2.24 h). A: Plasma 
sample at 290 nm at the end of the 24 h 6MP infu­
sion: 31.4' = presently, an unidentified peak, which 
is only present during and shortly after the infusion 
in plasma of patients treated with a high-dose 6MP 
infusion. This peak probably represents a metabolite 
of 6MP, but certainly is not methylthio-xanthine or 
methylthiouric acid, and is presently being inves­
tigated for identification. 32.9' = methylmercapto-
purine (478 nM), 41.7' = methylmercaptopurine 
riboside (3792 nM). B: Plasma sample of 1A at 320 
nm: 11.6' = 6MP (1363 nM). C: Urine sample 
(diluted lOx) at 342 nm of 6 h urine, collected from 
6 till 12 h after start of the 6MP infusion. 5.8' = 
thiouric acid (360 /¿mol/mmol creatinine), 13.6' = 
thioxanthine (14 μπιοΐ/inmol creatinine). 
.JJ лчілж 
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Figure 2 
C h r o m a t o g r a m s of 
( m e t h y l ) t h i o p u r i n e 
nucleotides in RBC 24 h 
after termination of a 
high-dose 6MP infusion. 
One patient with non-
Hodgkin lymphoma (A) 
was treated with a 24 h 
high-dose 6MP infusion 
(1300 mg/m2) and an­
other patient with ALL 
(B) was treated with a 24 
h infusion of metho­
trexate (5 g/m2) followed 
by a 24 h infusion of 
6MP (1300 mg/m2.24 h). 
A: 
UV detection at 290 nm: 
12.5' = MetIMP (342 
pmol/108 RBC), 22.6' = 
MetlDP, (97 pmol/108 
RBC), 34.8' = MetlTP 
(430 pmol/10" RBC). 
В: 
Fluorescent detection 
with excitation at 329 nm 
and emission at 410 nm: 
12.4' = tGMP (51 pmol/ 
8.108 RBC), 23.6' = 
tGDP (50 pmol/8.108 
RBC), 34.1' = tGTP 
(122 pmol/8.108 RBC) 
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Recovery of (methyl)thiopurine nucleosides and bases in plasma 
Standards of 6MP, thioxanthine, MPR, MeMP and MeMPR, metabolites which are 
produced during high-dose 6MP infusions, were added to plasma in a concentration range 
of 0.4-15 μΜ. The recovery of 6MP was in the range of 80-98 %, of thioxanthine 68-81 
%, of MPR 89-101 %, of MeMP 75-89 % and of MeMPR 68-102 %. 
Recovery of (methyl)thiopurine nucleotides 
The recoveries after extraction with PCA of (Me)TIN and of tGMP added to Molt-
F4 lymphoblasts in varying concentrations are indicated in Table 4. More than 89% of the 
standards was recovered in all cases. 
Recoveries of MetIMP after extraction with PCA in RBC (31-309 pmol/108 cells) 
were in the range of 87-109% and in peripheral mononuclear cells (18-180 pmol/105 cells) 
in the range of 70-106%. Recovery of tIMP and tGMP after extraction with PCA in 
peripheral mononuclear cells (18-180 pmol/106 cells) were 71-104 % and 87-104 %, 
respectively. TGN were poorly extracted from RBC or hemolysates with PCA. 
Extraction of RBC with EDTA, methanol and methylene chloride [18| and 
measurement with UV detection (290-340 nm) resulted in a large peak, which was caused 
by the combination of DTT and EDTA and which disturbed the chromatogram from 15-25 
minutes as well as the recoveries. After oxidation of the RBC extract and fluorescent 
detection TGN could be reproducibly measured in RBC at levels above 20 pmol per 10' 
RBC and the DTT-EDTA peak was not observed under these conditions. Simultaneous 
Table 4 Recovery of (methyl)thiopurine nucleotides in 4.7.10* Molt F4 lymphoblasts. 
Standard Concentration range Recovery 
(pmol/106 cells) (%) 
93-98 
96-99 
97-99 
89-98 
92-99 
92-99 
94-99 
tIMP 
tIDP 
tITP 
tGMP 
MetIMP 
MetlDP 
MetlTP 
51 
41 • 
78 
65 
46 
62 
87 
-819 
-866 
-1016 
-720 
-937 
-817 
-874 
Methods 33 
measurement with UV of MeTIN in the oxidized supernatant gave bad results at levels 
which are clinically obtained and became only reproducible at high levels above 100 μΜ. 
So, the MeTIN and TGN levels in RBC have to be measured by separate runs. 
Conclusion 
The two HPLC methods described here enable measurement of extracellular and 
intracellular (methyl)thiopurine metabolites in ALL cell lines and in patients materials. 
These methods are needed for preclinical [5] and clinical [25,26] research, involving the 
metabolism and cytotoxic pathways of thiopurines and the relation between thiopurine 
metabolites and treatment outcome in childhood ALL. 
The method for the measurement of extracellular thiopurine nucleosides and bases 
previously described [10] has been modified. The present method includes also measure­
ment of thioxanthine, thiouric acid and methylthiopurine nucleosides and bases in the same 
run. The recoveries of (methyl)thiopurine nucleosides and bases from plasma with PCA are 
good. The recovery of 6MP from plasma with trichloroacetic acid is even better (94%) [9]. 
The HPLC method with UV detection at two wavelength channels for intracellular 
metabolites, enables the measurement of the (methyl)thiopurine mono-, di- and triphospha-
tenucleotides in a single run. Extractions on ice with PCA result in good recoveries for 
(methyl)thiopurine nucleotides in lymphoblasts and peripheral mononuclear cells and for 
MeTIN in RBC. This extraction procedure is inadequate for TGN levels in RBC. 
Extraction and oxidation of TGN in RBC, according to the method of Rabel et al [18], and 
measurement with a fluorescence detector enables the detection of separate TGN in RBC at 
low concentrations. 
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Metabolism of intravenously administered high-dose 6-mercaptopurine 
with and without allopurinol treatment 
in patients with non-Hodgkin lymphoma 
CW Keuzenkamp-Jansen, RA De Abreu, JPM Bökkerink, MAH Lambooy, JMF Trijbels 
American Journal of Pediatric Hematology and Oncology, in press 
38 Chapter 3 
Abstract 
Purpose: We investigated the metabolism of HD-6MP infusions and its influence on 
the metabolism by allopurinol, an inhibitor of xanthine oxidase, the enzyme which 
catabolizes 6MP into thioxanthine and thiouric acid. 
Patients and Methods: Nine patients (aged 2-11 years) with NHL were treated with 
HD-6MP (1300 mg/m2.24 h) within a therapeutic window after diagnosis. Four patients 
received oral allopurinol (200 mg/m2.day) to prevent urate nephropathy and five did not. 
Plasma and RBC were isolated before and 4, 20, 24, 28 and 48 h after start of the 
infusión. All measurements were performed with HPLC. 
Results: Considerable variations were found in the plasma levels of 6MP, 
thioxanthine and thiouric acid and of RBC-MeTIN levels. 6MP-riboside was not detectable 
and MeMP and MeMPR levels were less than 1.3 μΜ in the plasma. In general, 6MP, 
thioxanthine and MeMP levels in plasma were higher and thiouric acid plasma levels and 
RBC-MeTIN levels were lower in the patients treated with allopurinol compared to those 
who did not receive allopurinol. 
Conclusions: 6MP is extensively metabolized in patients with NHL treated with HD-
6MP. Thiopurine methylation, at the levels of nucleotide, nucleoside and base, is an 
important metabolic pathway after HD-6MP. Co-administration of allopurinol can result in 
both a decreased catabolism and anabolism of 6MP compared to treatment with HD-6MP 
alone. This observation may have consequences for the therapeutic efficacy and toxic 
effects of 6MP in combination with allopurinol. 
Introduction 
6-Mercaptopurine (6MP) is used in the maintenance therapy of children with acute 
lymphoblastic leukemia (ALL) for many years. Recent studies have evaluated it as a high-
dose 6MP infusion (HD-6MP) [1]. An effect of allopurinol on the plasma pharmacokinetics 
of 6MP was demonstrated after oral [2], but not after intravenous [2-4] administration of 
6MP. However, urine analysis showed alterations in 6MP and its metabolites after HD-
6MP when allopurinol was coadministered [3,4]. The present study of HD-6MP infusions 
with or without allopurinol co-administration as a therapeutic window in nine patients with 
NHL is part of a national study in cooperation with the Dutch Childhood Leukemia Study 
Group [5]. 
We investigated the metabolism of 6MP in plasma and methylthioinosine nucleotides 
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(MeTIN) in red blood cells (RBC). We also measured endogenous purines, allopurinol and 
its metabolites in plasma. The patients were subdivided in two groups treated either with or 
without allopurinol in order to detect whether the metabolism of HD-6MP is influenced by 
allopurinol. Our study differs from the previous study on HD-6MP [3] by measurement of 
6MP and its metabolites, compared to 6MP alone, in plasma and by measurement of 
MeTIN, compared to thioguanine nucleotides (TGN), in RBC. 
Metabolism of 6MP and allopurinol 
6MP is an analogue of hypoxanthine and is metabolized similar as hypoxanthine 
(Scheme 1). 6MP is converted by hypoxanthine guanine phosphoribosyltransferase 
(HGPRT) into thioinosine monophosphate, with 5-phosphoribosylpyrophosphate (PRPP) as 
a co-substrate. Two cytotoxic pathways of 6MP have been described in vitro [6,7]. First, 
thioinosine monophosphate is converted into thioguanosine monophosphate (tGMP) and, 
after further phosphorylation, TGN are incorporated into DNA and RNA, thus causing a 
delayed cytotoxicity. Second, thioinosine monophosphate is converted by thiopurine 
methyltransferase (TPMT) into methylthioinosine monophosphate (MetIMP), which is a 
strong inhibitor of the purine de novo synthesis. Decrease of the purine nucleotide pool 
results in decreased DNA synthesis. 6MP is catabolized by xanthine oxidase into 
thioxanthine and thiouric acid, especially in the liver and the gut. These catabolites are 
excreted by the kidneys. 
Allopurinol, also a hypoxanthine analogue, is a competitive inhibitor of xanthine 
oxidase (Scheme 1). Oxypurinol (alloxanthine), the major metabolite of allopurinol, is 
produced by the action of xanthine oxidase and is a noncompetitive inhibitor of the enzyme. 
After oral administration of allopurinol peak plasma levels of this compound are reached 
within 30-60 minutes. It is rapidly cleared from plasma with a half-life time of 2-3 h. 
Oxypurinol has a half-life time of 18-30 h and is mainly responsible for the inhibition of 
xanthine oxidase [8]. Allopurinol can be converted into its ribonucleotide. This reaction 
consumes PRPP and seems to be responsible for the depletion of intracellular PRPP in man 
after allopurinol administration [9]. 
Patients and methods 
Informed consent was obtained from the children and/or the parents of all patients. 
Patients' characteristics at diagnosis and treatment since diagnosis are presented in Table 1. 
All patients presented with NHL or lymphomatous leukemia (bone marrow: >25% 
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Scheme 1 Metabolism of 6MP and allopurinol. Allopurinol and oxypurinol inhibit xanthine 
oxidase. Allopurinol, a competitive inhibitor of xanthine oxidase, is an analogue of hypoxanthine 
and oxypurinol, a non-competitive inhibitor of xanthine oxidase, is an analogue of xanthine. tIMP 
= thioinosine monophosphate, XO = xanthine oxidase. 
lymphoblasts, ALL/NHL stage IV) and received HD-6MP within 9 days after diagnosis. At 
the time of the 6MP infusion the uric acid levels were normal in all patients. Kidney and 
liver function was normal in all patients except in patient G, in whom the renal function 
had just normalized before the start of the infusion and in whom liver transaminases had 
decreased to 150 U/L during the infusion. Patients F, G, H and I, who had elevated serum 
uric acid levels or considerable tumor mass (Table 1), were treated with allopurinol before, 
during and after the 6MP infusion to prevent urate nephropathy. All patients continued with 
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effects of HD-6MP cannot be evaluated in this study. 
All standards for the HPLC measurements and dithiothreitol were obtained from 
Sigma (St. Louis, MA, USA), thiouric acid and MeTIN were synthesized in our 
laboratory. All other chemicals were from E. Merck (Darmstadt, Germany). 
6MP for intravenous administration was provided by the NCI. It was administered 
as a 24 h infusion starting with 100 mg/m2 (658 μιηοΐ/m2) in 0.5 hour followed by 1200 
mg/m2 (7895 μηιοΙ/m2) 6MP together with 120 ml/m2 NaHC03 8.4% and 90 ml/m2 KCl 
7.46 % in approximately 3000 ml/m2.23.5 h of a 0.25% saline and 3.3% glucose solution. 
Other studies administered single HD-6MP (50 mg/m2.h) in 1200 ml/m2.24 h [3] or 1800 
ml/m2.24 h [10]. The hyperhydration with 3000 ml/m2.24 h in our studies was done to 
compare the results of this study with those of the ALL study in which HD-6MP was 
preceded by HD-methotrexate [5]. To prevent hypervolemia in patient G, who had just 
recovered from renal failure, 6MP was administered with 1800 ml/m2.24 h. 
Blood was sampled just before and 4, 20, 24, 28 and 48 h after start of the 6MP 
infusion. Since diagnosis oral allopurinol was administered twice daily (200 mg/m2.day) in 
patients F-I. During the study it was administered 7 h before and 5, 17, 29 and 41 h after 
start of the 6MP infusion. 
Plasma and RBC were separated from heparinized blood, to which an excess of 
dithiothreitol was added to prevent oxidation of the thiol group of 6MP and its metabolites 
[11]. Plasma as well as RBC were deproteinized with perchloric acid and the supernatants 
were neutralized with K2HP04 [11]. The neutralized supernatants of plasma and RBC were 
stored at -20°C and -70CC, respectively. 6MP, allopurinol, their metabolites, hypoxanthine 
and xanthine in plasma and MeTIN in RBC were measured according to the method descri­
bed [11]. TGN and thioinosine monophosphate could not be measured due to bad 
recoveries from RBC with the perchloric acid extraction. 
Results 
The results of the measurements of 6MP, its metabolites, hypoxanthine and xanthine 
in plasma are presented in Figure 1. Within 4 h 6MP concentrations (Fig 1A) reached a 
steady state level with considerable interpatient variations. After termination of the infusion 
6MP levels decreased rapidly in all patients. 24 H after the end of the infusion 6MP was 
only detectable in plasma of patient G (0.6 μΜ). At the end of the infusion thioxanthine 
(Fig IB) was not detectable and thiouric acid levels (Fig 1A) were higher in plasma of the 
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patients treated without allopurinol. Neither thioxanthine nor thiouric acid were detectable 
in plasma of any of the patients 48 h after start of the infusion (data not shown). MeMP 
(Fig IB) was present in plasma of all patients during the infusion and decreased rapidly 
after termination of the infusion. 24 H after the end of the infusion MeMP was only detec­
table in plasma of patient H (0.1 μΜ). 6MP-riboside was not detectable in plasma of any of 
the patients. MeMPR was never detectable in plasma of 2 patients without (C and D) and 
of 2 patients with allopurinol (G and I). In the others it became detectable 20 h after start 
of the infusion and it increased till levels of 0.1-0.4 μΜ at the end of the study (48 h). 
The levels of hypoxanthine and xanthine in plasma just before start of the 6MP 
infusion are presented in Figure 1С. These levels were normal or slightly elevated in the 
patients treated without allopurinol at all sampling times during and after the 6MP infusion 
(data not shown). The levels of hypoxanthine and especially of xanthine were much higher 
in the patients treated with allopurinol. During and after the infusion these levels were 
rather constant in patients F and H and decreased gradually in patient G to normal levels. 
Patient I showed a 2-fold increase of hypoxanthine and xanthine during the infusion and a 
2-3 fold decrease after termination of the infusion. 
Allopurinol was not detectable in plasma of any of the patients treated with 
allopurinol at the times of blood sampling. Oxypurinol was present in all plasma samples of 
these patients and the mean levels during the study ranged from 23-95 μΜ (mean 53). 
RBC-MeTIN levels are presented in Table 2. MetIMP was detectable in RBC at 4 h 
after start of the infusion and increased during the next 20 h of the infusion in all patients. 
During the first 24 h after termination of the infusion MetIMP levels increased (B, C) or 
remained nearly constant (D, E) in the patients without allopurinol, but decreased in the 
patients with allopurinol. MetlDP and MetlTP became detectable after 20 h in patients D 
and E and increased until the end of the study. MetIMP as well as total MeTIN levels in 
RBC of the group treated without allopurinol were higher and increased further after 
termination of the infusion compared to the levels reached in the group treated with 
allopurinol. 
Discussion 
Our data suggest that thiopurine methylation is an important metabolic pathway of 
6MP in plasma and RBC after HD-6MP. This is reflected by the appearance of MeMP in 
plasma, especially during the infusion, and of MeMPR in plasma and MeTIN in RBC, 
especially after termination of the infusion. RBC-TGN levels were not measured in our 
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Figure 1 A 6MP steady state levels from 4-24 h, thiouric acid levels at 24 h. 
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Figure 1 В Thioxanthine levels at 24 h, MeMP steady state levels from 4-24 h. 
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Figure 1 С Hypoxanthine and xanthine levels before start of the 6MP infusion. Normal values 
of hypoxanthine and xanthine in children are < 4 μΜ and < 2 μΜ, respectively. 
Figure 1 Thiopurine and purine plasma levels in μΜ of patients treated without allopurinol (-) 
(n=5) and patients treated with allopurinol (+) (n=4). Markers, indicated in Figure C, correspond 
with individual patients mentioned in Table 1. Mean values are indicated by solid lines. 
study, but during maintenance therapy with low dose oral 6MP [12-14] and with HD-6MP 
[14] RBC-MeTIN levels were much higher compared to RBC-TGN levels. Although RBC 
are not the target cells for 6MP cytotoxicity they are a model for the study of the 
anabolism of 6MP because they have HGPRT and PRPP synthetase activity [9,15]. 
MetIMP levels must be high enough to inhibit the purine de novo synthesis to cause 
cytotoxicity. After low dose oral 6MP, RBC-MetIMP levels were much lower than after 
HD-6MP [5,15]. So the contribution of MetIMP to 6MP cytotoxicity might be different 
after low dose oral 6MP compared to HD-6MP. Direct methylation of 6MP into MeMP 
results in detoxification of the drug [16], which is in concordance with the simultaneous 
presence of MeMP and 6MP during the infusion and the rapid decrease of both compounds 
after termination of the infusion in our patients. As far as we know MeMP is not converted 
into MetIMP in vivo. 
Our data show that thiopurine methylation is an important metabolic pathway after 
HD-6MP infusions and suggest that methylation into MetIMP contributes to cytotoxicity, 
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whereas methylation into MeMP contributes to detoxification. 
The second aim of this study was to investigate effects of allopurinol on 6MP and 
its metabolites. Although there are considerable interpatient variations, our data suggest that 
allopurinol alters the metabolism of HD-6MP. In general 6MP, thioxanthine and MeMP 
levels are higher and thiouric acid and MeTIN levels are lower in patients treated with 
allopurinol compared to those who did not receive allopurinol. 
The higher levels of 6MP and thioxanthine and the lower ones of thiouric acid in 
the group treated with allopurinol can be explained easily by inhibition of xanthine oxidase 
by allopurinol and especially by oxypurinol. As a result of this inhibition more 6MP is 
methylated directly into MeMP, which might be considered as a detoxification pathway of 
6MP. In the group treated with allopurinol more 6MP was available for HGPRT in the 
salvage pathway. However, this did not result in higher RBC-MeTIN levels. In contrast, 
less MetIMP was present in RBC of the group treated with allopurinol (Table 2). This can 
be explained by earlier observations [9] that allopurinol treatment results in depletion of the 
intracellular PRPP pool. So, in the patients pretreated with allopurinol, the PRPP levels 
were presumably lower before start of HD-6MP and competition for PRPP between 6MP, 
hypoxanthine and allopurinol may have resulted in lower MeTIN levels and also 
contributed to the higher 6MP levels in this group. In future research more evidence for 
this hypothesis will be found if TGN levels show the same results. This cannot be excluded 
from the study of Zimm [3], because their RBC-TGN levels were only from patients 
treated without allopurinol. The lower MetIMP levels in the group treated with allopurinol 
cannot be explained by an inhibitory effect of allopurinol on TPMT activity. The higher 
levels of MeMP in the group treated with allopurinol demonstrate that TPMT was at least 
as active in these patients as in the patients without allopurinol. 
We cannot agree with the conclusions of the study of Zimm [3], that the 6MP 
steady state level in plasma was not influenced by allopurinol (300 mg/m2 daily), because 
our data suggest that RBC-MeTIN levels and all plasma metabolites, except MeMPR, are 
influenced by allopurinol. Moreover, the increase of 6MP and thioxanthine and the 
decrease of thiouric acid in urine of their patients treated with allopurinol |3] demonstrate 
that allopurinol did influence the overall metabolism of HD-6MP in their study too. Higher 
thioxanthine and lower thiouric acid levels were also measured in urine of one of our 
patients with allopurinol compared to urine of 3 patients without allopurinol in our study 
(data not shown. We could not collect urine of the other 5 patients). Allopurinol, which 
acts mainly in the liver and intestines, influenced the metabolism of 6MP after oral 
administration [2]. With parenteral administration the gastrointestinal tract is circumvented 
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before 6MP reaches the systemic circulation, but allopurinol still influences the metabolism 
of 6MP by depletion of intracellular PRPP [9] and inhibition of xanthine oxidase, especially 
in the liver [8]. 
Although all patients, except patient G, had normal kidney and liver function, there 
were differences in tumor type, tumor mass, initial serum uric acid levels and prior 
treatment among the patients treated with or without allopurinol. These differences could 
not explain the interpatient variations in the 6MP metabolism in or between the two groups. 
It is unlikely that the clinical condition, for which allopurinol was prescribed several days 
before (Table 1), has influenced the metabolism of HD-6MP on its own, because uridine 
levels were almost normal in all patients (data not shown) at the time of the infusion. So 
increased breakdown of DNA and RNA from the tumor with increased release of 
endogenous purines and pyrimidines might not have interfered with the 6MP metabolism. 
We conclude that 6MP is extensively metabolized in patients treated with HD-6MP 
and that thiopurine methylation, at the levels of nucleotide, nucleoside and base, is an 
important metabolic pathway after HD-6MP. Co-administration of allopurinol can result in 
both a decreased catabolism and anabolism of 6MP compared to treatment with HD-6MP 
alone. This observation may have consequences for the therapeutic efficacy and toxic 
effects of 6MP in combination with allopurinol. 
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Abstract 
6-Mercaptopurine (6MP) is an analogue of hypoxanthine. 6MP cytotoxicity can be 
modulated by physiological concentrations of hypoxanthine in vitro. Treatment of a patient 
with a 6MP infusion during a tumor lysis syndrome (TLS) suggests that competition 
between 6MP and hypoxanthine also occurs in vivo. 
After diagnosis, five non-Hodgkin lymphoma patients were treated within a 
therapeutic window with one high-dose 6MP infusion (1300 mg/m2.24 h). All received 
allopurinol (200 mg/m2.d) to prevent urate nephropathy. One patient had a TLS and WHO 
grade 1 renal failure. We studied the metabolism of 6MP in plasma and red blood cells of 
all patients. Although there were large interpatient variations of 6MP and its metabolites, 
the patient with TLS had, compared to the others, remarkably higher levels of 6MP (57 vs 
25 ± 7.8 μΜ), its metabolites (thioxanthine 47 vs 1.8 ± 2.1 μΜ, thiouric acid 20 vs 0.5 
± 1 . 0 μΜ) and hypoxanthine (84 vs 6.7 ± 5.1 μΜ) in plasma. The levels of oxypurinol, 
the main metabolite of allopurinol, were comparable, whereas the MetIMP level, an ana­
bolic metabolite of 6MP, was extremely low in the patient with TLS (72 versus 832 ± 752 
pmol/8.108 red blood cells). 
These findings could not be explained by allopurinol overtreatment or by enzyme 
deficiencies of HGPRT or TPMT. The renal failure in the patient with TLS has contributed 
to the high levels of 6MP, its metabolites and hypoxanthine, but cannot explain the low 
MetIMP levels. Despite high 6MP levels these low MetIMP levels suggest a relative low 
activity of the anabolic pathway of 6MP in the patient with TLS. This was probably caused 
by competition with hypoxanthine, which levels were increased due to tumor lysis. 
Introduction 
6-Mercaptopurine (6MP) is an antimetabolite which is used in the treatment of 
childhood ALL since many years. It is an analogue of the naturally occurring purine base 
hypoxanthine. The only difference between 6MP and hypoxanthine is a mercaptogroup 
(SH) instead of a hydroxygroup (OH) at the C6 position of the purine ring. 6MP and 
hypoxanthine are metabolized by the same enzymes and co-substrates. A study in the HL-
60 human acute promyelocytic cell line demonstrated modulation of thiopurine cytotoxicity 
by physiological concentrations of hypoxanthine'. Increases of hypoxanthine in the medium 
from 1 to 3 μΜ and from 3 to 10 μΜ both required a threefold increase of 6MP 
concentrations to obtain 50% cell kill [1]. 
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Hypoxanthine levels in plasma of healthy children are less than 4 μΜ [2]. During a 
tumor lysis syndrome (TLS) the levels of endogenous purine and pyrimidine nucleosides 
and bases in plasma increase due to the increased breakdown of nucleotides, DNA and 
RNA of the tumor cells. We treated 5 patients with non-Hodgkin lymphoma shortly after 
diagnosis with one high-dose 6MP infusion within a therapeutic window. One of these 
patients had a TLS at diagnosis. We investigated whether the metabolism of 6MP in vivo 
was modulated by the high levels of hypoxanthine during a TLS. 
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Figure 1 Thiopurine metabolism. 6MP = 6-mercaptopurine, MPR = mercaptopurine ribosi-
de, MeMP(R) = methylmercaptopurine (riboside), (Me)tlMP = (methyl) thioinosine monophos-
phate, tGMP (tGDP, tGTP) = thioguanosine mono- (di-, tri-) phosphate, HGPRT = hypoxanthine 
guanine phosphoribosyltransferase, TPMT = thiopurine methyltransferase, XO = xanthine oxidase. 
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Thiopurine metabolism 
The thiopurine metabolism is indicated in Figure 1 and is rather similar to the 
purine metabolism. 6MP enters the cell by facilitated transport over the hypoxanthine 
carrier, which has the same affinity for 6MP as for hypoxanthine [3]. The first step in the 
anabolic pathway of 6MP is the conversion into thioinosinemonophosphate (tIMP) by 
hypoxanthine guanine phosphoribosyl transferase (HGPRT), an enzyme of the purine 
salvage pathway. TIMP can be further metabolized in two cytotoxic pathways. Firstly, 
tIMP can be converted into thioguanosine monophosphate. Thioguanine nucleotides cause a 
delayed cytotoxic reaction after incorporation into DNA [4,5]. Secondly, tIMP can be 
methylated by thiopurine methyltransferase (TPMT) into methyl-tIMP (MetIMP). This 
compound is a strong inhibitor of the purine de novo synthesis [6-8]. MetIMP can be 
catabolized to methylmercaptopurine riboside (MeMPR). MeMPR cannot be catabolized 
into methylmercaptopurine (MeMP) [9], but MeMP is produced by methylation of 6MP. 
All methylation reactions are catalyzed by thiopurine methyltransferase (TPMT). 
6MP and hypoxanthine are catabolized by xanthine oxidase into (thio)xanthine and 
subsequently into (thio)uric acid. Allopurinol is a competitive inhibitor of xanthine oxidase 
and has a half life time of 2-3 hours. Oxypurinol, a non competitive inhibitor of xanthine 
oxidase and the major metabolite of allopurinol, has a half life time of 18-30 hours and is 
mainly responsible for the action of allopurinol [10]. 
Patients and methods 
Five patients with non-Hodgkin lymphoma, aged 3.5 to 9.5 years, were treated 
within 7 days after diagnosis with one high-dose 6MP infusion (1300 mg/m2.24 h) within a 
therapeutic window. The patients were treated with prednisone alone or with prednisone 
and cyclophosphamide since diagnosis. All patients were treated with allopurinol (200 
mg/m2 daily) to prevent urate nephropathy. One of the patients had a TLS at diagnosis, 
which is characterized by hyperuricemia, hyperkalemia, hyperphosphatemia and 
hypocalcemia [11]. Just before start of the 6MP infusion the hyperuricemia and hyperkale-
mia had disappeared, serum phosphate was 2.4 mM (normal 1.3-1.9) and calcium 1.9 mM 
(2.2-2.6). After start of the infusion serum creatinine and urate raised and showed WHO 
grade 1 renal toxicity in the patient with TLS. 
Blood was sampled before and 4, 20, 24, 28 and 48 hours after start of the 6MP 
infusion and plasma and red blood cells (RBC) were isolated. Thiopurines and purines were 
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measured with HPLC methods [12]. These methods were modifications of previous 
methods [6,13,14]. 
Results 
Plasma and RBC levels of 6MP and its metabolites are indicated in Table 1. 
Although there were considerable interpatient variations among the patients who had not 
suffered from a TLS, the patient with TLS can be clearly distinguished from the others. 
The levels of 6MP, thioxanthine, thiouric acid and to a lesser extent of MeMP were much 
higher in the patient with TLS, whereas MetIMP levels in RBC were extremely low in this 
patient. 
The plasma levels of hypoxanthine, xanthine and oxypurinol are indicated in Table 
2. The levels of these purines were extremely elevated in the patient with TLS. Allopurinol 
was not detectable in plasma of any of the patients. Oxypurinol levels were comparable 
between the patients with or without TLS. 
The HGPRT activity in the patient with TLS was 6.21 ± 0.18 nmol/106 peripheral 
mononuclear cells (normal 10.50 ± 3.98). 
Table 1 6MP and its metabolites in plasma and red blood cells. 
Time Four patients TLS patient 
(h) mean ± sd (range) 
Plasma (μΜ): 
6MP (mean) 
Thioxanthine 
Thiouric acid 
MeMP (mean) 
MeMPR 
4-24 
24 
24 
4-24 
48 
25.0 ± 7.8 
1.8 ± 2.1 
0.5 ± 1.0 
0.9 ± 0.4 
0.1 ± 0.1 
(16.7 - 35.4) 
( 0 . 0 - 4.8) 
( 0 . 0 - 2.0) 
( 0 . 3 - 1.3) 
( 0 . 0 - 0.3) 
57 
47 
20 
2 
0 
Red blood cells (pmol/8.1Ö>): 
MetIMP 24 
48 
1248 ± 1160 (400-2912) 
832 ± 752 (200 - 1896) 
64 
72 
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Table 2 Plasma levels of hypoxanthine, xanthine and oxypurinol (jM). 
Time Four patients TLS patient 
(h) mean ± sd (range) 
Hypoxanthine 0 6.7 ± 5 . 1 ( 3.5 - 14.4) 84 
Xanthine 0 17.0 ± 8.1 (6.3-25.4) 334 
Oxypurinol (mean) 0-48 53.4 ± 30.4 (22.9 - 95.4) 47 
Discussion 
The cytotoxic action of chemotherapeutic drugs against leukemic blasts depends 
mainly on two aspects. First, the drug has to reach the blasts, which is determined by the 
pharmacokinetics of the drug. Second, the drug has to kill the cell, which depends on the 
drug sensitivity or resistance of the cell. In case of an antimetabolite the drug also has to be 
converted into its active form. The data from the patient with TLS suggest that only 
minimal amounts of the drug were converted intracellularly to cytotoxic compounds, 
although extreme high levels of the drug were reached in plasma. There are several 
explanations for the observations that levels of hypoxanthine, xanthine, 6MP and its 
metabolites were higher in plasma and that the RBC-MetIMP level was lower in the patient 
with TLS compared to the other patients. The WHO grade 1 renal failure during the 
infusion in the patient with TLS may have contributed to the elevated plasma levels of 
6MP, hypoxanthine and their catabolites, which are normally excreted by the kidneys. 
Overtreatment with allopurinol, which might explain the extreme high levels of 
hypoxanthine and xanthine and of 6MP and thioxanthine in the patient with TLS, was 
excluded by the data of oxypurinol. 
Although the 6MP levels were highest in plasma of the patient with TLS only small 
amounts of MetIMP were produced in RBC. A HGPRT deficiency which might have 
explained a decreased intracellular anabolism of 6MP was excluded. Methylation of 6MP 
into MeMP and of tIMP into MetIMP are both catalyzed by TPMT. The patient with TLS 
produced highest levels of MeMP. Therefore it is unlikely that a TPMT deficiency has 
caused the low MetIMP levels. 
MetIMP is one of the products of the anabolic pathway of 6MP. The other ones are 
the thioguanine nucleotides, which we could not measure with our method. Although RBC 
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are not the target cells for 6MP cytotoxicity they are a model for the study of the anabolic 
pathway of 6MP because they show HGPRT activity [15]. Our results show that only 
minimal amounts of 6MP entered the anabolic pathway in the patient with TLS, which 
might be caused by a competition between 6MP and hypoxanthine. The extreme high levels 
of hypoxanthine and of other endogenous purines and pyrimidines were caused by the 
abrupt lysis of tumor cells. The competition for uptake by the membrane carrier3 and for 
the metabolism intracellularly resulted in a decreased anabolism and thus decreased 
effectiveness of 6MP during a TLS. The high levels of 6MP and its catabolites may cause 
hematuria and crystalluria, if hyperhydration is insufficient [16] and may cause further 
renal failure. 
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Abstract 
Thiopurine methyltransferase (TPMT) is an important enzyme in the metabolism of 
6-mercaptopurine (6MP), which is used in the treatment of acute lymphoblastic leukemia 
(ALL). TPMT catalyzes the formation of methylthioinosine monophosphate (MetIMP), 
which is cytotoxic for cultured cell lines, and it plays a role in detoxification of 6MP. 
Population studies show a genetic polymorphism for TPMT with high and low activity 
alleles. About 1 of 300 subjects is homozygote for the low activity. The function TPMT in 
detoxification or therapeutic efficay of 6MP in vivo is not clear. 
In this article the genetic polymorphism of TPMT is reviewed and the contribution 
of TPMT to the cytotoxic action or detoxification of 6MP in children with ALL is 
discussed. An induction of TPMT activity has been described during the treatment for 
ALL. We performed a pilot study on the influence of high-dose 6MP infusions (1300 
mg/m2 in 24 h) on TPMT activity of peripheral blood mononuclear cells (pMNC) of 11 
patients with ALL. 
The TPMT activities were in or above the normal range. There was no statistically 
significant difference between the TPMT activities before and after the 6MP infusions. 
MetIMP levels in pMNC increased during successive courses. This might be explained by 
TPMT induction, but other explanations are plausible as well. 25% of the TPMT assays 
failed, because less than the necessary 5*10* pMNC could be isolated from blood of the 
leukopenic patients. Red blood cells can not be used for TPMT measurements, since 
transfusions are frequently required during the treatment with 6MP infusions. Therefore, an 
influence of high-dose 6MP infusions on TPMT activity can only be further investigated 
when a TPMT assay which requires less pMNC has been developed. 
1 Thiopurine methyltransferase in the metabolism of 6-mercaptopurine 
Thiopurine methyltransferase (TPMT) is involved in the methylation reactions of 6-
mercaptopurine (6MP). 6MP is administered since 1953 in the treatment of childhood acute 
lymphoblastic leukemia (ALL) and is converted by several metabolic steps (Scheme 1). 
6MP is catabolized by xanthine oxidase into inactive thioxanthine and thiouric acid which 
are excreted by the kidneys [1-4]. In the anabolic pathway 6MP is first converted by 
hypoxanthine guanine phosphoribosyltransferase (HGPRT) into thioinosine monophosphate. 
To exert cytotoxicity this compound is either converted into a thioguanine nucleotide or it 
is methylated by TPMT into methylthioinosine monophosphate (MetIMP). Incorporation of 
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Scheme 1 Metabolism of 6-mercaptopurine. 
6MP(R) 6-mercaptopurine-(riboside); 6MeMP(R) 6-methylmercaptopurine (riboside); (Me)tlMP 
6-(methyl)thioinosine monophosphate; tGMP 6-thioguanosine monophosphate; PDNS purine de 
novo synthesis; (1) thiopurine methyltransferase; (2) hypoxanthine guanine phospho-
ribosyltransferase; (3) purine nucleoside Phosphorylase; (4) purine 5'-nucleotidase; (5) adenosine 
kinase; (6) inosine mono-phosphate dehydrogenase; (7) guanosine monophosphate synthetase; (8) 
guanosine monophosphate reductase; (9) xanthine oxidase. 
thioguanine nucleotides (TGN) into DNA and RNA and inhibition of the purine de novo 
synthesis by MetlMP both result in cytotoxicity in vitro [5-7]. The importance of each 
cytotoxic pathway in vivo is discussed in section 3. Apart from a decreased DNA and RNA 
synthesis [5], inhibition of the purine de novo synthesis can also lead to a decrease of 
intracellular S-adenosyl-L-methionine [8] and of DNA methylation [9] in vitro. S-adenosyl-
L-methionine is the methyldonor for thiopurine methylation reactions [10] and for other 
incorpormtton 
of TQM 
Into DNA 
tGMP _> tIMP 
6MPR 
6MP 
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methylation reactions, e.g. proteins, phospholipids and nucleic acids [11]. The effects of 
6MP on S-adenosyl-L-methionine [8] in lymphoblasts may account for an additional mecha-
nism of 6MP cytotoxicity. 
6-Mercaptopurine riboside is converted by TPMT into 6-methylmercaptopurine 
riboside (MeMPR), which can be phosphorylated intracellularly into MetIMP by adenosine 
kinase [12,13] and which can not be broken down by purine nucleoside Phosphorylase [14]. 
The methylation by TPMT of 6MP into 6-methylmercaptopurine (MeMP), which has no 
cytotoxic action, results in detoxification of the drug [3]. 
In conclusion, TPMT is an important enzyme in the metabolic pathways of 6MP. It 
catalyzes the formation of MetIMP, which is an inhibitor of the purine de novo synthesis in 
vitro, and it plays a role in detoxification of the drug. 
2 Genetic polymorphism of TPMT 
In view of its role in thiopurine metabolism, it became important to study the 
genetic background of the TPMT activity. These studies were facilitated by the develop-
ment of a quantitative assay for TPMT activity in red blood cell (RBC) lysates [15]. In this 
assay the transfer of 14C from S-adenosyl-L-methionine to 6MP is measured. 
It became apparent that a marked variation in TPMT activity exists between 
individuals [16,17]. The frequency distribution of TPMT activity in a population of white 
subjects is trimodal. 88.6% of the subjects displayed high activity, 11.1% had intermediate 
activity, while lysates of 0.3% did not contain detectable TPMT activity. A simple model 
for such a distribution is that a single genomic locus governs TPMT activity and that there 
are two alleles for the locus [17]. One allele corresponds to high activity (TPMTH), the 
other (TPMT L) to low activity. The locus is diploid and both copies are expressed. 
Individuals that are homozygous for TPMT H display high activity, heterozygotes have 
intermediate activity and TPMT L homozygotes have an activity that is below the detection 
level of the assay. The validity of this model was suggested by the distribution data which 
fit with Hardy-Weinberg statistics for inheritance by Mendelian laws. The frequency of 
TPMTH is 0.94 (0.06 for TPMT ') in the group of white subjects. The model was strongly 
supported by pedigrees with regard to TPMT activity which were also in agreement with 
Mendelian rules. Further studies and sophisticated statistical analyses led to the conclusion 
that TPMT activity is governed by a single locus although additional circumstances may 
influence TPMT activity [18,19]. 
Individual levels of RBC TPMT activity correlate to the TPMT activity in other 
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tissues, including liver, kidney, lymphocytes, platelets and lymphoblasts [20-23]. 
Apparently, the same genetic locus controls TPMT activity in these tissues. TPMT activity 
has further been detected in all other tissues examined: i.e. brain, lung, intestine and 
placenta [24]. The liver and kidney had the highest TPMT activity [24]. 
Age does not have an effect on TPMT activity and high levels of TPMT activity 
have been found in fetal tissues [24]. It has been reported that tissues derived from males 
have approximately 10% higher TPMT activity than those from females [19,23,25], but 
other studies do not find significant sex differences [26-28]. Uneven frequency distributions 
of TPMT activity are also found in diverse ethnic groups [26,28]. The frequency of TPMT 
L
 was 0.02 in a group of Chinese subjects [28]. Differences in the activity levels between 
ethnic groups may be caused by laboratory circumstances [28]. However, when measured 
at the same laboratory, the TPMT activity in samples from black subjects was 17% lower 
than from white subjects, while similar proportions of high and intermediate activity were 
present in both these groups [29]. 
Molecular biological studies were initiated with the partial purification of TPMT and 
production of specific antibodies [22]. TPMT is a cytoplasmic protein of 35 kDa [30,31]. 
Titration of the activity with antibodies indicated that variation of the TPMT activity 
between individuals corresponds to variation of the amount of TPMT protein [22]. 
The TPMT activity from kidney homogenates resolved in two peaks by ion 
exchange chromatography on DEAE sepharose [31]. These two activities behaved identical 
in all further experiments, which included kinetic studies, gel filtration, gel electrophoresis 
and column chromatography on hydroxylapatite [31,32]. The nature of the difference of 
these isozymes is not known. Studies of individual samples clearly ruled out any link 
between the genetic polymorphism and the existence of the two isozymes [31]. 
Extensive purification of TPMT was achieved after UV cross-linking of the protein 
to its labeled co-factor [3H-methyl] S-adenosyl-L-methionine. TPMT could thus be 
monitored through radioactivity instead of enzyme activity [32]. 
A cDNA of human TPMT mRNA was cloned on the basis of peptide sequences of 
purified protein fragments [33,34]. A liver cDNA of 1.8 kb was cloned which has an open 
reading frame of 245 amino acids [34]. The identity of this cDNA was confirmed by 
expression of the coding region in COS cells, which resulted in an increase of TPMT 
activity [33]. The derived amino acid sequence of TPMT lacks the three regions that are 
commonly found in other S-adenosyl-L-methionine binding proteins [33]. It will be 
interesting to see whether the methyldonor is a co-factor for the physiological function of 
this protein. 
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The gene structure including its regulatory sequences has not been resolved yet. 
Cloning of the gene is obstructed by the presence of a processed pseudo-gene on 
chromosome 18q21 [34]. The pseudo-gene originates from a reverse transcription event 
with TPMT mRNA. 
One patient with TPMT deficiency was analyzed at the molecular level [35]. Cloned 
cDNA of this patient is mutated in the open reading frame, leading to an amino acid 
substitution of Ala at position 80 to Pro. The corresponding cDNA was expressed in yeast 
and, contrary to the wildtype cDNA, the mutant protein had no TPMT activity. The 
pedigree of this patient indicates that the pointmutation accounts for only one copy of the 
gene. The second copy seems to be affected by another mutation. 
Mutations that affect TPMT activity may leave the physiological activity unchanged. 
Since TPMT is present in all tissues examined from an early stage of development, it may 
represent an important or essential household protein. Knock-out and mutation experiments 
in mice should be performed to test these ideas. 
The preliminary DNA sequence data indicate that different mutations are responsible 
for the TPMT L allele. Clearly, an inventory is required of existing mutations that lead to 
TPMT deficiency. 
3 TPMT and its contribution to the cytotoxic action or detoxification of 6MP 
The genetic polymorphism of TPMT is inapparent in healthy subjects, but becomes 
important when thiopurine drugs are administered which are metabolized by this enzyme. 
Several patients developed signs of severe toxicity from 6MP treatment and it was 
demonstrated that they were deficient for TPMT activity [36-38]. Apart from its influence 
on 6MP toxicity, TPMT activity also appears to play a role in the prognosis and survival of 
childhood ALL, reflecting its importance for the therapeutic efficacy of 6MP. All studies 
that reveal insight in the efficacy of 6MP and in the relevance of each cytotoxic pathway of 
6MP in vivo are performed in RBC during 1.5 to 2.5 years of maintenance therapy (MT) 
of childhood ALL with daily oral low dose 6MP (50-100 mg/m2) and weekly methotrexate 
(MTX) [36-44]. Lymphoblasts, which TPMT activity correlates with that in RBC [20], are 
not available for investigation, because the patients are in remission during MT. Several 
studies during MT with 6MP suggest that the formation of TGN is mainly responsible for 
treatment outcome and drug toxicity [36-42]. This is supported by a significant positive 
correlation between high TGN levels in RBC and thiopurine induced bone marrow toxicity 
[41] and by negative correlations between TGN concentrations and TPMT activity [39] or 
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between TGN concentrations and the incidence of relapses [39,40,42]. MetIMP levels were 
not measured in the latter studies. Another study with RBC showed that MetIMP and TGN 
concentrations, as well as TPMT activity, were below the population median in 6 out of 7 
patients who relapsed [43]. This rises the question whether low TGN levels alone or in 
combination with low MetIMP levels in RBC during MT are responsible for the worse 
prognosis. 
Evidences exist that the methylation of 6MP, catalyzed by TPMT, modulates 6MP 
cytotoxicity and that the production of TGN is not alone decisive for the cytotoxic action of 
6MP in vivo. TPMT deficient patients, in whom methylated metabolites could not be 
detected in RBC, did not suffer from toxicity after considerable dose reduction of 6MP, but 
still had elevated TGN levels in RBC compared to patients with unimpaired TPMT activity 
[36,38]. The tolerance of higher TGN concentrations without bone marrow depression in 
the TPMT deficient patients suggests that the methylated metabolites of 6MP also 
contribute to cytotoxicity. This is also illustrated by the preliminary results of a recent 
study which demonstrated identical effects on bone marrow toxicity in patients who were 
treated with either 6MP or 6-thioguanine. However, the patients who were treated with 
6MP reached five times lower TGN concentrations than those treated with 6-thioguanine 
[44]. So, in addition to the formation of TGN the methylated metabolites of 6MP 
intracellularly may also contribute to bone marrow toxicity in vivo. 
It is important to further elucidate whether methylation of thiopurines contributes to 
the cytotoxic action of 6MP in vivo, because this may have clinical implications for the 
application of 6MP or 6-thioguanine, which is converted directly into TGN. If methylation 
of 6MP only results in detoxification of the drug, it would be better to administer 6-
thioguanine instead of 6MP, especially in patients with high TPMT activity. If the 
formation of MetIMP adds to the cytotoxic action of 6MP, a high TPMT activity would 
enhance the therapeutic effect of 6MP in the lymphoblasts. The cytotoxicity by inhibition of 
the purine de novo synthesis would be lost if 6-thioguanine was administered instead if 
6MP, because MetGMP is a 12 fold less potent inhibitor of the purine de novo synthesis 
compared to MetIMP [45]. 
4 Induction of TPMT activity 
TPMT activities in RBC during MT of childhood ALL were higher compared to 
those at diagnosis [20] and those of healthy controls [39]. TPMT activities showed low 
intrapatients variability (13.5%) during MT and were not influenced by high-dose MTX 
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infusions [20]. After cessation of MT the elevated TPMT activities in RBC decreased to 
normal [20,39]. The first results of another study showed that TPMT activities in RBC 
were elevated at the end of the intensive induction and consolidation treatment, i.e. just 
before start of MT, and that they decreased during MT in comparison to the levels just 
before start of the MT [46]. These observations suggest that induction of the TPMT activity 
in RBC occurs during the induction, consolidation or maintenance treatment of childhood 
ALL [20,39,46]. It is not known whether the induction of TPMT activity also occurs in 
other tissues or in lymphoblasts, but the latter will be difficult to investigate because no 
lymphoblasts are available as soon as the patient is in remission. The biochemical 
mechanism for the induction of TPMT activity is not known. 
High-dose 6MP infusions are currently being investigated in induction and 
consolidation treatment of childhood ALL [47]. Since methylation of 6MP and its 
metabolites occurs to a large extent, especially during high-dose 6MP infusions [36,48,49] 
and since 6MP infusions are administered during several courses [47], it is important to 
investigate the influence of high-dose 6MP infusions on the TPMT activity. In order to 
evaluate the consequence of TPMT induction with respect to the therapeutic effect of 6MP, 
it is essential to elucidate the contribution of the methylation pathway to 6MP cytotoxicity 
or detoxification in vivo. 
4.1 Effects of high-dose 6MP infusions on the TPMT activity (pilot study) 
A pilot study has been performed to investigate an influence of high-dose 6MP 
infusions on the TPMT activity and to explore relations between this activity and (methyl) 
thiopurine nucleotide levels. In the consolidation treatment with high-dose MTX infusions 
of the Dutch Childhood Leukemia Study Group (ALL 8 study) patients with ALL were 
randomized for the administration of high-dose intravenous 6MP or low dose oral 6MP. 
We investigated the low-dose oral 6MP group as the control group for the high-dose 6MP 
group, because both groups received MTX infusions which may influence TPMT as well. 
We analyzed peripheral blood mononuclear cells (pMNC), instead of RBC, because the 
patients frequently received RBC transfusions for anaemia. This pilot study was the first 
study in ALL which investigated the TPMT activity and the metabolism of 6MP in pMNC 
during high-dose 6MP infusions. 
4.2 Experimental 
Twenty children with medium-risk ALL (age 2-9 years) were treated in our center. 
After induction of bone marrow remission all patients received the M-protocol, a 
consolidation treatment which consisted of 4 courses with high-dose MTX infusions (5 g/m2 
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in 24 h) in 8 weeks. In addition, 11 of these patients were randomized for intravenous 
administration of 6MP (1300 mg/m2.24 h immediately after the MTX infusion from 24 to 
48 h). The other 9 patients received 6MP orally (25 mg/m2 daily during 8 weeks). Patients 
or parental approval were obtained according to the guidelines of the ethical committee of 
our hospital. 
pMNC were isolated from 20 ml defibrinated blood with density gradient 
centrifugation and contaminating RBC were removed by a NH4C1 shock [50]. pMNC were 
isolated for measurement of TPMT activity before and 2 weeks after the M protocol. 
TPMT activity was measured according to the method of Van Loon and Weinshilboum 
[21], which is based on the methylation of 6MP with S-adenosyl-L-^Cl-methionine. In 
short, 5*10* pMNC were incubated with a solution of potassium phosphate buffer, pH 7, 
6MP in dimethylsulfoxide, S-adenosyl-L-['4C]-methionine, reduced glutathione and 
allopurinol. The incubation was performed in a shaking water bath at 37 °C for 90 min 
after which the reaction was terminated with borate buffer, pH 10. 14C-MeMP was 
extracted from the incubate with 20% isoamylalcohol in toluene. Radioactivity was 
measured for 10 min in a liquid scintillation counter and corrected for 3 separate blanks as 
described [21]. 
During the 4 courses, pMNC were isolated before and 24, 28, 48, 52 and 72 h after 
start of each MTX infusion from 8 intravenous and 4 oral patients. The (methyl)thiopurines 
were extracted from pMNC on ice with perchloric acid and adjusted with dipotassium 
hydrogenphosphate to pH 6-7. The (methyl) thiopurine nucleotides were separated by anion 
exchange HPLC (Partisil-10-SAX, 250x4.6 mm I.D., particle size 10 μπι, Whatman, 
Clifton, NJ, USA) and measured using UV absorbance at 290 nm for MetIMP and at 320 
nm for thiopurine nucleotides as described [50]. 
4.3 Results and Discussion 
TPMT activities in pMNC were measured before and after the M protocol (Table 
1). Before start of the M protocol they (range 4.6-27.2 IU/109 pMNC, mean 13.7) were in 
or above the range of lymphocytes of healthy adults (range 4.8-17.7 IU/IO9, mean 11.0) 
[21]. The higher activities might be caused by other chemotherapeutic drugs used during 
the induction treatment [20,39,46]. There was neither a statistically significant difference 
between the TPMT activities before and after the M protocol in either of the groups (paired 
t test P=0.50 in the intravenous and ρ =0.94 in the oral group) nor in the TPMT values 
after the M protocol between the two groups (Mann-Whitney-Wilcoxon rank sum test 
Ρ =0.77). 
The necessary 5*10* pMNC for the TPMT assay could not be obtained in 9 out of 
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36 cases, because several patients were leukopenic. For future research in ALL an assay 
for the TPMT activity, which requires less pMNC is needed. We recently reported a non-
radiochemical HPLC procedure for other purine enzymes in 1,500-15,000 pMNC [51], but 
until now we could not develop a sensitive HPLC assay for TPMT activity which required 
less than 5*10* pMNC. Immunological techniques to detect the TPMT protein may be a 
sensitive alternative for the activity measurement [22]. However, more insight in the 
genetic basis for TPMT deficiency in the population is required before this technique can 
be used reliably. 
Table 1 TPMT activity in pMNC (IU/10' pMNC) before and after start of the M protocol. 
Patients Before M protocol After M protocol 
Intravenous group 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
mean (sent) 
Oral group 
1 
2 
3 
4 
5 
6 
7 
8 
9 
mean (sem) 
Both groups 
Range 
Mean (sem) 
12.9 
14.4 
not done 
17.8 
22.5 
7.8 
27.2 
15.7 
4.6 
9.7 
7.8 
20.3 
not enough 
17.2 
7.3 
not enough 
not enough 
not enough 
7.1 
not done 
4.6 - 27.2 
13.7(1.8) 
not enough 
7.6 
10.6 
not enough 
29.4 
not enough 
not enough 
not done 
not done 
3.5 
4.1 
11.0 (4.8) 
7.2 
22.6 
28.9 
7.0 
4.7 
16.1 
7.3 
not enough 
6.2 
12.5 (3.2) 
3.5 - 29.4 
11.9(2.6) 
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Table 2 MetIMP levels in pMNC (pmol/106) during 4 courses from patients treated with 
HD-MTX followed by HD-6MP infusions. 
Patient 
1 
2 
3 
4 
5 
7 
10 
11 
mean 
(sem) 
TPMT 
Before After 
12.9 
14.4 
n.d. 
17.8 
22.5 
27.2 
9.7 
7.8 
n.d.A 
7.6 
10.6 
n.d. 
29.4 
n.d. 
3.5 
4.1 
Course 1 
13.3 
21.2 
0.0 
15.2 
7.2 
20.0 
n.d 
0.0 
8.5 
(3.1) 
MetIMP at 72 h 
Course 2 
14.6 
29.3 
0.0 
n.d. 
14.4 
8.8 
n.d. 
14.9 
13.7 
(3.9) 
Course 3 
21.9 
52.7 
0.0 
17.2 
29.1 
13.3 
38.5 
32.2 
25.6 
(5.7) 
Course 4 
18.4 
48.0 
n.d. 
30.4 
18.5 
17.8 
47.7 
24.7 
29.4 
(5.1) 
paired t test (p) compared to course 1 0.035 0.023 0.004 
Levels found 24 h after termination of the 6MP infusion (72 h) are indicated. TPMT activities 
(IU/10' pMNC) before and after the M protocol are also indicated. A n.d. = not done. 
In the intravenous group MetIMP levels (Table 2) were measurable at the end of the 
6MP infusion (48 h) and increased or remained constant after termination of the infusion 
from 48 - 72 h. Patient 3 did not produce any MetIMP during the courses although the 
TPMT activity was 10.6 IU/IO9 pMNC after the M protocol. The other patients produced 
significantly more MetIMP during course 4, compared to course 1 (paired t test P=0.004, 
11 patients). During the successive courses patients 5 and 7 produced MetIMP at an earlier 
point of time (at 48 h instead of 52 or 72 h) as compared to the first course. During course 
4 patient 5 already demonstrated MetIMP 4 h after start of the 6MP infusion (2.3 pmol/105 
pMNC at 28 h). In the oral group MetIMP levels could not be detected. Thiopurine nucleo-
tides were not detectable in both groups (detection limits are 13 and 38 pmol for MetIMP 
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and tGMP respectively per injection of 100 μΐ [50]). 
In the intravenous group there was no correlation between TPMT activity before 
start of the M protocol and MetIMP levels at 72 h of the first course or between TPMT 
after the M protocol and MetIMP levels of the fourth course (Spearman's correlation 
coefficients 0.029 and -0.400, respectively), but a larger number of patients has to enter the 
study before a conclusion can be drawn. 
The significant increase of MetIMP levels in each patient during the successive 
courses with high-dose 6MP and the acceleration of MetIMP formation during the infusions 
in successive courses in patients 5 and 7 suggest that there might be induction of TPMT 
activity by high-dose 6MP. This observation needs confirmation by measurement of TPMT 
activity in more patients, because higher MetIMP levels could also be caused by other 
enzymes, which are involved in the 6MP metabolism (Scheme 1). HGPRT activity in RBC 
was significantly higher in children during MT for leukemia compared to healthy control 
children [52]. An induction of HGPRT during chemotherapy might be another explanation 
for the increasing MetIMP levels in our study (Table 2), but HGPRT activity has never 
been investigated during high-dose 6MP infusions. Xanthine oxidase activity has not been 
studied with respect to the metabolism of high-dose 6MP. We described three patients who 
developed severe leukopenia due to thiopurine therapy for rheumatoid arthritis, who had 
very low 5'nucleotidase activities in pMNC [53]. So far, it is clearly demonstrated in 
literature that TPMT activity has a major influence on the metabolism of 6MP, but other 
purine enzymes, which is are less well studied, may interfere with it as well. 
This pilot study is the first which measured TPMT activity in pMNC during the 
consolidation treatment of ALL and it demonstrated an increase of MetIMP levels in 
pMNC during successive courses with high-dose 6MP. This pilot study also showed the 
limitation in using pMNC: a high percentage of TPMT assays failed due to leukopenia in 
the patients. Since leukopenia often occurs and RBC transfusions are frequently required 
during the consolidation treatment, an influence of high-dose 6MP infusions on TPMT 
activity can only be further investigated when a TPMT assay which requires less pMNC 
has been developed. 
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during intravenous administration 
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Abstract 
6-Mercaptopurine (6MP), a hypoxanthine antimetabolite, is used in the treatment of 
acute lymphoblastic leukemia in children. Extensively metabolized before it exerts cytotoxic 
action, it is catabolized into 6-mercapto-2,8-dihydroxypurine (thiouric acid), which is 
excreted by the kidneys. 
We describe a metabolite of 6MP, 6-methylmercapto-8-hydroxypurine, whose 
presence has not been previously reported in plasma. This compound was found in high 
concentrations in plasma during high-dose 6-mercaptopurine infusions (1300 mg/m2 in 24 
h). This previously as unknown described compound was identified by reversed phase 
HPLC with ultraviolet absorbance detection and by gas chromatography-mass spectrometry. 
The pathways leading to 6-methylmercapto-8-hydroxypurine in vivo are not fully 
understood yet. 
In a group of 17 patients treated with four courses of high-dose 6-mercaptopurine 
infusions according to the ALL-8 treatment protocol of the Dutch Childhood Leukemia 
Study Group, the steady state concentrations of 6-methylmercapto-8-hydroxypurine in 
plasma were one fifth of the parent drug concentrations with wide interindividual variation. 
The formation of high concentrations of 6-methyImercapto-8-hydroxypurine in 
plasma, especially during the infusion, probably indicates another catabolic pathway of 
high-dose 6-mercaptopurine, apart from its conversion into thiouric acid. 
Introduction 
6-Mercaptopurine (6MP) is a hypoxanthine antimetabolite used in the treatment of 
acute lymphoblastic leukemia. It has no intrinsic cytotoxic activity, but is converted into 
active metabolites before it exerts its cytotoxic action. The first step in the anabolic 
pathway of 6MP is its conversion into the nucleotide, thioinosine monophosphate (Figure 
1). This compound is converted into thioguanosine monophosphate, which is cytotoxic after 
incorporation into DNA and RNA |1J, or into methylthioinosine monophosphate, which is 
an inhibitor of the purine de novo synthesis [2]. 6MP can be methylated into 6-methylmer-
captopurine (6MeMP). 6MeMP riboside (6MeMPR) is the product of the breakdown of 
methylthioinosine monophosphate or of methylation of 6MP-riboside. Xanthine oxidase (EC 
1.2.3.2), which is mainly active in the liver and kidney [3], catabolizes 6MP into thiouric 
acid (6-mercapto-2,8-dihydroxypurine). This oxidation occurs via 6-mercapto-8-hydroxypu-
rine (6M80HP) and to a lesser extent via thioxanthine (6-mercapto-2-hydroxypurine) [4]. 
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Figure 1 Metabolism of 6-mercaptopunne 
(TGN) thioguanine nucleotides, (PDNS) purine de novo synthesis, (tGMP) 6-thioguanosine 
monophosphate, (tIMP) 6-thioinosine monophosphate, (MetIMP) 6-methylthioinosine monophos­
phate For all other metabolites Me = methyl, M = mercapto, OH = hydroxy, Ρ = purine (1) 
thiopunne methyltransferase (EC 2 1 1 67), (2) xanthine oxidase (EC 12 3 2) The dotted line 
represents pathways not definitely established 
Previous studies in humans demonstrated that 6MP and thiounc acid are the major com­
pounds, and thioxanthine and 6MP riboside the minor ones, which are excreted in urine 
during 6MP administration [5-10], indicating that degradation of 6MP occurs mainly via 
xanthine oxidase. Another pathway leading to the mactivation of 6MP in humans is 
desulfuration of the drug, which probably occurs via methylthiopunnes [7] 
When treating patients with high-dose 6MP infusions we found considerable 
amounts of a hitherto unknown compound in plasma [11] After purification the compound 
was identified by HPLC and gas chromatogrhaphy-mass spectrometry (GC-MS) as 6-
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methylmercapto-8-hydroxypurine (6MeM80HP). The presence of this metabolite of 6MP in 
plasma has not been described before and may point to another catabolic pathway of high-
dose 6MP. 
Patients and Methods 
Patients 
Patients with acute lymphoblastic leukemia (n=17) were treated in our center 
according to the treatment protocol of the Dutch Childhood Leukemia Study Group (ALL 8 
Study). They received four courses with high-dose methotrexate infusion (5 g.m"2 in 24 h, 
from 0 to 24 h) followed immediately by a high-dose 6MP infusion (1300 mg.nr2 in 24 h, 
from 24 to 48 h). Plasma was sampled before and at 24, 28, 42, 48, 52 and 72 h after the 
start of the methotrexate infusion. Informed consent was obtained from the patients or their 
parents according to the guidelines of the ethical committee of our hospital. 
Materials 
Standards of 6MP, 6MP riboside, 6MeMP, 6MeMPR, thioxanthine and 
methylthioxanthine were obtained from Sigma Chemical Co, St. Louis, MO, USA. 
Thiouric acid and methylthiouric acid were synthesized as described [11]. 6M80HP, 
6MeM80HP and 6-methylsulfinyl-8-hydroxypurine were provided by Dr. Gertrude B. 
Elion, Wellcome Research Labs, Research Triangle Park, NC 27709, USA. 
Procedures 
HPLC HPLC was carried out as described [11]. In short, plasma was extracted with 
perchloric acid on ice and neutralized to pH 6-7 with K2HP04. The metabolites were 
separated by reversed phase HPLC (Supelcosil LC-18-DB, 250x4.6 mm I.D., particle size 
5 μίτι, Supelco, Bellefonte, PA, USA). The mobile phase (flow rate 1.25 ml/min) consisted 
of a gradient from 0 to 25 min of two buffers, starting with 98% buffer A (25 mmol/L 
KH2PO<) and 2% buffer В (3 volumes of 50 mmol/L KH2P04 plus 1 volume of 25% 
methanol) and changing to 20% buffer A and 80% buffer B; the latter conditions were 
maintained until 45 min after sample injection. Eluting analytes were detected a variable 
ultraviolet-visible absorbance detector (Spectra Focus 2000 HR system, Thermo Separation 
Products, Fremont, CA). For routine measurement the wavelengths were set at 290 and 
320 nm; occasionally, the spectra of the peaks were scanned between 250 and 350 nm [11]. 
GC-MS The unknown compound was collected from plasma by HPLC. To form the 
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trimethylsilyl (TMS) derivative we dissolved the isolated and lyophilized material in 50 μ ι 
of an equivolume mixture of chloroform and N,0-bis(Trimethylsilyl)trifluoroacetamide 
containing 10 mL/L trimethylchlorosilane (Pierce, Rockford, IL, USA). We carried out the 
derivatization at 60 °C for 30 min after which, we diluted the mixture with 50 /¿L of 
chloroform. The 6MeM80HP standard was trimethylsilylated by the same procedure and 
used as reference. To separate products, we used a HP5890 gas Chromatograph (Hewlett 
Packard, Amsterdam, The Netherlands) using a 25 m χ 0.32 mm (i.d.) CP-sil-8CB column 
with a film thickness of 0.12 μτη m (Chrompack, Middelburg, The Netherlands) and split 
injection. The carrier gas was helium at a column head pressure of 48.3 kPa. The oven 
temperature was programmed from 70°C to 280CC. 
The metabolite of 6MP was identified with a VG-trio-2 quadrupole mass 
spectrometer (Fisons Instruments, Cheshire, UK) in electron impact ionization mode at 70 
eV and a source temperature of 200°C. Scan measurements were performed from 40-650 
amu with a scan time of 1 sec and an inter-scan delay of 0.1 sec. Selected ion recording 
(SIR) measurements were performed at the specific ions 254 (M+ - 1TMS) and 326 (M+, 
di-TMS derivative) by a span of 0.4 amu, a dwell time of 0.08 sec and an interchannel 
delay of 0.02 sec. 
Statistics 
Statistics for 6MP and 6MeM80HP plasma concentrations were performed with the 
Software Package for the Social Sciences (SPSS). Descriptive statistics at each time point 
were calculated for each course of treatment. A paired t test (confidence interval 95%) was 
performed at each time point to compare the levels reached during successive courses. 
When the paired Τ tests did not reach significance (P<0.05), the concentrations of 6MP 
and MeM80HP reached during successive courses, were not significantly different. Then, 
we calculated the individual means of the four courses for each patient at each time point, 
from which we calculated the descriptive statistiscs for the four courses together. 
Results 
On the basis of their retention time and ultraviolet absorbance we determined that 
none of the standards described in Materials could account for the unknown peak. In 
HPLC, the unknown compound in plasma eluted at 29 min, i.e. 1.5 min before 6MeMP 
(Fig 2A). When we added 1.8 μηιοΙ/L 6MeM80HP to the plasma, the peak of the 
unidentified compound at 290 nm increased (Fig 2A). In a different mobile phase, starting 
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Figure 2 
Chromatograms at 290 nm 
of plasma sampled at 42 
h of a patient treated 
with 24 h of high-dose 
methotrexate followed 
by 24 h of high-dose 
6MP. 
1.8 /tmol/L 6MeM80HP was 
then added to the plasma 
sample. 
A: Mobile phase as 
described in Materials 
and Methods, with the 
unknown compound and 
6MeM80HP eluting at 
29.4 min and 6MeMP at 
31 min. 
В: Mobile phase as 
described in Results,
 D 
with the unknown compound s 
and 6MeM80HP eluting at E 
24 min. 
f -J 
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with 75% buffer A and 25% В changing to 25% buffer A and 75% buffer В at 25 min, the 
unknown compound eluted at 24 min, as did 6MeM80HP (Fig 2B). Moreover, the absor-
bance spectra of the unknown compound and of 6MeM80HP were identical (Fig 3). 
The derivatized form of the 6MeM80HP standard showed a peak with a retention 
time of 22.8 min by GC, the mass of which showed an abundant molecular ion at m/z 326 
(M+) and specific ions at m/z 311 (loss of CH3), m/z 254 (loss of TMS) and m/z 239 (loss 
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Figure 3 Absorbance spectrum at 250-350 nm (top) and scan at the maximum at 29 min 
(bottom) of the unidentified compound in plasma (A) and of 6MeM80HP (B). 
of TMS and CH3). The chromatogram of the isolated and derivatized unknown compound 
showed a peak with a retention time of 23.0 min by GC with a mass spectrum identical to 
that of the derivatized 6MeM80HP standard (Fig 4A). SIR measurements at the masses m/z 
326 and 254 for both compounds showed retention times of 22.8 and 23.0 min for the 
derivatized standard and the derivatized unknown compound respectively. The ratio 
between the ions was comparable (0.12 and 0.19 respectively) (Figure 4B). 
The areas under the peak of the unknown compound in the patients samples were 
registered from the chromatograms at 290 nm, the wavelength at which 6MeMP and 
6MeMPR were measured. The concentrations of the unknown compound were calculated in 
retrospect. When the unknown compound was identified we made calibration curves at 290 
nm of 6MeMP, which eluted 1.5 min after 6MeM80HP, and of 6MeM80HP. The 
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Figure 4 A: Mass spectra of the 6MeM80HP standard and the unknown compound. B: Selec­
ted ion recording (SIR) measurements of the standard 6MeM80HP and the unknown compound. 
correlation between the calibration curves of 6MeM80HP (y, dependent) and 6MeMP (χ, 
independent) was: у = 0.9468*x + 68.9 nM). The concentrations of the unknown com­
pound were first calculated with the areas of the unknown compound at 290 nm and the 
calibration curves of 6MeMP at 290 nm, which we had from all series of HPLC 
measurements. The result of this (Rl) was corrected for the difference between the two 
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calibration curves (6MeM80HP concentration = (Rl)*0.9468 +68.9 nM). 
There were no significant differences in the levels of 6MP or 6MeM80HP reached 
during the successive courses at 28, 48, 52 or 72 h (paired Τ tests, ρ values 0.159-0.994, 
15-17 pairs). The minimum, median and maximum concentrations of 6MP and 6MeM-
80HP in 17 patients during four courses are indicated in Figure 5. 6MeM80HP levels 
were about one fifth of the parent drug levels. The median interindividual variation 
coefficient during the 6MP infusion is 39% (min 6%, max 118%) for 6MeM80HP and 
28% (min 1%, max 132%) for 6MP. 6MeM80HP was not detec-table in urine, neither 
during the infusion, nor in the next 24 h. 
μητιοΙ/Ι 
24 48 72 
Figure 5. 
Minimum, median and maximum plasma concentrations of 6MeM80HP (solid line) and 6MP 
(dotted line) during four courses with high-dose methotrexate infusions (5 g.m-2 in 24 h) 
immediately followed by high-dose 6MP infusions (1300 mg.m-2 in 24 h) in 17 patients. 
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Discussion 
This study provides strong evidence for the presence of 6MeM80HP in plasma 
during and after high-dose 6MP infusions. The mass spectra of 6MeM80HP and of 6-
methylthioxanthine (6-methylmercapto-2-hydroxypurine) might be identical, but HPLC 
excluded the possibility that the unknown compound was 6-methylthioxanthine (showing a 
retention time of 18.7 min for the latter compound and different absorbance spectra). 
To our knowledge, the presence of 6MeM80HP in plasma has not been described 
before. A metabolite of 6MeMP described in urine of one patient, accounted for 0.5% of 
the excretion of orally administered 6MeMP and was probably 6MeM80HP [6]. In our 
study plasma 6MeM80HP concentrations were about one fifth of the parent drug 
concentrations, both of which displayed wide interindividual variation. For 6MeM80HP 
part of this variation may be caused by the wide interindividual variation in thiopurine 
methyltransferase (TPMT, EC 2.1.1.67) activity. TPMT shows a genetic polymorphism 
with 88.6% of the subjects demonstrating high activity and 11.1% intermediate activity. 
About one in 300 subjects has undetectable TPMT activity [12]. TPMT activity is highest 
in liver and kidney, but has been detected in all other tissues examined (erythrocytes, 
lymphocytes, thrombocytes, lymphoblasts, lung, intestine, brain and placenta) [13). 
How 6MeM80HP is formed in vivo is not known. Two metabolic routes may lead 
to the formation of this compound: methylation of 6M80HP or 8-oxidation of 6MeMP. 
Evidences exist from in vitro studies that oxidation of 6MP by xanthine oxidase 
preferentially occurs first at the 8 position and then at position 2, in contrast to hypoxan-
thine which is first oxidized on C-2 and subsequently on C-8 [4]. 6M80HP has not been 
described in vivo, which may be explained by a higher activity of xanthine oxidase towards 
6M80HP than towards 6MP [4]. We did not find 6M80HP in plasma or urine of the 17 
patients. However, plasma of two patients treated in a therapeutic window phase with one 
high-dose 6MP infusion and with the xanthine oxidase inhibitor allopurinol [14,15], 
contained a peak at 320 nm with the same retention time as 6M80HP, i.e. 1 min ± 6 sec 
before the peak of 6MP. This peak was present during and after the 6MP infusion and the 
area under the peak was 20-31% of that of 6MP in one patient (6MP steady state 57 
/imol/L) [14] and 6-11% in the other patient (6MP steady state level 35 μπιοΙ/L) [15]. We 
received the 6M80HP standard only recently from Dr. Elion. However, no more plasma 
from these two patients is available for analysis, so we can not confirm that this peak was 
actually 6M80HP. The presence of this peak in the chromatograms of plasma of two 
patients with high 6MP steady state concentrations and allopurinol treatment - the absence 
of it in all chromatograms of the 17 patients treated with high-dose 6MP without 
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allopurinol - suggest that 6M80HP can be produced in vivo and is rapidly further oxidized 
by xanthine oxidase into thiouric acid. Recently Deininger et al. demonstrated a Vmax/Km 
ratio of 16.9 for TPMT with 6M80HP as substrate (Km 96.1 ± 2.3 μΜ), whereas that 
with 6MP substrate was only 2.34 (Km 383 ± 7.0 μΜ), indicating that 6M80HP is a 
better substrate than 6MP for TPMT [16]. Thus 6MeM80HP might be produced by 
methylation of 6M80HP. On the other hand, 6MeM80HP might also be produced by 
oxidation of 6MeMP. In vitro studies have shown that the relative oxidation rate of 
6MeMP (relative to that of purine) was 15% for aldehyde oxidase (aldehyde: oxygen 
oxidoreductase purified from rabbit liver, EC 1.2.3.1) and less than 3% for xanthine 
oxidase (xanthine: oxygen oxidoreductase purified from bovine milk, EC 1.2.3.2) [17]. In 
our experience xanthine oxidase (xanthine: oxygen oxidoreductase from buttermilk; EC 
1.1.3.22, Sigma) converted only about 10% of 6MeMP into 6MeM80HP in 4 h. Studies 
showing that thiouric acid is the main catabolite of 6MP in vivo [5-8,10], as well as in 
vitro data, demonstrate that oxidation of 6MP occurs preferentially first on C-8 [4]; also, 
the Vmax/Km ratio for TPMT is higher with 6M80HP as substrate than with 6MP [16]. 
These findings suggest that 6MeM80HP may well be produced by methylation of 
6M80HP. Enzyme kinetic studies of xanthine oxidase and aldehyde oxidase (which is 
mainly active in the liver) with (methyl)thiopurine substrates are needed to elucidate the 
pathway leading to 6MeM80HP. Given the wide interindividual variation of TPMT [12], it 
is important to know whether this enzyme acts to methylate 6M80HP, which is a catabolite 
of 6MP, or 6MP, which is available for the anabolic pathway leading to cytotoxicity. 
We treated nine patients with non-Hodgkin lymphoma at diagnosis with one high-
dose 6MP infusion within a therapeutic window. Four patients received oral allopurinol and 
five did not. Plasma concentrations of 6MP, thioxanthine and 6MeMP were higher and 
those of thiouric acid lower in the allopurinol-treated patients than in who did not receive 
allopurinol [15]. The present study shows that 6MeM80HP concentrations were higher in 
the group treated with allopurinol (3.7-17 ¿imol/L) than those with no allopurinol (1.1-2.9 
μπιοΙ/L). The higher concentrations of 6MeM80HP in the allopurinol group may be the 
result of the higher concentrations of 6MP and 6MeMP in this group [15], the allopurinol 
induced inhibition of further oxidation of 6M80HP, or the involvement of xanthine oxidase 
in any further metabolism of 6MeM80HP. 
The absence of 6MeM80HP in urine of our patients might be explained by 
glucuronidation or further oxidation into 6-methylthiouric acid or 6-methylsuIfinyl-8-
hydroxypurine. 6MeM80HP glucuronide accounted for 12-20% of the administered 
6MeMP dose in urine [6]. In urine of two patients treated either orally or intravenously 
with 6-p5S]MP considerable amounts of 6-methyl-["S]-suIfinyl-8-hydroxypurine and some 
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["SJ-sulfate was excreted [7]. In a patient treated with ó-methyl-f^-MP 36% of the 
administered dose was excreted in urine as ó-methyl-pSJ-sulfinyl-S-hydroxypurine and 
27% as radioactive sulfate [6]. In humans, desulfuration of the thiopurine with formation of 
inorganic sulfate appears to occur via the methylthiopurines, which yield to a larger amount 
of sulfate than the thiopurines do [7]. Because desulfuration of 6MP is not affected by 
allopurinol [18], xanthine oxidase probably is not involved in desulfuration of the 
methylthiopurines. 
In conclusion, the present study shows that 6MeM80HP is a major metabolite of 
6MP in plasma during high-dose 6MP infusions, whereas smaller amounts of 6MeMP, 
6MeMPR and thioxanthine are produced in plasma [19]. The metabolic pathway leading to 
the formation of 6MeM80HP or the further metabolism of this catabolite is not completely 
solved. Measurement of the 8-hydroxyIated metabolites of 6MP in plasma and urine during 
high-dose 6MP infusions as well as enzyme kinetic studies for xanthine oxidase and 
aldehyde oxidase with (me-thyl)thiopurine substrates, must be performed before we can 
obtain better insight in the catabolism of 6MP and the role of TPMT in the detoxification. 
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Abstract 
1. The present study was designed to explore the catabolic pathways of 6MP and the 
contribution of the thiopurine methylation pathway to elimination of 6MP. 
Thiopurine methyltransferase shows wide interindividual variation due to a genetic 
polymorphism. 
2. Fifty-two patients with acute lymphoblastic leukemia received a methotrexate 
infusion (5 g nr2 in 24 h) immediately followed by a 6MP infusion (1300 mg m 2 in 
24 h) (four courses in eight weeks) as part of central nervous system prophylaxis. 
3. The main metabolites of 6MP in plasma (mean steady state levels (C
ss
) 14.1 μπιοί Γ' 
sem 1.0) were thiouric acid (CM 4.2 μπιοί I"1 sem 0.2) and 6-methylmercapto-8-
hydroxypurine (MeM80HP) (C
ss
 3.2 μπιοί l 1 sem 0.2). Thioxanthine, methyl-
mercaptopurine (MeMP), its riboside (MeMPR) and methylthiouric acid reached C
ss 
plasma levels less than 1 μηιοί Γ1. 
4. Thioxanthine was present in plasma of 26.9% of the patients and MeMPR levels 
were significantly lower in this group compared to the thioxanthine absent group 
(Mann Whitney U/Wilcoxon rank sum test, Ρ < 0.01 during and after the 
infusion). 
5. Urinary excretion of 6MP, thioxanthine and thiouric acid accounted for 45.5% (sem 
3.5) of the administered dose in the first 48 h. MeMPR accounted for 0.3% of the 
dose, whereas traces of MeM80HP or 6-mercaptopurine riboside were detectable in 
only a few cases. 
6. This study shows that MeM80HP is a major and MeMP and MeMPR are minor 
methylated metabolites of 6MP in plasma. They account for less than 1% of the 
administered dose in urine. In view of the role of thiopurine methyltransferase for 
the elimination of 6MP, further research is needed to elucidate the pathway leading 
to MeM80HP and to explain the relatively small amounts of methylated metabolites 
of 6MP in urine. 
Introduction 
Since 1983 prolonged infusions of 6-mercaptopurine (6MP), a hypoxanthine 
analogue, have been administered to children with malignancies [1]. A dosage of 50 mg m2 
per hour for up to 48 h can be administered safely h [2]. A non-randomized clinical trial in 
children with acute lymphoblastic leukemia (ALL) by the Pediatric Oncology Group used a 
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combination of intermediate dose methotrexate (MTX) during 24 h followed by high-dose 
6MP (HD-6MP) during 8 h, resulting in high event-free survival with few side effects 
[3,4]. Incubation of several leukemic cell lines with combinations of MTX and 6MP 
showed a synergism in the cytotoxic action of these two drugs [5-7]. Incubation of 
leukemic cells with MTX prior to incubation with 6MP, resulted in enhanced incorporation 
of 6MP into DNA and RNA, as compared to incubation with 6MP alone [5]. Based on 
these results, the Dutch Childhood Leukemia Study Group (DCLSG) started a randomized 
clinical trial in ALL (DCLSG-ALL-8 study) in 1991. Children with medium risk ALL 
received high-dose MTX infusions (HD-MTX) as part of central nervous system 
prophylaxis. After parental consent the patients were randomized for either daily oral 
administration of low dose 6MP (the common regimen) or for a HD-6MP infusion 
immediately after the MTX infusion (HD-MTX/HD-6MP). 
There are two pathways for 6MP leading to cytotoxic action. The first one leads to 
DNA damage due to the incorporation of thioguanine nucleotides into DNA [8-10]. The 
second one leads to inhibition of the purine de novo synthesis by methylthioinosine 
monophosphate (MetIMP) [9,11] (Figure 1). It has not been established as yet to what 
extent either pathway contributes to the cytotoxic action of 6MP in vivo. Studies in red 
blood cells during maintenance treatment of ALL showed that the formation of thioguanine 
nucleotides is mainly responsible for the action of 6MP [12-14], whereas other studies 
indicate that both thioguanine nucleotides and methylthioinosine nucleotides add to the 
cytotoxicity [15,16]. Methylation of 6MP and its metabolites occurs on the mercaptogroup 
(sulfur), which is attached to carbon atom 6 of the purine ring. This reaction is catalyzed 
by thiopurine methyltransferase (TPMT) [17]. TPMT shows a genetic polymorphism with 
88.6% of the population displaying high, 11.1% intermediate and 0.3% undetectable 
activity [18]. TPMT activity in red blood cells correlates with that in lymphoblasts [19], 
lymphocytes, thrombocytes [20], kidney [21] and liver [22]. Thus, TPMT catalyzes the 
methylation of thioinosine monophosphate in lymphoblasts, which may add to the cytotoxic 
action of 6MP, as well as the methylation of 6MP and its metabolites in other tissues, 
which may result in loss of cytotoxic action of the drug. 6MP is catabolized by xanthine 
oxidase into thiouric acid. Pharmacokinetic studies during HD-6MP showed that thiouric 
acid (6-mercapto-2,8-dihydroxypurine) is the main catabolite of 6MP in urine and that 6-
mercaptopurine riboside and thioxanthine (6-mercapto-2-hydroxypurine) are present to a 
lesser extent [2,23]. In these studies the methylated metabolites of 6MP were not 
investigated. 
The aim of the present study is to explore the metabolic fate of 6MP, especially 
with regard to the methylated metabolites, in plasma and urine during HD-MTX/HD-6MP 
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chemotherapy to obtain more insight into the catabolic pathways of 6MP and the 
contribution of the thiopurine methylation pathway to elimination of 6MP. 
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Figure 1 The metabolism of 6MP 
(M80HP) 6-mercapto-8-hydroxypurine; (MeM80HP) 6-methylmercapto-8-hydroxypurine; (6MP) 6-
mercaptopurine; (MeMP(R)) 6-methylmercaptopurine (riboside); (methylthiouric acid) 6-methyI-
mercapto-2,8-dihydroxypurine; (MetIMP) 6-methylthioinosine monophosphate; (PRPP) 5-phospho-
ribosylpyrophosphate; (thiouric acid) 6-mercapto-2,8-dihydroxypurine; (thioxanthine) 6-mercapto-2-
hydroxypurine; (tGMP) 6-thioguanosine monophosphate, (tIMP) 6-thioinosine mono-phosphate. 
1. TPMT 2. HGPRT; 3. xanthine oxidase; 4. purine nucleoside Phosphorylase; 5. purine 5* 
nucleotidase; 6. adenosine kinase; 7. inosine monophosphate dehydrogenase; 8. guanosine 
monophosphate synthetase; 9. guanosine monophosphate reductase. 
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Methods 
Patients 
From August 1992 till August 1995 a total of 52 patients received HD-MTX/HD-
6MP therapy in the Netherlands (DCLSG-ALL-8 protocol). Forty eight patients had 
medium risk ALL. The medium risk group includes patients who have a BFM risk factor 
above 0.8 [24], mediastinal mass, initial CNS involvement, or pre-T or T-ALL 
immunophenotype, but who lack high risk criteria: t(4;ll) or t(9;22) translocation, BCR-
ABL gene rearrangement, poor steroid response after one week prednisone monotherapy or 
acute undifferentiated leukemia. These 48 patients were randomized by the DCLSG for the 
HD-MTX/HD-6MP regimen. Four additional patients in our center also received the 
DCLSG-ALL-8 protocol with HD-MTX/HD-6MP treatment. One of them was treated for 
Τ cell malignant lymphoma and three were treated for secondary ALL or lymphoma after 
being treated for osteosarcoma, astrocytoma or hepatoblastoma. 
All patients were in complete remission after a remission induction therapy of 10 
weeks with prednisone, vincristine, daunorubicin, L-asparaginase, cyclophosphamide, 
cytarabine and oral 6MP. They had recovered from prior therapy before start of the 
treatment with four courses HD-MTX/HD-6MP in 8 weeks. MTX and 6MP were 
administered as 24 h infusions (500 mg m"2 MTX in 0.5 h plus 4500 mg m2 MTX in 23.5 
h, during the first 24 h, followed by 100 mg nr2 6MP in 0.5 h plus 1200 mg ην2 6MP in 
23.5 h, during the next 24 h). Leucovorin rescue was started at 36 h after start of HD-
MTX and was continued till MTX plasma levels were below 0.25 μπιοί Г1. To enhance 
renal excretion of MTX and 6MP, diuresis was forced with 3 1 m"2 in 24 h and the patients 
were alkalinized with 10 g m"2 NaHC03 per day. Furosemide (0.5-1 mg kg1) was 
administered intravenously 6 h after start of the MTX infusion in all patients and again 
when urinary production was less than 1200 ml m2 in 12 h. An age dependent dose of 
MTX, cytarabine and prednisolone was administered intrathecally 1.5 h after start of the 
MTX infusion. Patient or parental approval was obtained according to the guidelines of the 
ethical committees of the participating hospitals. 
Drugs 
MTX and 6MP were obtained from the hospital pharmacy. The standards of (meth-
yl)thiopurine nucleosides and bases were obtained from Sigma (St. Louis, MO, USA). 
Standards of thiouric acid and methylthiouric acid were synthesized in our laboratory 
during the study [25]. 6-Mercapto-8-hydroxypurine (M80HP), 6-methylmercapto-8-
hydroxypurine (MeM80HP) and 6-methylsulfinyl-8-hydroxypurine were provided by Dr. 
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G.B. Elion, Wellcome Research Laboratories, Research Triangle Park, NC, USA. 
Methods 
Heparinized blood was sampled and preserved with dithiothreitol to prevent 
oxidation of the thiol groups before start of the MTX infusion and 24, 28, 42, 48, 52 and 
72 h later. Blood was centrifuged and plasma was isolated within one hour after collection 
and frozen at -20° С Plasma samples from the other hospitals were sent on dry ice to our 
center in the week following a HD-MTX/HD-6MP course. 
Plasma was deproteinized with perchloric acid and the supernatant was adjusted to 
pH 6-7 with dipotassium hydrogen phosphate on ice [25]. 6MP and its metabolites, except 
methylthiouric acid, were measured with reversed phase HPLC using ultraviolet absorbance 
at 290, 320 and 342 nm [25]. An unidentified peak, which eluted close to the peak of 
methylthiouric acid, complicated the interpretation of the methylthiouric acid peak since the 
ratios between 342 nm and 320 nm and especially between 342 nm and 290 nm were often 
not identical with the ratios of the standard methylthiouric acid. Therefore, methylthiouric 
acid was measured in a few patients with the same HPLC method using photodiode array 
absorbance (Photodiode Array Detector, Waters 996, Milford, MA, USA), which identified 
methylthiouric acid by its spectrum. 
Since a previously unidentified peak in plasma [25] was identified recently by us as 
MeM80HP [26], the concentrations of this compound were calculated in retrospect. The 
concentrations were first calculated on the calibration curves of 6-methylmercaptopurine 
(MeMP), which elutes 1.5 min after MeM80HP and which has the same absorbance 
spectrum as MeM80HP. These results (Rl) were then corrected for the difference in the 
calibration curves of MeMP and MeM80HP (MeM80HP concentration = (Rl) * 0.9468 
+ 68.9 nM) [26]. 
Urine was collected and preserved with dithiothreitol during 36 courses from 11 
patients treated in our center. Only during two courses in four patients and during three 
courses in one patient could all urine be sampled without loss during the 6MP infusion and 
during the next 24 h. 
Pharmacokinetic parameters were calculated with the MW/Pharm computer program 
(Proost and Meyer, Mediware", Groningen, The Netherlands) [27]. 
Statistics 
Statistics were performed with the Statistical Package for the Social Sciences (SPSS 
Inc. Chicago, USA). Descriptive statistics were made for each course. Differences in the 
levels of 6MP and its metabolites during the successive courses per patient were estimated 
HD-6MP: metabolism and renal excretion 95 
using the paired t test (confidence interval (CI) 95%). When these differences did not reach 
significance (P<0.05), descriptive statistics of these compounds were calculated as a mean 
of the four courses. To maintain independence for this, the means of the metabolites of the 
four courses per patient were calculated first at each time point, after which the mean 
levels during the four courses of the whole group were calculated. Differences in 
metabolite levels in subgroups of the HD-MTX/HD-6MP group were estimated using the 
Mann-Whitney-U/Wilcoxon-Rank-Sum-test. 
Results 
6MP and its metabolites in plasma 
6MP, thioxanthine, thiouric acid, MeMP and MeM80HP were present during the 
6MP infusion and their levels decreased after termination of the infusion (Figure 2). In 
contrast, MeMPR levels increased slowly during the 6MP infusion and remained almost 
constant during the next 24 h (Figure 3). MeMPR levels at 72 h were significantly higher 
during the fourth course compared to the first course (paired t test, CI=-0.98- -0.20, 
P=0.03, df 32), but differences with other courses or at other time points were not signifi­
cant (paired t test, ρ 0.07-0.75). There were no significant differences in the levels of 6MP 
or its other metabolites during the successive courses. 6-Mercaptopurine riboside, M80HP, 
6-methylsulfinyl-8-hydroxypurine and methylthioxanthine were not detectable in plasma. 
The presence of thioxanthine in plasma varied among the patients. 14 Patients 
(26.9%) demonstrated thioxanthine during at least 3 of the courses, 4 patients (7.7%) 
during 2 courses and it was absent or present only during one course in the other 34 
patients (65.4%). At 42, 48, 52 and 72 h MeMPR levels of the 14 patients with measurable 
amounts of thioxanthine in plasma, were significantly lower compared to the 32 patients 
who hardly demonstrated thioxanthine (Table 1). There were no differences in the plasma 
levels of 6MP, thiouric acid, MeMP or MeM80HP among the latter two groups. 
The pharmacokinetic parameters of two patients, from whom blood was sampled 
more frequently after termination of the 6MP infusion, are shown in Table 2. 
Methylthiouric acid was measured in the plasma of two other patients. In one of them this 
compound was not detectable and in the other the levels were 0.9 μπιοί 1' and 0.5 /¿mol 1 ' 
at 48 and 52 h, respectively. 
6MP and its metabolites in urine 
In all urine samples, 6MP and thiouric acid were present in much higher amounts, 
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Figure 2 Ріаыгы concentration time curves of 6MP and its metabolites 
Means and sem (μπιοί 1 ') of four courses HD-MTX/HD-6MP of 52 patients are indicated for 6MP, 
MeMP, MeM80HP and thiounc acid Thioxanthine levels are indicated for 14 out of 52 patients, 
who demonstrated thioxanthine during at least 3 courses 
48 72 (h) 
Figure 3 Plasma concentration time curves of MeMPR 
Means and sem (/¿mol l1) are indicated of each of the four courses HD-MTX/HD-6MP of 52 
patients There was a significant difference in MeMPR levels at 72 h during the fourth course 
compared to the first course (paired t test, CI -0 98- -0 20, P=0 03, df 32) 
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Table 1 MeMPR levels (μπιοί Γ1) in plasma (mean (sem)) are higher in thioxanthine absent 
patients as in thioxanthine present patients. 
Time 
(h) 
28 
42 
48 
52 
72 
Thioxanthine 
(n = 14) 
0.01 (0.01) 
0.23(0.11) 
0.67(0.19) 
0.32 (0.06) 
0.64(0.16) 
present patients Thioxanthine absent 
(n=34) 
0.02 (0.01) 
0.45 (0.07) 
0.98(0.16) 
1.17(0.27) 
1.01 (0.10) 
patients 
p A 
not significant 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
Ρ value of Mann-Whitney-U/Wilcoxon-Rank-Sum-test. 
compared to thioxanthine and MeMPR. In only a few samples were traces of MeM80HP 
or 6-mercaptopurine riboside detectable. During eleven courses in five patients with 
complete 48 h urine, 45.5% (sem 3.5) of the administered dose was excreted as 6MP, 
thiouric acid and thioxanthine and 0.3% (sem 0.1) as MeMPR (Table 3). 
Patients with measurable amounts of thioxanthine in plasma had higher 
concentrations of 6MP, thiouric acid and thioxanthine in urine (expressed per mmol 
creatinine), compared to patients with undetectable thioxanthine in plasma (data not shown). 
Since 48 h urine collections were not complete during 25 of the 36 courses, these 
differences could not be tested for significance. One of the five patients from whom 
complete 48 h urine was collected, demonstrated thioxanthine in plasma during the four 
courses. The excreted amount of thioxanthine of this patient was the highest (1.6 and 2.3% 
of the administered dose during two courses), when compared to the excretion of the four 
thioxanthine absent patients (0.1-0.6% during 11 courses). 
Figure 4 shows the plasma concentration (4A) and the renal excretion rate (4B) of 
6MP and its metabolites during one HD-MTX/HD-6MP course in one particular patient, 
from whom fractionated urine samples of 5-7 h were collected. The renal clearance of 
6MP, thiouric acid and thioxanthine correlated with the renal creatinine clearance, although 
renal creatinine clearance differed greatly between the 5-7 h time periods of urine sampling 
(Figure 5). The correlation between renal creatinine clearance and renal clearance of 6MP 
and thiouric acid was also found in a second patient (r2 0.91 and 0.82 respectively; renal 
creatinine clearance 45-170 ml min'1). These correlations were not found in a third patient 
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in whom renal creatinine clearance was in the physiological range (Table 4) In urine of the 
latter two patients methylthiounc acid was measured In one patient methylthiounc acid 
accounted for 0 4 % (not detectable in plasma) and in the other for 9 7% of the 
administered dose (plasma levels 0 9 and 0 5 μπιοί 1 ' at 48 and 52 h, respectively, 
correlation coefficient of renal creatinine clearance with renal clearance of methylthiounc 
acid 0 70) 
Table 2 Pharmacokinetic parameters of 24 h intravenous 6MP (Π00 mg πΓ) after 24 h 
intravenous MTX (5 g m2) 
Gender 
Age (y) 
Dose (mg) 
6MP 
C
ss
 (μπιοί 1 ') 
AUC (h μπιοί 1 ') 
t., (h) 
MRT (h) 
Clearance (1 h ') 
Volume of distribution (1) 
MeM80HP 
С^ОлпоІІ
1) 
AUC (h μπιοί 1 ') 
t* (h) 
MRT (h) 
MeMP 
C
ss
 Otmol 1 ') 
AUC (h μπιοί 1 ') 
t., (h) 
MRT (h) 
Thiouric acid 
C 5 S (μΠ10ΐ 1 ' ) 
AUC (h μπιοί 1 ') 
t¿ (h) 
MRT (h) 
female 
5 2/12 
975 
7 3 
166 
0 7 
10 
38 6 
38 3 
2 0 
44 
8 1 
11 7 
0 3 
10 
0 6 
0 9 
not done 
male 
7 6/12 
1085 
13 7 
385 
0 7 
1 0 
18 5 
19 0 
7.5 
236 
4 8 
6 9 
1 0 
28 
1 5 
2 2 
4 1 
63 
15 
2.2 
С
а
= plasma concentration during steady state, AUC = area under the concentration time curve, t
w 
= half-life, MRT = mean residence time 
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Table 3 Excretion of 6MP and its metabolites in urine, expressed as percentage of the 
administered dose, during HD-MTX/HD-6MP courses. 
6MP 
Thiouric acid 
Thioxanthine 
MeMPR 
mean (sem) 
% 
27..3 (2.1) 
17.6 (2.3) 
0.6 (0.2) 
0.3 (0.1) 
Urine was collected during the 24 h 
HD-6MP infusion and the next 24 h. 
Mean and sem are indicated of two 
courses in four patients and three 
courses in one patient. 
Table 4 Renal clearances (ml min'1 per 1.73 m2) of 6MP and its metabolites during one HD-
MTX/HD-6MP course. 
Time 
(h) 
0-7 
7-12 
12-19 
19-24 
creatinine 
125 
114 
129 
120 
6MP th 
481 
455 
590 
441 
iiounc aci 
534 
511 
728 
625 
methylthiouric acid 
1386 
1681 
755 
Mean (sem) 122 (3) 492 (34) 600 (49) 1281 (267) 
Time in hours after start of HD-6MP. * Renal clearance could not be calculated, since plasma 
levels were undetectable. The same was true for thioxanthine. 
Discussion 
6MP and its metabolites in plasma 
We investigated the metabolic fate of 6MP in plasma and urine during HD-
MTX/HD-6MP courses to gain more insight into the catabolism of 6MP and the contribu­
tion of the thiopurine methylation pathway to elimination of 6MP. The mean steady state 
levels of 6MP in plasma (C
ss
) were 14.1 μπιοί Γ1 (sem 1.0) in our study. In other studies, 
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levels of 6MP in plasma (Css) were 14.1 ¿tmol Γ1 (sem 1.0) in our study. In other studies, 
also using 50 mg m2 6MP per hour, mean 6MP C!S levels were 4.8 and 6.9 ftmol l"
1
 [2,28], 
with peak plasma levels up to 40 μιηοΐ Γ' [29]. The higher levels in our study may be 
caused by the use of a bolus dose of 100 mg ητ2 6MP, by the immediate preservation of 
blood with dithiothreitol, preventing oxidation of 6MP, and by the HD-MTX pretreatment. 
In vitro, MTX inhibits human xanthine oxidase activity [30,31]. In vivo, the concurrent 
administration of oral low dose MTX and 6MP during the maintenance treatment of ALL, 
resulted in significant 
increases in the AUC (31%) and in the peak plasma concentration (26%) of 6MP compared 
to the administration of 6MP alone [32], suggesting an inhibition of the catabolism of 6MP 
by MTX. 
The main catabolite of 6MP in plasma via the xanthine oxidase pathway was 
thiouric acid (mean C,
s
 4.2 μπιοί l"1 sem 0.2). In vitro, the oxidation of 6MP occurs 
preferentially first on carbon atom 8 (M80HP) and then on carbon atom 2 (thiouric acid), 
but the formation of thiouric acid also proceeds via thioxanthine (oxidation first on carbon 
atom 2 and then on 8) [33]. After administration of HD-6MP in humans, thioxanthine has 
been identified in urine [2], but to our knowledge M80HP has not yet been found. In the 
present study M80HP was neither detectable in plasma nor in urine and thioxanthine was 
present in only 26.9% of the plasma samples and in all urine samples. Thus the 2-oxidation 
shows a phenotype, whereas the product of the 8-oxidation is further oxidized rapidly into 
thiouric acid. The oxidation rate of xanthine oxidase with 6MP as substrate is lower than 
with M80HP [33,34] or thioxanthine [33] as substrates, but Km and Vmax values are not 
given in these studies. Therefore M80HP and thioxanthine probably remain undetectable in 
plasma because they are rapidly oxidized by xanthine oxidase into thiouric acid. The fact 
that M80HP was undetectable in all patients, whereas thioxanthine was detectable in 
26.9%, may be caused by different affinity of these compounds for methylation by TPMT. 
Recently it was demonstrated that TPMT with M80HP as substrate, has a Vmax/Km ratio 
of 16.9 and with 6MP as substrate only 2.3, whereas thioxanthine and thiouric acid are 
potent inhibitors of TPMT [35]. This indicates that M80HP is a better substrate for TPMT 
than 6MP, and that thioxanthine and thiouric acid can not be methylated by TPMT. 
MeM80HP was recently identified as a metabolite of 6MP in plasma [26] and is a 
major metabolite of 6MP in plasma (C!5 3.2 μπιοί 1 ' sem 0.2). It is not exactly known 
along which pathway MeM80HP is formed. It is either produced by methylation of 
M80HP as described above, or by 8-oxidation of MeMP. MeMP is the product of direct 
methylation of 6MP by TPMT. The affinity of TPMT for 6MP is much lower than for 
M80HP [35]. In our study, mean MeMP C
ss
 levels were only 0.6 /¿mol 1' (sem 0.03). 
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MeMP can be oxidized by xanthine oxidase or aldehyde oxidase, but again, Vmax and Km 
values were not given [34] Since it has been demonstrated by others [2,23] and in the 
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Figure 4 Plasma concentration time curves (A, top) and renal excretion rate time profiles (B, 
bottom) of 6MP and its metabolites during one exemplary HD-MTX/HD-6MP course Renal 
excretion rate of 6MP and its metabolites during HD-6MP and the next 24 h Cumulative excreted 
amounts are expressed as percentage of the administered dose Urinary pH was between 8 5 and 9 0 
in all samples 
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Figure 5 Renal clearance of 6MP and its metabolites during one HD-MTX/HD-6MP course 
correlate with the renal creatinine clearance. Average renal clearance of 6MP and its metabolites 
during one exemplary HD-MTX/HD-6MP course and the next 24 h. Renal clearance over 48 h: 
6MP 218 ml min1, thiouric acid 305 ml min1, thioxanthine 64 ml min"1, MeMPR 31 ml min"1, 
creatinine 98 ml min"1. 
present study, that thiouric acid is the main catabolite of 6MP, and since it has been shown 
that oxidation of 6MP by xanthine oxidase preferentially occurs via M80HP [33], which is 
also a good substrate for TPMT [35], it may well be that MeM80HP is produced in vivo 
by methylation of M80HP. Elucidation of this pathway may be important to revealing the 
contribution of TPMT to the elimination of 6MP. M80HP is a catabolite of 6MP and 
further methylation or oxidation of this compound will not influence the therapeutic effect 
of 6MP. On the other hand, direct methylation of 6MP into MeMP results in decreased 
availability of 6MP, which is, in contrast to M80HP and MeMP, a substrate for the 
anabolic pathway leading to cytotoxic action. 
Renal excretion 
6MP and its metabolites are excreted by the kidneys [36]. Figure 5 demonstrates 
that the excretion of 6MP, thiouric acid and thioxanthine is correlated with renal function. 
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There was a wide variation in renal creatinine clearance over the 48 h period, due to the 
non-physiological circumstances of hyperhydration, alkalinization, HD-MTX/HD-6MP 
treatment and furosemide administration, the latter inhibiting renal reabsorption. The renal 
clearance of MeMPR was not correlated with renal function, probably because MeMPR 
plasma levels reached a steady state only after termination of the 6MP infusion. Since the 
renal clearances of 6MP, thioxanthine and thiouric acid exceed the creatinine renal 
clearance, these compounds are probably excreted by glomerular filtration and active 
secretion. In plasma MeM80HP was a major and MeMP a minor metabolite, but only 
traces of MeM80HP were detectable in the urine of a few patients. The absence or 
presence of very small amounts of MeMP and MeM80HP in urine might be the result of 
active tubular reabsorption, desulfuraron, oxidation or glucuronidation. Desulfuraron 
seems to occur via MeMP as demonstrated earlier [37,38]. Oxidation of MeMP [34] has 
been described above. MeM80HP can be further oxidized in man into 6-methylsulfinyl-8-
hydroxypurine, which was found in urine after oral or intravenous administration of 6MP 
[37], but not in our study. МеМвОНР can also be oxidized into methylthiouric acid, which 
was found in very small amounts in urine after oral administration of MeMP [39]. 
Glucuronidation of MeM80HP can result in an extremely stable linkage of glucuronic acid 
to the N7 or N9 of the purine ring [37]. The excretion of MeM80HP glucuronide in urine 
of patients treated with MeMP accounted for 11-20 % of the administered dose [39]. 
In our study the methylated metabolites of 6MP in urine, MeMPR and MeM80HP, 
accounted for less than 1 % of the administered high dose during the first 48 h. In order to 
quantitate the contribution of the thiopurine methylation pathway to elimination of 6MP 
further, it would be worthwhile to measure methylthiouric acid and to develop methods to 
determine the amount of glucuronidation and desulfuration of 6MP and its metabolites. 
MeMPR and anabolism of 6MP 
The appearance of MeMPR in plasma, with increasing levels during the infusion 
and almost constant levels in the next 24 h, differs from that of 6MP and the other 
metabolites in plasma (Figures 2,3). The appearance of MeMPR in plasma closely 
resembles that of MetIMP in peripheral blood mononuclear cells and red blood cells 
[40,41]. MeMPR levels at 72 h were significantly higher during the fourth course 
compared to the first. In the same way, MetIMP levels in peripheral blood mononuclear 
cells of patients treated with four HD-MTX/ HD-6MP courses were significantly higher 
during each successive course compared to the first one [40]. These results suggest a 
relation between the appearance of MeMPR in plasma and the formation of MetIMP 
intracellularly. 
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Levels of MeMPR, the only anabolic metabolite of 6MP detectable in plasma, were 
significantly lower in the thioxanthine present group compared to the thioxanthine absent 
group. These data suggest that the catabolic pathway, catalyzed by xanthine oxidase, is 
relatively more predominant than the anabolic pathway in the thioxanthine present group 
compared to the thioxanthine absent group. Evidence for this hypothesis could be obtained 
from complete urine data in more patients, to quantitate the catabolic pathway, and from 
complete intracellular data, to quantitate the anabolic pathway. Increased inhibition of 
xanthine oxidase, as a result of delayed MTX excretion, might be another explanation for 
the presence of thioxanthine in a subgroup. However, the levels of xanthine were not 
increased in the thioxanthine present group as compared to the thioxanthine absent group 
(data not shown), which makes this explanation less likely. MTX plasma levels were 
available from the patients treated in our center. There was no indication that delayed MTX 
excretion was related to the presence of thioxanthine in plasma. 
This study shows that MeM80HP is a major and MeMP and MeMPR are minor 
methylated metabolites of 6MP in plasma during HD-MTX/HD-6MP courses and that they 
account for less than 1 % of the administered dose in urine. Further quantitation of the 
contribution of the thiopurine methylation pathway to elimination of 6MP may be achieved 
by measurement of methylthiouric acid and by investigation of the degree of 
glucuronidation and desulfuration of 6MP and its metabolites. Elucidation of the pathway 
leading to the formation of MeM80HP may be relevant in view of the contribution of 
TPMT to elimination of 6MP. The observed differences in thioxanthine and MeMPR levels 
make it worthwhile to investigate whether thioxanthine in plasma reflects the degree of 
elimination of 6MP by xanthine oxidase and whether MeMPR reflects the degree of 
anabolism of 6MP. 
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Abstract 
Methotrexate (MTX) and 6-mercaptopurine (6MP) demonstrate a synergism in the 
cytotoxic action in leukemia cell lines. Based on these results, the Dutch Childhood 
Leukemia Study Group started a randomized clinical trial in acute lymphoblastic leukemia 
in 1991. All patients received four courses of high-dose MTX infusions (5 g/m2 in 24 h) in 
eight weeks. They were randomized for the administration of either low dose oral 6MP (25 
mg/m2 daily during eight weeks) or four times high-dose intravenous 6MP (1300 mg/m2 in 
24 h, immediately after the MTX infusion). We investigated the methylthioino-sine 
nucleotides (MeTIN) and thioguanine nucleotides (TGN) in RBC or peripheral mono­
nuclear cells (pMNC) of 17 patients treated with oral 6MP and 29 patients treated with 
intravenous 6MP. 
In the oral group TGN were the main metabolites and MeTIN remained 
undetectable. At the start of the first two courses tGTP levels were significantly higher in 
the oral group (Mann-Whitney-U/Wilcoxon-Rank-Sum-Test, Ρ <0.01). In the intravenous 
group MeTIN levels (median 52 nmol/109 RBC, range 6-122) were much higher as 
compared to TGN levels (median 333 pmol/10' RBC, range 162-741). In RBC, methylthio-
IMP (MetIMP) and thio-GTP (tGTP) accounted for 60-70% of the total MeTIN pool and 
TGN pool, respectively. 
MetIMP in pMNC and MeTIN in RBC, at 24 h after termination of the 6MP 
infusion, were significantly higher during the four successive courses (paired t test, 
Ρ<0.05), whereas TGN levels remained comparable with previous courses. 
In vitro, TGN contribute to the cytotoxicity by incorporation into DNA and RNA, 
whereas MetIMP acts by inhibition of the purine de novo synthesis. It is important to 
elucidate whether different pathways, which are enhanced by daily oral administration of 
low-dose 6MP (formation of TGN) or intravenous administration of high-dose 6MP 
(formation of MeTIN), contribute to the cytotoxic action of 6MP in vivo as well. 
Introduction 
Methotrexate (MTX) and 6-mercaptopurine (6MP) have been used in the treatment 
of acute lymphoblastic leukemia (ALL) for many years. Incubations of several ALL cell 
lines with combinations of MTX and 6MP show a dose-, time- and sequence dependent 
synergistic effect on cell growth and viability [1]. Incubation of ALL cell lines with MTX 
prior to incubation with 6MP, results in enhanced incorporation of 6MP into DNA and 
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Figure 1 The metabolism of 6MP 
6MP 6-mercaptopunne, MeMP(R) 6-methylmercaptopunne (riboside), (Me)M80HP 6-(methyl)-
mercapto-8-hydroxypunne, MetIMP (MetlDP, MetlTP) 6-methylthioinosine mono- (di-.tn-) phos-
phate, tGMP (tGDP, tGTP) 6-thioguanosine mono- (di-,tn-) phosphate, tIMP 6-thioinosine mono-
phosphate, PRPP 5-phosphonbosylpyrophosphate, 1 hypoxanthine guanine phosphonbosyltrans-
terase, 2 purine nucleoside Phosphorylase, 3 purine 5' nucleotidase, 4 adenosine kinase, 5 
thiopunne methyltransferase, 6 inosine monophosphate dehydrogenase, 7 guanosine monophos-
phate synthetase, 8 guanosine monophosphate reductase, 9 xanthine oxidase, 10 guanase 
RNA, as compared to incubation with 6MP alone [2]. The biochemical basis for the 
synergism between MTX and 6MP lies in the increased availability of 5-phosphonbosyl-
pyrophosphate (PRPP) after pretreatment with MTX. MTX inhibits two folate dependent 
enzymes in the purine de novo synthesis (PDNS), resulting in an increase of the PRPP pool 
[1] PRPP is an essential co-substrate in the first step of the anabolic pathway of 6MP 
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(Figure 1). Thus, MTX enhances the anabolic pathway of 6MP. 
In the early sixties, the administration of combination therapy of MTX and 6MP 
resulted in improved treatment outcome in ALL, compared to monotherapy of each drug 
[3]. Recent clinical trials of the Pediatric Oncology Group in ALL with intermediate-dose 
intravenous MTX (1 g/m2 in 24 h) followed by high-dose intravenous 6MP (1 g/m2 in 8 h), 
showed high event-free survival [4,5]. The benefit of sequential administration of 
intravenous MTX and 6MP, compared to conventional administration of intravenous MTX 
and daily oral 6MP, could not be evaluated in these non-randomized trials. In a phase 1 
study [6] patients with pediatric malignancies were treated with low-dose intravenous MTX 
(30 mg/m2 in 24 h) followed by escalating doses of intravenous 6-thioguanine (150-375 
mg/m2 in 2 h). The PRPP levels in lymphoblasts and mononuclear cells increased twofold 
to threefold after 24 h low-dose intravenous MTX. This indicates that the desired 
biochemical modulation by MTX can be achieved in vivo. 
Based on the in vitro results showing synergism between MTX and 6MP in ALL 
cell lines, the Dutch Childhood Leukemia Study Group (DCLSG) started a randomized 
clinical trial in ALL (DCLSG-ALL-8 study) in 1991. During the treatment for prevention 
of central nervous system relapse with high-dose MTX infusions (HD-MTX), the patients 
were randomized for either daily oral administration of low dose 6MP (the common 
regimen) or for a HD-6MP infusion immediately after the MTX infusion (HD-MTX/HD-
6MP). The aim of the present study was to obtain more insight in the anabolic pathways of 
6MP in peripheral blood mononuclear cells (pMNC) and RBC during courses with HD-
MTX in combination with low dose oral 6MP or high-dose intravenous 6MP. 
Patients and Methods 
Patients 
From August 1992 to January 1996 46 patients were studied. All patients, except 
four, had medium risk ALL. Inclusion criteria for the medium risk group were a risk factor 
above 0.8 (based on initial peripheral blood blast count and hepatosplenomegaly), 
mediastinal mass, initial central nervous system involvement, pre-T or T-ALL 
immunophenotype, without the presence of high risk criteria, as t(4;ll) or t(9;22) 
translocation, BCR-ABL gene rearrangement, poor steroid response after one week 
prednisone monotherapy or acute undifferentiated leukemia by immunophenotype. Four 
patients received the DCLSG-ALL-8 protocol with HD-MTX/HD-6MP treatment without 
randomization in our center, the Pediatric Oncology Center/South-East Netherlands (РОС-
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SEN). One of these patients was treated for Τ cell lymphoma and three were treated for 
ALL or lymphoma as a second malignancy after osteosarcoma, astrocytoma or hepato­
blastoma. 
All patients were treated according to the DCLSG-ALL-8 protocol, which is very 
similar to the German Berlin-Frankfurt-Münster 90 (BFM-90) trial. They were in complete 
remission after a remission induction therapy of 10 weeks and had recovered from prior 
treatment. The treatment for prevention of CNS relapse consisted of four courses with 
intravenous HD-MTX (500 mg/m2 MTX in 0.5 h plus 4500 mg/m2 MTX in 23.5 h) and 
intrathecal triple therapy in eight weeks [7]. Leucovorin rescue was given at 36 h after start 
of HD-MTX and continued every 6 hours till MTX plasma levels were below 0.25 μΜ. 
The patients were randomized by the DCLSG for the administration of 6MP. One group 
received 6MP orally during eight weeks (25 mg/m2 daily), as in earlier BFM studies [7]. 
Patients in the oral group started with 6MP intake seven days before start of the first MTX 
infusion. The other group received 6MP intravenously (100 mg/m2 6MP in 0.5 h plus 1200 
mg/m2 6MP in 23.5 h immediately after the MTX infusion). If necessary, RBC transfusions 
were given between two courses. As described previously, there was no clear decrease in 
MeTIN levels in RBC of the intravenous group when a RBC transfusion was given in the 
week between two courses [8]. 
In РОС-SEN, seventeen patients treated in the oral group and eighteen patients 
treated in the HD-MTX/HD-6MP group were studied. In addition, RBC from eleven 
patients in the HD-MTX/HD-6MP group treated in other pediatric oncology centers in the 
Netherlands were sent to РОС-SEN. Patients or parental approval was obtained according 
to the guidelines of the ethical committees of all participating hospitals. 
Methods 
Blood was sampled before start of the MTX infusion and 24, 48, and 72 h later, in 
РОС-SEN also 28 and 52 h later. pMNC were isolated from defibrinated blood and RBC 
from heparinized blood, which was preserved with dithiothreitol to prevent oxidation of the 
thiol groups [9]. RBC samples from the other hospitals were sent on dry ice to POC-SEN 
in the week following a HD-MTX/HD-6MP course. The methods used for measurement of 
(methyl)thiopurine nucleotides have been described [9]. Briefly, pMNC and RBC were 
deproteinized with perchloric acid and the supernatants were neutralized with K2HPO„. The 
nucleotides were separated as mono-, di- and triphosphate nucleotides by anion-exchange 
chromatography and detected using UV absorbance at 290 nm (detection limit 13 pmol per 
100 μ\ injection) for methylthioinosine nucleotides (MeTIN) and at 254 nm for endogenous 
nucleotides. Measurement of tIMP and thioguanine nucleotides (TGN) in pMNC occurred 
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using UV absorbance at 320 nm (detection limits 11 and 38 pmol per injection for tIMP 
and tGMP respectively). Extraction of TGN from RBC was performed with EDTA, 
methanol and methylene chloride. TGN were oxidized with potassium permanganate and 
detected using fluorescence absorbance (λ,„=329 nm, λ
αη
=410 nm, detection limit 1.5-3.5 
pmol per injection) [9]. Measurement of separate mono-, di- and triphosphate nucleotides is 
less sensitive for total (Me)TIN or TGN pools, compared to measuring the bases, 6-
(methyl)mercaptopurine or 6-thioguanine, after hydrolysis of the nucleotides. However, the 
separate measurements of the nucleotides as nucleotides gives a better picture of the 
metabolic pathways of 6MP. 
Statistics 
Statistics were performed with the Statistical Package for the Social Sciences (SPSS, 
Chicago, USA). Descriptive statistics were made for each course. Differences in nucleotide 
levels during successive courses were estimated using the paired t test (confidence interval 
95%). When these differences did not reach significance (P<0.05), descriptive statistics of 
these compounds were calculated as a mean of the four courses. To maintain independence, 
the means of the metabolites of the four courses per patient were calculated first at each 
time point, after which the mean levels of the whole group were calculated. Differences in 
metabolite levels between groups were estimated using the Mann-Whitney-U/Wilcoxon-
Rank-Sum-test. 
Results 
pMNC 
In pMNC of 12 patient studied in the intravenous 6MP group methylthioinosine 
monophosphate (MetIMP) levels increased slowly during the 6MP infusion and did not 
change substantially during the next 24 h (Figure 2). MetIMP levels at 72 h of the first 
course were significantly lower compared to those of the third and fourth course (paired t 
test, P=0.08 for course l->2, P=0.02 for course l ->3 and P=0.01 for course l->4) 
There was no MetIMP present at the start of the next course. None of the other 
(methyl)thiopurine nucleotides were detectable in pMNC of this group. In pMNC of 10 
patients studied in the oral 6MP group, no of (methyl)thiopurine nucleotides were 
detectable. The endogenous purine and pyrimidine nucleotide levels in both groups were in 
the normal range [10] and remained constant during the MTX or 6MP infusion (data not 
shown). 
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Figure 2 MetIMP levels in pMNC (pmol/10* pMNC) of 12 patients during four courses HD-
MTX/HD-6MP.The mean and sem are indicated for each course. 
RBC 
MeTIN levels in RBC of 20 patients studied in the intravenous 6MP group are 
shown in Figure 3. MetIMP levels increased during as well as after the 6MP infusion. At 
48 and 72 h they were significantly higher during the fourth course compared to the first or 
second course (paired t test, all Ρ values < 0.05). At the start of the next course there was 
little or no MetIMP detectable in RBC. MetlDP levels increased slightly after termination 
of the 6MP infusion. There were no significant differences in MetlDP levels between the 
courses (Figure ЗА). MetlTP levels increased especially after termination of the 6MP 
infusion (Figure 3B). At 72 h they were significantly higher during each course compared 
to the previous course (paired t test, all Ρ values <0.05). At the start of the next course 
MetlDP and MetlTP were still present in RBC. 
TGN levels in RBC of the intravenous 6MP group were much lower than MeTIN 
levels (Figure 4). tGMP levels at 0, 24 and 72 h were significantly higher during the fourth 
course compared to those of the first course (paired / test, all Ρ values < 0.02) and during 
the third or fourth course compared to the second (all Ρ values < 0.05). tGDP levels 
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increased slightly during the 6MP infusion and did not differ significantly between the 
courses (Figure 4B). tGTP levels increased rapidly during the 6MP infusion and remained 
rather constant after termination of it. At all time points tGTP levels were higher during 
the fourth course compared to the first one (paired t test, Ρ values < 0.05). Only at 0 and 
24 h, but not at 48 and 72 h, tGTP levels were significantly higher during the third and 
fourth course compared to those of the second one (paired t test, Ρ values < 0.02). 
At 72 h there was no correlation (r=0.19) between total MeTIN (median 52 
nmol/109 RBC, range 6-122) and total TGN levels (median 333 pmol/109 RBC, range 162-
741). 
In RBC of 6 patients studied in the oral 6MP group, MeTIN were not detectable 
during any of the four courses. TGN levels were detectable at the start of the first MTX 
course, seven days after start of 6MP intake. They remained constant at the various time-
points during a course. No significant differences were observed in tGMP (mean 23.9 (sem 
1.3) pmol/109 RBC) and tGDP (mean 25.4 (sem 3.2) pmol/10' RBC) levels between the 
four courses. tGTP levels were significantly lower during the fourth course (48.6 (sem 3.8) 
pmol/109 RBC) compared to the first course (68.2 (sem 6.3) pmol/109 RBC) (paired t test, 
Ρ 0.000). 
tGMP and tGTP levels were significantly higher in RBC of patients receiving daily 
oral low dose 6MP, compared to patients in the intravenous group at 0 and 24 h of the first 
two courses (Mann-Whitney-U/Wilcoxon-Rank-Sum-test, Ρ values for tGMP < 0.05 and 
for tGTP <0.01). There were no differences in tGDP levels between these groups. 
(Methyl)thiopurine nucleotides and thioxanthine 
Thioxanthine is an intermediate in the conversion of 6MP into thiouric acid. In 
plasma of 26.9% of the patients we found thioxanthine during at least three out of four 
HD-MTX/HD-6MP courses. These patients had significantly lower plasma levels of 6-
methylmercaptopurine riboside (MeMPR) at 42, 48, 52 and 72 h, compared to those who 
did not have thioxanthine in plasma during three or four courses of HD-MTX/HD-6MP 
[11]. 
During the last three courses, total TGN, tGMP and tGDP levels in RBC were 
significantly lower at 0 and 24 h in the thioxanthine present group compared to the 
thioxanthine absent group (Mann-Whitney U/Wilcoxon-Rank-Sum-test, Ρ values: <0.01 
for TGN and <0.05 for tGMP and tGDP). TGDP levels were significantly lower at 48 and 
72 h of all four courses in the thioxanthine present group (Mann-Whitney U/Wilcoxon-
Rank-Sum-test, Ρ < 0.001). Total TGN, tGMP or tGTP levels were not significantly 
different. There were no differences in MeTIN levels, in RBC or pMNC, at any time. 
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Discussion 
6MP is a prodrug and has to be converted into anabolic metabolites to become 
cytotoxic (Figure 1). Two cytotoxic pathways of 6MP are known. First, the incorporation 
of TGN into DNA and RNA leads to cytotoxicity [12]. Second, MetIMP is an inhibitor of 
the PDNS, which leads to decreased DNA and RNA synthesis [13]. It is not exactly known 
whether both pathways contribute to the cytotoxic action of 6MP in vivo. Studies in 
patients on maintenance treatment for ALL with daily oral 6MP (75 mg/m2) by Lennard et 
al., showed a positive correlation between high TGN levels in RBC and high event free 
survival [14-16]. These data suggest that TGN are responsible for the action of 6MP, but 
the results could not be confirmed by another study [17]. In these studies [14-17], data on 
correlations between MeTIN levels in RBC and event free survival lack. Preliminary 
results of a German study during maintenance therapy of ALL show comparable toxicity in 
patients treated with 6MP or 6-thioguanine, the latter being directly converted into TGN. 
Interestingly, the patients treated with 6MP reached five times lower TGN levels in RBC as 
compared to the patients treated with 6-thioguanine [18]. These data suggest that TGN 
alone are not responsible for the cytotoxic action of 6MP. 
The present study provides insight into the production of separate intracellular 
nucleotides derived from 6MP which are produced in vivo. In RBC, tGMP is rapidly 
further phosphorylated into tGTP. tGTP accounts for 60-70% of total TGN in RBC, which 
was also found by Zimm et al. [19]. MetIMP is the main MeTIN and accounts for 60-70% 
of the total MeTIN pool in RBC. 
Differences between the oral and intravenous 6MP group 
With daily oral administration of low dose 6MP, TGN are the main metabolites in 
RBC, whereas with high-dose intravenous administration, MeTIN levels are the main 
metabolites. At the start of the first course patients in the oral group have already TGN in 
RBC, since these patients received 6MP already for seven days. At the end of the first 
course (at 72 h) TGN levels are higher in the intravenous group. Since the half-life-time of 
TGN in RBC is 3.6 (sem 0.4) days [19], TGN levels are probably higher in the intravenous 
group in the week between two courses. 
Striking differences between the oral and intravenous group are found with respect 
to MeTIN levels in pMNC and RBC. The absence of detectable amounts of MeTIN in the 
oral group is probably due to the low dose of 6MP, which is administered during eight 
weeks (25 mg instead of 50-75 mg, which is the standard dose during two years of 
maintenance treatment). In RBC of the intravenous group, the MeTIN levels at 72 h are 
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comparable to one third of the adenine nucleotide pool, which is by far the largest purine 
pool in RBC [10]. Median MeTIN levels at 72 h are ten times higher in the intravenous 
group, when compared to MeTIN levels reached during continuous maintenance therapy 
with daily oral 75 mg/m2 6MP (median 5.2 nmol/10' RBC, range 0.3-27 [20] ). In 
contrast, TGN levels at 72 h in the intravenous group are lower as compared to those 
reached during maintenance therapy (median 402 pmol/109 RBC, range 173-1516 [20]). 
Thus, to reach and maintain high TGN levels in RBC daily administration of 6MP is 
crucial, whereas the formation of MeTIN is greatly advanced by high-dose intravenous 
administration. So, it is extremely important to elucidate whether both formation of TGN 
and MeTIN contribute to the cytotoxic action of 6MP in vivo. 
Differences between the courses 
tGTP levels in RBC of the oral group are significantly lower during the last course 
compared to the previous courses. This may be due RBC transfusion or treatment delay for 
toxicity. 6MP intake is discontinued when the next course is postponed. However, the 
decrease in tGTP levels could not be ascribed to these factors in all patients (data not 
shown). 
After termination of the 6MP infusion mean MeTIN levels increase further during 
the next 24 h, whereas those of TGN remain rather constant. MetIMP as well as MetlTP 
levels were significantly higher at 72 h during the four successive courses, but there was no 
greater production of tGTP during the 6MP infusion and the next 24 h. These data suggest 
that the capacity of the methylation pathway is not maximized at this time-point, whereas 
the formation of TGN in RBC is maximized. 
The increasing levels of MeTIN in pMNC [21] and RBC and the increase of 
MeMPR in plasma [11] during successive courses, together with the constant TGN levels in 
RBC, may indicate an induction of thiopurine methyltransferase (TPMT) activity by HD-
6MP [21]. The molecular basis of TPMT induction is unknown, but it is clear that an 
increase in TPMT activity in RBC occurs during the treatment for ALL [14,21-23]. 
Anabolic and catabolic pathway of 6MP 
6MP is catabolized by xanthine oxidase into thiouric acid. This reaction proceeds 
via thioxanthine or 6-mercapto-8-hydroxypurine, the latter being the favorite intermediate 
in vitro [24]. As mentioned, thioxanthine is present in the plasma of 26.9% of patients 
treated with HD-MTX/HD-6MP, whereas 6-mercapto-8-hydroxypurine is not detectable in 
plasma of any of the patients [11]. We hypothesized that the presence of thioxanthine in 
plasma may reflect a decreased anabolism of 6MP or an increased catabolism via xanthine 
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oxidase. This hypothesis was supported by lower MeMPR levels in plasma of thioxanthine 
present patients [11]. There were no differences in the plasma levels of 6MP, thiouric acid 
or the methylated metabolites, 6-methylmercaptopurine or 6-methylmercapto-8-
hydroxypurine [11]. So, interindividual variations in TPMT activity were probably not 
responsible for the lower MeMPR levels in the thioxanthine present group. 
The present study does not provide evidence for the hypothesis, that thioxanthine in 
plasma reflects a decreased anabolism. During and after the 6MP infusion there were only 
significant differences in tGDP levels, but not in total TGN or MeTIN levels between the 
thioxanthine present and absent groups. However, at 0 and 24 h TGN levels were 
significantly lower in the thioxanthine present group. So far, we have no sound explanation 
for the differences in TGN and MeMPR levels between the two groups. 
Cytotoxic effect ofMetIMP 
MetIMP was present in pMNC of the intravenous 6MP group only. These levels 
remained constant during at least 24 h after termination of the 6MP infusion. MetIMP is an 
inhibitor of the PDNS, but MetlDP and MetlTP do not have known direct cytotoxic 
activity in vitro [25,26]. ATP and GTP pools decreased to 40-60% in leukocytes after 
incubation with MeMPR in vitro [25]. In our study adenine and guanine nucleotide pools 
remained constant, which is probably because pMNC do not have an active purine de novo 
synthesis, as lymphoblasts do [27]. Nonetheless, the presence of constant MetIMP levels 
during at least 24 h after termination of the 6MP infusion, shows that (methyl)thiopurine 
nucleotide levels can be maintained in mononuclear cells in vivo. 
Differences with between HD-MTX/HD-6MP and HD-6MP alone 
We treated five non-Hodgkin lymphoma patients with one HD-6MP infusion within 
a therapeutic window phase shortly after diagnosis [28]. The MeTIN levels in RBC of these 
patients were much lower compared to the levels reached during the first course with HD-
MTX/HD6MP. Maximum MetIMP levels 24 h after termination of the 6MP infusion were 
10.7 nmol/10' RBC in the HD-6MP group [28], whereas mean MetIMP levels in the HD-
MTX/HD-6MP group were 24.2 nmol/109 RBC (maximum 46.3). MetlTP was present in 
RBC of all patients in the HD-MTX/HD-6MP group at the end of the 6MP infusion. But in 
the HD-6MP group MetlTP was present only in RBC of half of the patients at 24 h after 
termination of the 6MP infusion [28]. Although the number of patients in the HD-6MP 
group is small, these data suggest that pretreatment with HD-MTX enhances the anabolic 
pathway of 6MP, even in RBC. RBC do not have a complete PDNS, but they can 
synthesize PRPP from ribose-5-phosphate [29]. As a consequence of the inhibition of the 
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PDNS by MTX, resulting in high PRPP levels in tissues with an active PDNS, less ribose-
5-phosphate is required for PRPP synthesis. In this way, an increased availability of ribose-
5-phosphate might enhance the anabolic pathway of 6MP even in RBC. 
In conclusion, we found that oral administration of low-dose 6MP enhances the 
formation of TGN, whereas the formation of MeTIN is enhanced by HD-6MP infusions. 
During successive courses with HD-MTX/HD-6MP the formation of MeTIN, but not of 
TGN, is further enhanced. For a rational use of 6MP in patients, it needs to be known how 
both the formation of TGN and MeTIN contribute to the cytotoxic action of 6MP in vivo, 
as they do in vitro. 
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infusions during consolidation treatment of acute lymphoblastic leukemia 
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Abstract 
6-mercaptopunne (6MP) cytotoxicity is caused by thioguanine and methylthioinosine 
nucleotides Thiopunne methylation occurs to a large extent in vivo and in vitro In this 
reaction S-adenosyl-L-methionine (AdoMet), produced from methionine and ATP, is 
converted into S-adenosyl-L-homocysteine (AdoHcy), which in turn is hydrolyzed into 
homocysteine. Remethylation of homocysteine into methionine is inhibited by methotrexate 
(MTX) In cultured lymphoblasts AdoMef AdoHcy ratio and DNA methylation decrease 
after incubation with 6MP The aim of the present study was to investigate the influence of 
high-dose 6MP on the methylation capacity in children with acute lymphoblastic leukemia 
Five patients received 4 courses with high-dose intravenous MTX (5 g m 2 in 24 hr) 
immediately followed by high-dose 6MP (1300 mg.m2 in 24 hr) Five control patients 
received high-dose MTX and oral 6MP (25 mg m2 daily for 8 weeks) Leucovorin rescue 
was started at 36 hr in both groups. 
In the intravenous 6MP group 6-methylmercaptopunne, its riboside, and 6-
methylmercapto-8-hydroxypunne were detectable in plasma in concentrations of 0 3-2 6 
μΜ (6MP steady state levels: 11.6 μΜ). In red blood cells mean methylthioinosine 
nucleotide levels were one third of those of ATP (13.1 nmol/lO8) AdoHcy levels (10 
pmol/108) remained constant in both groups and AdoMet was not detectable (< 20 
pmol/108) In both groups plasma homocysteine increased and methionine decreased 
following administration of MTX. The delay in the recovery of methionine in the 
intravenous 6MP group after MTX infusion is probably the result of an increased demand 
on methyl groups during 6MP infusion 
Introduction 
6-mercaptopunne (6MP) is used in the treatment of acute lymphoblastic leukemia 
(ALL). It has no intrinsic cytotoxic activity, but is converted into active metabolites 
intracellularly (Scheme 1). 6MP is first converted with 5-phosphonbosyl-l-pyrophosphate 
as cosubstrate into thioinosine monophosphate (tIMP), which itself can be converted either 
into thioguanosine monophosphate (tGMP) or methylthioinosine monophosphate (MetIMP) 
Both pathways result in cytotoxicity in vitro, either by incorporation of thioguanine 
nucleotides into DNA and RNA [1,2] or by inhibition of purine de novo synthesis by 
MetIMP [2,3]. 6MP is methylated into 6-methylmercaptopunne (MeMP) and 6MP-nboside 
into 6-methylmercaptopurineriboside (MeMPR) (Scheme 1) The thiopunne methylation 
Transmethylation 127 
* М М Р 
ι 
ι 
1 l· 
thioxanthine M 8 0 H P * Μ θ Μ β Ο Η Ρ 
thiouric acid 
Schemel The metabolism of 6MP. 1=TPMT; 2=HGPRT (EC 2.4.2.8); M80HP 6-
mercapto-8-hydroxypurine, PRPP 5-phosphoribosyl-l-pyrophosphate. 
reactions are catalyzed by thiopurine methyltransferase (EC 2.1.1.67) (TPMT). The TPMT 
activity is controlled by a genetic polymorphism and the activity in red blood cells (RBC) 
correlates with that in lymphoblasts, lymphocytes, platelets, liver and kidney [4-7]. 
Population studies showed that the frequency distribution is trimodal with 88.6 % of the 
subjects displaying high activity, 11.1 % intermediate activity and 1 out of 300 subjects 
having undetectable TPMT activity [8]. Thiopurine methylation requires S-adenosyl-L-
methionine (AdoMet) as methyldonor [9]. AdoMet is the universal methyldonor for many 
methyltransferase reactions of small molecules, DNA, RNA, proteins and phospholipids, 
and plays an important role in the regulation of the action of these compounds [10]. 
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Scheme 2 shows the transmethylation pathway with its principal metabolites, 
AdoMet, S-adenosyl-L-homocysteine (AdoHcy), homocysteine and methionine. By donation 
of the methylgroup, AdoMet is converted into AdoHcy, which is hydrolyzed into 
homocysteine and adenosine Homocysteine can be degraded into cysteine in the 
transsulfuration pathway or remethylated into methionine. Two enzymes catalyze the 
remethylation of homocysteine. Betaine-homocysteine methyltransferase (EC 2.1 1.5) uses 
betaine as methyldonor and is active only in the liver [11] 5-Methyltetrahydrofolate 
homocysteine methyltransferase (EC 2.1.1.13) is active in many if not all tissues and uses 
5-methyltetrahydrofolate as methyldonor [11]. Next to its role in protein synthesis the 
essential aminoacid methionine can be activated as methyldonor by formation of AdoMet, 
using ATP as cosubstrate [11] 
Recently we reported the effect of 6MP on the principal transmethylation 
metabolites in vitro [12]. Incubation of Molt-F4 human malignant ALL lymphoblasts with 
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6MP resulted in a decrease in AdoMet and the AdoMet/AdoHcy ratio, in an increase in 
AdoHcy and methionine in these cells and a decreased release of homocysteine into the 
culture medium [12]. The decreased AdoMet/AdoHcy ratio could theoretically be caused by 
a depletion of the AdoMet pool, due to its consumption for thiopurine methylation. 
However, similar effects on AdoMet, AdoHcy, methionine and homocysteine were 
demonstrated after incubation of these cells with MeMPR, which already contains a 
methylgroup. Thus, the effects of 6MP and MeMPR on these transmethylation metabolites 
were ascribed to the reduced conversion of methionine into AdoMet, due to ATP depletion 
produced by MetlMP [12]. More recently we observed that incubation of Molt-F4 
lymphoblasts with 6MP or MeMPR resulted in a decrease in the incorporation of [14C] 
from [14C]-methionine into total DNA [13], suggesting that thiopurines can influence DNA 
methylation in vitro. 
It is well known that quantitative large amounts of 6MP are methylated in vivo. In 
RBC of ALL patients treated daily with oral 6MP (75 mg.m2) the median 
methylthioinosine nucleotide levels were 4.36 ηπιοΙ/β^ΊΟ8 RBC (range 0.25-22.5), 
compared to the much lower median thioguanine nucleotides levels of 335 ртоІ/вЧО8 RBC 
(range 144-1263) [14]. Methylthioinosine nucleotide levels were even higher in RBC [15] 
and mononuclear cells [16], as compared to those of thioguanine, when high doses of 6MP 
were administered intravenously. Influences of 6MP on the transmethylation metabolites in 
vivo have not been investigated up to now. 
In the present study we investigated influences of high-dose 6MP infusions on 
methylation capacity in vivo. In the consolidation treatment of the Dutch Childhood 
Leukemia Study Group (DCLSG-ALL-8 protocol) ALL patients are randomized for high-
dose intravenous 6MP or low-dose oral 6MP. We investigated the oral 6MP group as the 
control group for the intravenous 6MP group, since both groups also received methotrexate 
(MTX) infusions. This inhibits dihydrofolate reductase (EC 1.5.1.3), causing a depletion of 
active tetrahydrofolate compounds (Scheme 2). Thus, it indirectly inhibits folate-dependent 
reactions, such as remethylation of homocysteine into methionine, purine de novo synthesis 
and thymidylate synthesis [17]. 
The amounts of 6MP methylated in vivo were investigated by measurement of the 
methylated metabolites of 6MP in RBC, plasma and urine. The influence of the infusions 
on the transmethylation metabolites was investigated by measurement of methionine and 
homocysteine in plasma and AdoMet, AdoHcy and purine nucleotides intracellularly. 
Lymphoblasts were not available for investigation, because the patients were in complete 
remission. We used RBC, because TPMT activity in RBC correlates with that in lympho-
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blasts and other tissues [4-7]. RBC can synthesize 5-phosphoribosyl-l-pyrophosphate [18], 
an essential cofactor for the conversion of 6MP into tIMP, but do not manifest an active 
purine de novo synthesis, as ALL lymphoblasts do [19]. 
Methods 
Ten children with ALL were treated in our center according to the DCLSG-ALL-8 
protocol with a consolidation therapy of high-dose MTX (5 g.m2 in 24 hr, 4 courses in 8 
weeks). Leucovorin rescue (Scheme 2) was started at 36 hr after the MTX infusion was 
begun and continued every 6 hr until MTX plasma levels were less than 0.25 μΜ. Five of 
the ten patients were randomized for oral 6MP (25 mg.nr2 daily for 8 weeks, starting 7 
days before the first MTX course) and the other five received 6MP intravenously (1300 
mg.m2 in 24 hr, from 24 until 48 hr after MTX infusion, 4 courses in 8 weeks). Patient or 
parental approval were obtained according to the ethical guidelines of our hospital. 
Blood was sampled during the four courses of all patients in the oral and 
intravenous group, before and 24, 28, 48, 52 and 72 hr after the MTX infusion was begun. 
Plasma and RBC were isolated as described [20]. RBC transfusions, an essential part of the 
supportive treatment during the intensive consolidation treatment, were given between the 
courses, but never during a course. Dithiothreitol was added to plasma, RBC and urine to 
prevent oxidation of the thiol groups [20J. Urine was collected during the 24 hr of the 6MP 
infusion as well as during the next 24 hr, either as a pooled 24 hr sample or as fractionated 
samples of approximately 6 hr. In children with nappies we collected one urine sample at 
the end of the infusion. The methylated metabolites of 6MP and the purine nucleotides 
were extracted and measured with HPLC using ultraviolet absorbance. Detection limits for 
the methylated metabolites in plasma were 20-50 nM and for MetIMP 11 pmol per 100 μ\ 
injection [20]. A previously indeterminate metabolite of 6MP [20] was identified as 6-
methylmercapto-8-hydroxypurine (6MeM80HP). It was measured as the other 
methylthiopurine metabolites and eluted at 30 min [20]. Total homocysteine was measured 
with HPLC after reduction with sodium borohydride and derivatization with 
monobromobimane [21]. Methionine was measured as described [12]. AdoMet and AdoHcy 
were extracted from 200 μ ι RBC (2-3.Iff2 RBC/L 0.9% (w/v) saline with 0.1% (w/v) 
dithiotreitol) and 200 μ-L water with 40 /¿L 55% trichloroacetic acid and kept on ice for 10 
min. After centri fugation 300 ^L of the supernatants were washed 3 times with 2 volumes 
of peroxide free diethylether to remove the trichloroacetic acid. The samples were flushed 
with nitrogen to a final volume of 150 ^L. AdoMet and AdoHcy were measured with 
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HPLC [12] at 248, 254 and 260 nm. 
Results 
Methylated metabolites of 6MP in plasma, RBC and urine 
Figure 1 shows the mean levels of the methylated metabolites of 6MP in plasma of 
the intravenous 6MP group. Steady state levels of 6MP and MeMP were 11.6 (sem 1.6) 
and 0.6 (sem 0.1) μΜ, respectively. MeM80HP reached levels of 2.6 (sem 0.5) μΜ 
during the 6MP infusion. Upon its termination, MeMP and MeM80HP were rapidly 
cleared from plasma. MeMPR increased slowly during the 6MP infusion and reached levels 
of 0.3 (sem 0.05) μΜ 24 hr after its termination. Methylthioxanthine and methylthiouric 
acid were not detectable in plasma of these patients. 
Figure 2 shows the levels of MetIMP, MetlDP and MetITP in RBC of patients in 
the intravenous 6MP group. These levels increased during and after the infusion. At 72 hr 
the mean levels of MetIMP were 3.1 (sem 0.6), of MetlDP 0.8 (sem 0.3) and of MetITP 
1.4 (sem 0.4) nmol/108 RBC. At the start of the next course the mean MetIMP levels were 
decreased to less than one tenth of the level at 72 hr of the previous course, whereas those 
of MetlDP were one half and of MetITP one third. Four children each received a RBC 
transfusion once between the courses. After this, the methylthioinosine nucleotide levels at 
the start of the next course were in the same range or higher as compared to those of the 
previous course. Interindividual variation coefficients of 6MP and the methylated 
metabolites in plasma and RBC were between 30 and 50 %. 
In urine 6MP, thioxanthine and thiouric acid were the main metabolites. MeMP, 
MeM80HP, methylthioxanthine and methylthiouric acid were not detectable in urine. 
MeMPR accounted for less than 2% of all excreted metabolites of 6MP in urine during the 
6MP infusion. 
Urine of the oral group was not collected. In plasma and RBC samples of the oral 
6MP group at 0, 24, 28, 48, 52 and 72 hr, none of the metabolites of 6MP was detectable. 
Oral 6MP (25 mg.m2) was given at 7 a.m., whereas blood was sampled at 1 or 5 p.m.. 
Purine nucleotides in RBC 
Adenine and guanine nucleotide levels in RBC of the oral and intravenous 6MP 
group were in the normal range [22) and remained constant during the MTX and 6MP 
infusions of all courses. ATP levels were 13.1 (sem 0.9) nmol/108 RBC. 
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Figure 1 Methylated metabolites of 6MP in plasma of the intravenous 6MP group. 
Patients were treated with an MTX infusion from 0-24 hr and a 6MP infusion from 24-48 hr. The 
means of all courses and all patients are indicated by the markers, the error bars indicate the sem. 
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Figure 2 Methylated metabolites of 6MP in RBC of the intravenous 6MP group. 
Patients were treated with an MTX infusion from 0-24 hr and a 6MP infusion from 24-48 hr. The 
means of all courses and all patients are indicated by the markers, the error bars indicate the sem. 
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AdoMet and AdoHcy in RBC 
AdoMet levels were analyzed in both groups, but were not detectable in any of the 
samples. The detection limit of AdoMet in RBC is 20 pmol/108 RBC. AdoHcy levels 
remained constant in both groups. Mean AdoHcy levels were 10.8 (sem 1.3) pmol/108 RBC 
in the intravenous and 9.1 (sem 1.0) pmol/108 RBC in the oral group. 
Methionine and homocysteine in plasma (Figure 3) 
In both groups homocysteine levels increased by 130-250% upon administration of 
MTX and returned to initial values after the start of leucovorin administration. Until 48 hr 
there were no significant differences in homocysteine levels between both groups, but at 52 
and 72 hr they were significantly lower in the intravenous group (t test, two-tailed, Ρ = 
0.03 and 0.002 resp., df 34, all courses). Methionine levels decreased by 35-50 % from 0 
to 24 hr during all courses in the oral group and during the third and fourth course in the 
intravenous group. This decrease in methionine was not present during the first or second 
course in the intravenous group. After termination of the MTX infusion methionine levels 
immediately returned to initial levels in the oral group. In the intravenous group methionine 
levels began to increase 4 hr after termination of the 6MP infusion and reached levels 
137% above the initial levels at 72 hr. At 48 and 52 hr methionine levels were significantly 
higher in the oral group (t test, two-tailed, Ρ = 0.05 and 0.05 resp., df 33, all courses). At 
0, 24, 28 and 72 hr there were no significant differences. Methionine in unwashed RBC of 
ten random samples of the oral and intravenous 6MP group were in the range of 60-200 
pmol/108 RBC. 
Discussion 
The importance of a balanced transmethylation pathway and its role in 
carcinogenesis and malignancy has been stressed by several studies and reviewed by Laird 
and Jaenisch [23]. The methylation pattern of DNA of human malignant cells is often 
characterized by widespread hypomethylation, regional hypermethylation and elevated 
expression levels of DNA methyltransferase activity. In animals, the administration of 
AdoMet was able to prevent or even reverse the development of tumors, whereas methyl 
deficient diets were able to induce tumors, which is consistent with the widespread 
hypomethylation in tumor DNA [23]. Recently it was shown that DNA methyltransferase 
activity contributes substantially to the development of intestinal adenomas [24]. However, 
it remains unclear whether or not changes in the methylation status (i.e. methionine 
134 Chapter 9 
Figure 3 Homocysteine (triangles) and methionine (circles) in plasma of the oral (solid lines) 
and intravenous (dotted lines) 6MP group. Patients in both groups were treated with a MTX 
infusion from 0-24 hr. Patients in the oral group received 6MP daily per os. whereas patients in the 
intravenous 6MP group received 6MP as an infusion from 24-48 hr. The means of all courses and 
all patients are indicated by the markers, the error bars indicate the sem. 
metabolites, DNA methyltransferase activity or DNA methylation) play a causal role in 
carcinogenesis or are a property of the malignant cell. Even without this knowledge, the 
methylation status might be a target for chemotherapeutic agents. In line with this view we 
recently demonstrated that incubation of Molt F4 lymphoblasts with 6MP resulted in 
changes in the concentrations of transmethylation metabolites [12] and in DNA methylation 
[13]. 
The present study is the first to investigate the influence of high-dose 6MP on 
transmethylation metabolites in vivo. Large amounts of methylated thiopurines were 
detectable in plasma and RBC after high-dose intravenous 6MP, with interpatient 
variabilities of 30-50% (Figures 1,2). TPMT activities in peripheral mononuclear cells 
ranged from 4.6-16.1 IU/109 cells in the present group, demonstrating intermediate and 
high activity [25]. The genetic polymorphism of TPMT may be partially responsible for 
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the interpatient variability. We could not demonstrate a correlation between TPMT activity 
and (methyl)thiopurines. This is due to a high percentage of TPMT assays in mononuclear 
cells which fail due to lack of cells in leukopenic patients as well as to other enzymes 
involved in thiopurine metabolism [25] (Scheme 1). Measurement of TPMT in RBC would 
not be informative, because RBC are transfused during the induction and consolidation 
treatment. The presence of methylated metabolites of 6MP in urine was less pronounced 
compared to that in plasma and RBC. The absence of MeMP and MeM80HP in urine 
might be the result of oxidation [26] or glucuronidation [27] of these compounds or of 
desulfuration of the drug [27]. Methylthioxanthine and methylthiouric acid were not 
detectable in plasma or urine, which is in concordance with the results obtained from 
patients treated with 6MP and MeMP [28) and with in vitro data demonstrating that 
thioxanthine and thiouric acid are inhibitors of TPMT [29]. 
In the oral group 6MP and its metabolites were not detectable in plasma nor RBC. 
Blood sampling was timed after the start of MTX, as in the intravenous group, and not 
after 6MP intake. Detection of mono-, di- and triphosphate nucleotides in RBC require 
higher intracellular concentrations of methylthioinosine nucleotides, compared to 
measurement of MeMP after hydrolysis of the nucleotides. The administered dose (25 
mg.m"2 daily for eight weeks) was one third of the dose administered daily during 1.5-2 
years maintenance therapy of ALL [14], too low for detection of methylthioinosine 
nucleotides in the oral group. 
The high levels of methylthioinosine nucleotides in RBC in the intravenous group 
indicate that the transmethylation rate and thus the rate of AdoMet synthesis must have 
been high in RBC. AdoMet levels were below the detection limit in all RBC samples, but 
the increasing levels of methylthioinosine nucleotides in RBC after termination of the 
infusion indicate that sufficient AdoMet was available for this methylation reaction. In RBC 
of healthy controls mean AdoMet levels were 3.5-5.2 ¿¿mol/L packed fresh RBC [30-32] 
(±10*1012 RBC/L packed cells). Roughly, these levels are just above our detection limit 
(20 pmol/108 RBC). AdoHcy levels were approximately 10 pmol/108 RBC and remained 
constant during the MTX and 6MP infusions. In one study, mean AdoHcy levels were one 
third of those of AdoMet in fresh RBC of healthy subjects [31], whereas in our study 
AdoMet levels were lower than AdoHcy levels. We used stored RBC of patients treated for 
leukemia, which may have influenced the difference. We are not aware of a study having 
been conducted on AdoMet and AdoHcy levels in RBC under similar conditions. 
Changes in homocysteine and methionine levels in plasma were observed in both 
groups. The increase in homocysteine and the decrease in methionine in plasma after the 
start of MTX administration could be ascribed to the decreased remethylation of 
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homocysteine, itself the result of the decreased availability of tetrahydrofolate derivatives 
due to inhibition of dihydrofolate reductase by MTX (Scheme 2). These changes have also 
been demonstrated by others [33-35|. A decrease in methionine levels was not detectable 
during the first two courses in the intravenous group, probably because we did not measure 
between 0 and 24 hr when the nadir was reached [35]. 
After termination of the MTX infusion methionine and homocysteine levels were 
different for the two groups. Upon leucovorin administration, homocysteine levels 
decreased in both groups, but decreased to significantly lower levels at 52 and 72 hr in the 
intravenous 6MP group. Methionine levels increased immediately to initial levels after 
termination of the MTX infusion in the oral group, but remained low in the intravenous 
group during the 6MP infusion, after which they rebounded above initial levels. Because 
leucovorin, which increases methylation of homocysteine into methionine, was administered 
12 hr after the start of the 6MP infusion, the pure effect of high-dose 6MP on the 
transmethylation metabolites may be masked. The delay in the recovery of methionine after 
termination of the MTX infusion in the intravenous group may be the result of the high 
consumption of methionine for methylation of thiopurines. 
Thus, our study in children with ALL in remission shows an effect of high-dose 
6MP in plasma (i.e. a delay in the recovery of the decrease in methionine due to MTX). 
This study does not show evidence for an effect of high-dose 6MP in RBC. This does not 
exclude the possibility that high-dose 6MP influences the transmethylation metabolites in 
the lymphoblasts. However, as all patients were in complete remission during the 
consolidation treatment, lymphoblasts are not available. It would be worthwhile to 
investigate the effects of high-dose 6MP alone on the transmethylation pathway in the 
lymphoblasts immediately after diagnosis, which will probably be done in a window phase 
of the next DCLSG study (ALL-9). 
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Toxicity of low-dose oral or high-dose intravenous 6-mercaptopurine 
in combination with high-dose methotrexate infusions: 
a study of the Dutch Childhood Leukemia Study Group 
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Abstract 
Purpose: Toxicity of high-dose methotrexate (MTX) infusions in combination with 
low-dose oral 6-mercaptopurine (6MP) or high-dose intravenous 6MP was investigated in 
children treated for acute lymphoblastic leukemia. 
Patients and Methods: All patients received four courses with a high-dose MTX 
infusion (5 g/m2 in 24 h) in eight weeks. The group randomized for oral 6MP received 25 
mg/m2 6MP daily during eight weeks. The group randomized for intravenous 6MP received 
a 6MP infusion (100 mg/m2 6MP in 0.5 h plus 1200 mg/m2 6MP in 23.5 h, four times in 
eight weeks) immediately after MTX infusion. Sixty-five patients, randomized for oral 
6MP, and sixty-one patients, randomized for intravenous 6MP, were studied for toxicity. 
Results: Treatment delay was necessary in 14 patients treated with oral 6MP 
(21.5%) and in 27 patients treated with intravenous 6MP (44.3%). In the oral group 19 out 
of 194 évaluable courses (9.8%) had to be postponed compared to 36 out of 169 évaluable 
courses (21.3%) in the intravenous group. The reasons for treatment delay were 
hematologic, hepatic or clinical toxicity. Treatment had to be reduced for unacceptable 
toxicity in four patients in the intravenous group and in one patient in the oral group. 
Vomiting and mucositis were the main clinical toxicities in the intravenous group. Grade 3 
to 4 elevation of liver transaminases occurred in 40 to 50% of the intravenous group. This 
was reversible within a week in most patients, but in 11 out 174 courses (6.3%) the next 
course had to be postponed. Vomiting, mucositis, diarrhoea, skin lesions, 
thrombocytopenia and transient rise in liver transaminases occurred significantly more often 
in the intravenous group (Mann-Whitney-U/Wilcoxon-Rank-Sum-test, Ρ values: range 
0.0001-0.016). 
Conclusion: Toxicity of combination therapy of high-dose MTX and high-dose 
intravenous 6MP is more severe than of high-dose MTX and low-dose oral 6MP. Although 
treatment with intravenous 6MP had to be delayed relatively more often, irreversible or 
intractable toxicity was not observed. 
Introduction 
Previous work in our laboratory has demonstrated synergism in the cytotoxic action 
of methotrexate (MTX) followed by 6-mercaptopurine (6MP) in leukemic cell lines. The 
biochemical background of this synergism could be demonstrated [1-3]. In these studies 
6MP concentrations of 2 and 10 μΜ were used. In vivo, these levels can be reached in 
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plasma using intravenous administration of 50 mg/m2 6MP per hour (mean 6MP steady 
state plasma levels 6.9 ± 0.4 sem μΜ) [4]. In 1991 the Dutch Childhood Leukemia Study 
Group (DCLSG) started a randomized clinical trial in acute lymphoblastic leukemia (ALL) 
for the administration of 6MP (DCLSG-ALL-8 study). The study was based on the 
potential synergistic effect of sequential administration of high-dose MTX and 6MP. 
During the consolidation treatment for prevention of central nervous system relapse with 
high-dose MTX infusions, patients were randomized to either daily oral administration of 
low dose 6MP (the common regimen) or intravenous administration of high-dose 6MP 
immediately after the MTX infusion. 
In a phase I trial [4] a dosage of 50 mg/m2 6MP per hour was administered for 12-
60 h. Dose limiting toxicity was mucositis. Myelosuppression and increase in liver 
transaminases did occur, but were reversible. Renal or central nervous system toxicity was 
not observed and nausea and vomiting were mild. A dosage of 50 mg/m2 6MP per hour for 
48 h could be administered safely [4]. In phase II trials [5,6] administering this dose to 
children with refractory solid tumors, lymphoma or leukemia, toxicity was similar [5,6|. 
6MP infusions have been administered in combination with methotrexate (MTX) to children 
with ALL [7,8]. MTX infusion was given as 1 g/m2 for 24 h, followed by 1 g/m2 6MP for 
8 h. After a remission induction therapy of four weeks, twelve of these cycles were given 
in 24 weeks. Myelosuppression, mucositis and infection were seen in 12%, 9% and 5%, 
respectively [7,8]. Event free survival at four years was 94% for lower risk ALL and 57% 
for higher risk ALL [8]. Although these results are very promising, the trials were not 
randomized. 
This article reports the toxic effects in both arms of the randomized DCLSG-ALL-8 
study: high-dose MTX in combination with low dose oral 6MP or high-dose intravenous 
6MP. 
Patients and methods 
From August 1992 through January 1996, 126 patients with medium risk ALL from 
eleven Dutch hospitals were enrolled in the randomized DCLSG-ALL-8 trial. Inclusion 
criteria for the medium risk group were: a risk factor above 0.8 [9], mediastinal mass, 
initial central nervous system involvement, or pre-T or T-ALL immunophenotype. 
Exclusion criteria were: t(4;ll) or t(9;22) translocation, BCR-ABL gene rearrangement, 
poor steroid response after one week prednisone monotherapy or immunophenotypic acute 
undifferentiated leukemia. AH patients were in complete remission after a remission 
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induction therapy of 10 weeks with prednisone, vincristine, daunorubicin, L-asparaginase, 
cyclophosphamide, cytosine arabisnoside and oral 6MP. They had recovered from prior 
therapy before start of the consolidation therapy, which was based on that of the Berlin-
Frankfurt-Münster group (BFM-90). The consolidation therapy consisted of four courses 
high-dose MTX (0.5 g/m2 MTX in 0.5 h plus 4.5 g/m2 MTX in 23.5 h) in eight weeks. 
Standard leucovorin rescue was administered at a dosage of 30 mg/m2 at 42 h and of 15 
mg/m2 at 48 and 54 h after start of the MTX infusion. Plasma MTX levels were measured 
at 24, 36, 42 and 48 h. When they were above the critical levels of 150 μΜ at 24 h, 3 μΜ 
at 36 h, 1 μΜ at 42 h or 0.4 μΜ at 48 h, leucovorin was increased and given every 6 h till 
MTX plasma levels were below 0.25 μΜ. An age dependent dose of MTX, cytosine 
arabinoside and prednisolone was administered intrathecally 1.5 h after start of the MTX 
infusion. In addition the patients received 6MP, either orally or intravenously. The oral 
6MP group received 25 mg/m2 6MP daily during eight weeks, as in the BFM studies [9]. 
The intravenous group received a 6MP infusion (100 mg/m2 6MP in 0.5 h plus 1200 
mg/m2 6MP in 23.5 h, four times in eight weeks) immediately after MTX infusion. Patient 
or parental consent was obtained according to the institutional guidelines. 
Sixty-five patients, randomized for oral 6MP, and sixty-one patients, randomized 
for intravenous 6MP, were studied. Clinical toxicity was recorded for all patients who were 
treated with intravenous 6MP in the Netherlands and for those patients treated with oral 
6MP in our department, the Pediatric-Oncology-Center-South-East-Netherlands (POC-
SEN). Hematologic and hepatic toxicity were recorded by the DCLSG data managers. 
Toxicity was classified in grades according to WHO criteria (Table 1). MTX plasma levels 
were registered from all patients treated in РОС-SEN. Statistics were performed with the 
Statistical Package for the Social Sciences (SPSS, Chicago, USA). Differences between the 
two groups were estimated using the Mann-Whitney-U/Wilcoxon-Rank-Sum-test. 
Results 
Change of treatment and treatment delay 
Sixty-four patients in the oral group received four courses with HD-MTX. One 
patient did not receive the fourth course due to grade 4 clinical and hematologic toxicity 
from the previous courses (Table 2). In the intravenous 6MP group four patients received 
only two or three courses due to high toxicity. One of these patients had grade 4 hepatic 
toxicity and did not receive the third and fourth courses. Another patient with grade 4 
thrombocytopenia received oral instead of intravenous 6MP during the third and fourth 
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courses The other two patients received one or two courses with 3 g/m2 MTX instead of 5 
g/m2, followed by full dose intravenous 6MP, because of severely delayed MTX excretion 
Two patients in the intravenous group had to change to high-risk treatment after the first or 
second course due to early relapse One patient did not receive one high-dose 6MP course, 
due to a prescription error The number of évaluable courses was 259 in the oral 6MP arm 
and 231 in the intravenous 6MP arm 
Table 2 Treatment delay in 65 patients treated with oral 6MP and 61 patients treated with 
intravenous 6MP 
Number of courses Oral 6MP group Intravenous 6MP group 
(65 patients) (61 patients) 
Scheduled 260 244 
Not given due to 
- prescription error 
- early relapse 
- high toxicity 
Actually administered 
Evaluable for treatment 
Delay of 
- one course 
- two courses 
- three courses 
delayA 
Reasons for treatment delay 
- gr 3-4 leukopenia 
- gr 3-4 thrombopenia 
- gr 3-4 leukopenia and thrombopenia 
- gr 3-4 hepatic toxicity 
- clinical side effects 
mucositis 
infection 
malaise 
- unknown 
2 
1 
259 
194 
10 
6 
3 
4 
4 
1 
0 
10 
1 
5 
7 
231 
169 
17 
20 
0 
2 
8 
3 
11 
12 
8 
3 
1 
0 
A
 The number of courses which is évaluable for treatment delay is smaller than the number of 
courses which is actually administered The reasons for this are a therapy pause of two weeks after 
the fourth course and protocol adjustment due to relapse 
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Treatment delay was necessary in 14 out of 65 patients treated with oral 6MP 
(21.5%) and in 27 out of 61 patients treated with intravenous 6MP (44.3%). Since there 
was a therapy pause after the fourth course, treatment delay after this course could not be 
evaluated. In the oral group 19 out of 194 évaluable courses (9.8%) had to be postponed 
compared to 36 out of 169 évaluable courses (21.3%) in the intravenous group. It treatment 
had to be postponed, it was delayed for one week in 52 cases and for more than one week 
only in 4 cases. The reasons for treatment delay were hematologic, hepatic or clinical 
toxicity (Table 2). 
Toxicity 
Clinical side effects of all patients in the intravenous group of the DCLSG study are 
indicated in Table 3. Comparison with the oral group of the DCLSG study was not 
possible, since clinical toxicity from patients in the oral group was recorded from patients 
treated in РОС-SEN only. Detailed data on toxicity in both treatment groups from those 
patients treated in РОС-SEN, are indicated in Table 4. Vomiting, mucositis, diarrhoea, 
skin lesions, thrombocytopenia and transient rise in liver transaminases occurred 
significantly more often in the intravenous group. At the start of the next course SGOT 
levels were comparable in both groups, but SGPT levels were still significantly higher in 
the intravenous group (Mann-Whitney-U/Wilcoxon-Rank-Sum-Test, P<0.0001). 
Clinical toxicity was compared between patients treated in РОС-SEN and those 
treated in other centers. Vomiting was less severe, whereas infection was more severe in 
РОС-SEN (Mann-Whitney-UAVilcoxon-Rank-Sum-Test, P=0.0055 and 0.0014, respec­
tively). 
Table 3 Clinical toxicity according to WHO scale during 231 courses in 61 patients treated 
with intravenous 6MP (expressed as percentage of the number of évaluable courses). 
WHO grade 
Vomiting 
Mucositis 
Diarrhoea 
Skin 
Infection 
0 
30.2 
54.1 
86.4 
70.0 
82.5 
1 
13.1 
19.4 
7.1 
11.5 
10.0 
2 
34.2 
13.3 
5.6 
14.0 
3.5 
3 
17.1 
8.2 
1.0 
4.5 
4.0 
4 
5.5 
5.1 
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MTX excretion 
MTX plasma levels of 17 patients treated with oral 6MP and of 14 patients treated 
with intravenous 6MP in РОС-SEN are indicated in Table 5. MTX plasma levels were 
significantly higher in the intravenous group compared to the oral group at 36 h after start 
of the MTX infusion (Mann-Whitney-U/Wilcoxon-Rank-Sum-test, Ρ = 0.015) (Table 5A). 
At 24, 36 and 42 h MTX levels in the intravenous group exceeded the critical values more 
often (Mann-Whitney-U/Wilcoxon-Rank-Sum-test, Ρ = 0.049, 0.002 and 0.006, 
respectively) (Table 5B). At 48 h there was no significant difference in MTX plasma 
concentrations between the two groups. 
Table 5 MTX plasma levels (A) and percentage of courses with MTX plasma levels above 
critical levels (B) during 68 courses in 17 patients treated with oral 6MP and during 
51 courses in 14 patients treated with intravenous 6MP in РОС-SEN. 
A 
Time (h) 
24 
36 
42 
48 
В Critical 
MTX level 
μΜ 
24 > 150 
36 > 3 
42 > 1 
48 > 0.4 
Oral 6MP group 
MTX plasma levels 
mean (sem) 
71.60 (3.52) 
1.65 (0.12) 
0.63 (0.04) 
0.43 (0.03) 
Intravenous 6MP group 
(μΜ) 
mean (sem) 
84.80 (8.96) 
5.39 (2.54) 
2.28 (0.96) 
1.52 (0.65) 
Percentage of courses with MTX 
plasma level above critical level 
% 
1.6 
2.9 
7.3 
45.2 
% 
10.0 
32.0 
27.5 
51.0 
pA 
n.s. 
0.015 
n.s. 
n.s. 
0.049 
0.002 
0.006 
n.s. 
A
 Ρ value of Mann-Whitney-U/Wilcoxon-Rank-Sum-test. 
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Discussion 
High-dose MTX infusions followed by high-dose 6MP infusions resulted in 
significantly higher toxicity compared to high-dose MTX infusions in combination with 
low-dose oral 6MP. The total cumulative dose of 6MP was higher in the intravenous group 
as compared to the oral group (5200 versus 1400 mg/m2). Treatment had to be reduced or 
postponed more frequently in the intravenous 6MP group as compared to the oral group. 
Patients in the intravenous 6MP group suffered significantly more often from nausea and 
vomiting, mucositis, diarrhoea or skin lesions. These toxic effects were also seen in a 
Pediatric Oncology Group (POG) study with intermediate dose MTX (1 g/m2 in 24 h) and 
high-dose 6MP (1 g/m2 in 8 h) [7,8]. 
Differences in vomiting of patients treated in the intravenous group in РОС-SEN or 
the other centers, may be explained by differences in the (prophylactic) use of antiemetics. 
Antiemetic therapy was not standardized in the DCLSG study. We have no sound 
explanation for differences in the degree of infection between the two groups. The 
significant difference is mainly due to differences in grade 1 infection, which is mild 
toxicity, not requiring therapeutic intervention. 
Grade 3-4 thrombocytopenia occurred significantly more often in the intravenous 
group of the DCLSG study (8.7%) compared to the oral group (1.7%), but also compared 
to the POG study (platelets less than 100.1071 in 21 out of 960 courses) [8]. On the other 
hand, severe leukocytopenia was less common in our study (4.3% grade 3, 0% grade 4) 
than in the POG study (granulocytes less than 0.5.ΙΟ^/Ι in 12% of the courses) [8]. In our 
study there were no significant differences in leukocytopenia and infection between the oral 
and intravenous group. 
Grade 3 to 4 elevation of liver transaminases occurred in 40 to 50% of the 
intravenous group and was reversible within a week in most patients. Nonetheless, in 11 
out of 174 courses (6.3%) the next course had to be postponed for this reason. In the POG 
study elevation of liver transaminases was observed in only four percent of the courses [8]. 
The differences in elevation of liver transaminase levels between the DCLSG study and the 
POG study, may be explained by a five times higher MTX dosage in our study and a 
prolonged infusion time of 6MP during 24 h instead of 8 h in the POG study. 
At 24, 36 and 42 h MTX plasma levels were above the critical value significantly 
more frequently in the intravenous group as compared to the oral group. So, patients in the 
intravenous group received more Ieucovorin rescue. Absolute MTX plasma levels were 
higher in the intravenous group only at 36 h. However, at 48 h there were no longer 
differences in MTX excretion between the two groups. Already at 24 h, which is before 
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start of the 6MP infusion, there was a difference in MTX levels between the two groups. 
This indicates that the intravenous group had a higher percentage of patients having a 
delayed MTX excretion. On the other hand, it can not be excluded, that the start of the 
high-dose 6MP infusion immediately after termination of the MTX infusion is responsible 
for the delay in the excretion of MTX at 36 and 42 h in the intravenous group. Anyway, 
this delay is temporary, since there is no difference in MTX plasma levels 24 h after 
termination of the MTX infusion. 
In conclusion, toxicity of combination therapy of high-dose MTX and high-dose 
intravenous 6MP is more severe than of high-dose MTX and low-dose oral 6MP. Although 
treatment with intravenous 6MP had to be delayed more frequently, irreversible or 
intractable toxicity was not observed. 
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Knowledge from the past 
Despite more than forty years of research and clinical use of 6-mercaptopurine 
(6MP), its metabolism is still an enigma. Although clinical experience has demonstrated the 
therapeutic efficacy of 6MP in the treatment of childhood acute lymphoblastic leukemia 
(ALL) and although laboratory research has shown pathways along which 6MP exerts its 
cytotoxic action in leukemia cell lines, it is still not known how 6MP kills the lymphoblasts 
in patients. Answering this question is not only of scientific interest, but also of clinical 
importance, as will be discussed in 'future directions'. 
6MP has been administered to children with ALL since 1953 [1]. Oral 
administration of 6MP and methotrexate (MTX) has become the backbone of maintenance 
therapy, which works in children with ALL, but not in patients having other malignancies 
[2]. It remains, however, unclear how this maintenance chemotherapy actually works and 
why some patients do respond and others do not. The prognostic value of the plasma 
pharmacokinetics of 6MP during maintenance for treatment outcome have been 
investigated. One study showed a positive correlation between myelotoxicity and the area-
under-the-plasma-concentration-time-curve (AUC) of 6MP [3], but another study did not 
confirm this finding [4]. Positive correlations have been found between event-free survival 
and AUC of 6MP [5] or 'standard' AUC (AUC divided by administered dose) [6]. The 
validity of 'standardization' of the AUC for the dose in the latter study [6] has been 
questioned [7], since there is an apparent lack of correlation between the dose and AUC of 
6MP [8-12]. Overall, the value of monitoring 6MP plasma levels is limited, since 6MP is a 
prodrug which is extensively metabolized before it exerts its cytotoxic action. 
Since the cytotoxic effect of 6MP depends on the formation of (methyl)thiopurine 
nucleotides intracellularly, measurement of intracellular metabolites could be of greater 
importance to monitor the therapeutic efficacy of 6MP [13]. The group of Lennard and 
coworkers performed many studies during maintenance therapy of ALL on the relationship 
between the levels of total thioguanine nucleotides (TGN) in red blood cells (RBC) and 
treatment outcome. They did not find correlations between RBC TGN levels and the dose 
of oral 6MP [14], but there was an inverse correlation between RBC TGN levels and 
absolute neutrophil count two weeks later [4,14]. They also demonstrated a positive 
correlation between RBC TGN levels and event-free survival [15,16]. The latter correlation 
could not be confirmed by Schmiegelow et al [17]. But in that study another factor (i.e. the 
mean MTX polyglutamate levels multiplied by the mean TGN levels in RBC, measured 
several times during maintenance therapy) was identified as a significant parameter to 
predict risk of relapse: patients with levels below the median of the group had increased 
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risk for relapse [17J. In another study, six out of seven patients who developed a relapse, 
had TGN and methylthioinosine nucleotides (MeTIN) levels and thiopurine 
methyltransferase (TPMT) activities below the median of the whole group [18]. So, it is 
clear that thiopurine metabolism during maintenance therapy plays an important role in 
treatment outcome of childhood ALL. But the mechanisms, underlying the interindividual 
variabilities in thiopurine metabolite levels, are still an enigma. 
Many studies during maintenance therapy have demonstrated large interindividual 
and intraindividual variations in plasma 6MP levels and RBC TGN levels after oral 
administration of 6MP [4,11,12,15,19-26]. Several factors which might cause these 
variations (reviewed in [10]) have been investigated: sex [27], time at the day of 6MP 
intake [28-32], 6MP dose [8-12,14,33], concurrent food intake [19,34,35], non-compliance 
[36] and drug interactions with MTX [9,37], folate [38], Cotrimoxazol [39], or allopurinol 
[40-42]. None of these factors was consistently found to be responsible for the interpatient 
variations. One factor which undoubtedly plays an important role in interindividual 
variations in thiopurine metabolism is TPMT activity, which displays wide interindividua] 
variation due to a genetic polymorphism [25,43]. The activities of other enzymes involved 
in the thiopurine metabolism, as xanthine oxidase [44], hypoxanthine guanine 
phosphoribosyltransferase (HGPRT) [45] and 5'-nucleotidase [46], have been studied less 
well. So, the cause of the interpatient variabilities in the levels of thiopurine metabolites is 
probably multifactorial. 
Attempts have been made to increase bioavailability and decrease interindividual 
variations of orally administered 6MP. The bioavailability of oral 6MP (i.e. the percentage 
of the drug which reaches the systemic circulation) was only 16% (sd 11) of that observed 
with the same dose administered intravenously [11]. By oral administration of higher doses 
of 6MP (175-500 mg/m2 instead of 75 mg/m2) bioavailability did not increase [8] and 
intraindividual variations decreased in some patients, but not in all [23]. Intravenous 
administration of 6MP was introduced in the treatment of ALL more than thirty years after 
the first use of 6MP. In a phase I study administering an infusion of 50 mg/m2 6MP per 
hour, steady state levels of 6MP could be reached in plasma and cerebrospinal fluid, with 
little interpatient variability [47]. Since the eighties, intravenous administration of 6MP 
have been incorporated in treatment protocols for childhood ALL [48]. 
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Summary of the present study 
The metabolism of 6MP during high-dose 6MP infusions and during daily oral 
administration of a low dose has been investigated in the present study. The background of 
the study is the synergism in cytotoxic action which was found in lymphoblastic cell lines 
after incubation with MTX followed by incubation with 6MP. This study is a randomized 
trial of the Dutch Childhood Leukemia Study Group (DCLSG), which compares oral or 
intravenous administration of 6MP during eight weeks of treatment with four courses of 24 
h high-dose MTX infusions (5 g/m2). Oral administration of 6MP consisted of 25 mg/m2 
6MP daily during eight weeks, whereas high-dose 6MP infusions (1300 mg/m2 in 24 h, 
four courses in eight weeks) were administered immediately after the MTX infusion. In this 
study parent drug levels and those of its extracellular and intracellular metabolites were 
investigated. 
In chapter 2 the methods are described for measurement of (methyl)thiopurine 
bases, nucleosides and mono-, di- and triphosphate nucleotides. Analysis of methylated and 
non-methylated metabolites of 6MP in plasma, urine, cerebrospinal fluid, mononuclear cells 
and lymphoblasts can be performed in single runs using three wavelengths. For the 
detection of mono-, di- and triphosphate TGN and MeTIN in RBC, two extraction 
procedures and two analyses are still needed. MeTIN are detected using UV absorbance, 
whereas TGN are detectable with fluorescence absorbance. 
In chapter 3 and 4 the results obtained from ten patients treated with one high-dose 
6MP infusion are described. These infusions were given in a therapeutic window shortly 
after diagnosis and were not preceded by a high-dose MTX infusion. Differences in the 
metabolism of 6MP during high-dose 6MP infusions with and without allopurinol co-
administration are discussed in chapter 3. The presence of higher levels of 6MP and 
thioxanthine and of lower levels of thiouric acid in the patients who were treated with 
allopurinol, demonstrate the inhibition of the catabolic pathway via xanthine oxidase by 
allopurinol. The presence of higher levels of 6-methylmercaptopurine (MeMP) and 6-
mefhylmercapto-8-hydroxypurine (MeM80HP) (the latter is mentioned in chapter 6) in the 
patients treated with allopurinol, indicates that the alternative catabolic route via TPMT was 
increased. Despite higher 6MP levels, MeTIN levels in RBC were lower in the patients 
treated with allopurinol. This is probably due to competition for HGPRT and 5-
phosphoribosyl-pyrophosphate (PRPP) between 6MP, hypoxanthine and allopurinol. The 
decreased anabolism of 6MP during high-dose 6MP infusions in combination with 
allopurinol, may have consequences for 6MP therapy. 
Indications for a competition between hypoxanthine and its analogue 6MP in vivo 
Summary 155 
are described in chapter 4 There were large interpatient variations in plasma and RBC 
levels of 6MP and its metabolites. Nonetheless, one patient who had a tumor lysis 
syndrome, could be distinguished from the other four patients by remarkably higher levels 
of 6MP, thioxanthine, thiounc acid and hypoxanthine MeTIN levels in RBC were 
extremely low in this patient. These observations could not be explained by allopunnol 
overtreatment or enzyme deficiencies of HGPRT or TPMT. Renal failure in this patient 
contributed to the high plasma levels of 6MP, its metabolites and hypoxanthine, but could 
not explain the low MeTIN levels The relatively low activity of the anabolic pathway of 
6MP in the patient with a tumor lysis syndrome was probably caused by competition with 
endogenous levels of hypoxanthine, which were increased due the increased breakdown of 
DNA and RNA during tumor lysis. This observation has consequences for the efficacy of 
6MP therapy in patients with a large tumor burden 
The genetic polymorphism of TPMT and the contribution of TPMT to the cytotoxic 
action or detoxification of 6MP in vivo are reviewed in chapter 5 The results of a pilot 
study on induction of TPMT by high-dose 6MP infusions are presented. This pilot study 
stresses the need for a more sensitive TPMT assay in mononuclear cells. 25% of the assays 
failed, since the necessary amount of cells could not be obtained from the leukopenic 
patients. Therefore, conclusions on TPMT induction by high-dose 6MP infusions could not 
be drawn. However, the increasing levels of MetlMP in mononuclear cells during 
successive courses point to an induction of TPMT, although they may also be explained by 
induction of HGPRT. 
The identification of MeM80HP in plasma of patients treated with 6MP infusions is 
described in chapter 6. MeM80HP is a major metabolite of 6MP in plasma The pathway 
leading to the formation of MeM80HP and its further metabolism are not fully understood 
yet. Given the wide intenndividual variation of TPMT, it is important to know whether this 
enzyme acts to methylate 6MP, which is available for the anabolic pathway leading to 
cytotoxicity, or the catabolite 6-mercapto-8-hydroxypunne, which is a better substrate than 
6MP for TPMT in vitro. 
The pharmacokinetics of 52 patients treated according to the ALL-8 protocol of the 
DCLSG with four courses high-dose MTX followed by high-dose 6MP, are described in 
chapter 7. The mean 6MP steady state levels were 14.1 μΜ (sem 1 0) The main 
metabolites in plasma were thiounc acid (steady state level 4.2 μΜ, sem 0.2) and 
MeM80HP (steady state level 3 2 μΜ, sem 0.2). Thioxanthine, MeMP and MeMPR 
reached levels less than 1 μΜ. The levels of these metabolites were comparable during the 
four courses, but MeMPR levels were significantly higher during the four successive 
courses Thioxanthine was present in plasma of 27% of patients. These patients had 
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significantly lower MeMPR levels when compared to patients who did not have detectable 
amounts of thioxanthine in plasma. These observations might indicate an increased 
catabolism via xanthine oxidase and a decreased anabolism of 6MP in patients who 
demonstrate thioxanthine in plasma. 
6MP was excreted in urine, mainly as 6MP, thiouric acid and thioxanthine (45.5% 
of the administered dose in the first 48 h). The clearance of these compounds was 
correlated with the creatinine clearance. They were excreted by glomerular filtration and 
active secretion. This could be concluded from the higher clearances of these compounds as 
compared to creatinine clearance. MeMPR was found in urine of all patients studied, 
accounting for only 0.3% of the administered dose. Traces of MeM80HP or 6MP-riboside 
were detectable in a few cases. The plasma pharmacokinetics in the oral 6MP group were 
not mentioned in chapter 7. In this group, neither 6MP, nor its metabolites were detectable 
in plasma at the fixed times of blood sampling (i.e. five or nine hours after 6MP intake). 
Peak plasma levels after oral administration are reached within four hours. 
Measurements of (methyl)thiopurine nucleotides were performed in mononuclear 
cells and RBC of patients on the oral or intravenous arm of the randomized DCLSG study. 
The results are described in chapter 8. MetIMP was detectable in mononuclear cells of the 
intravenous 6MP group. TGN were the main metabolites of 6MP in RBC of the oral 
group, whereas MeTIN remained undetectable. TGN levels remained constant during the 
courses. TGTP levels accounted for 60-70% of the total TGN pool. In the intravenous 
group, MeTIN levels were much higher than TGN levels. MetIMP and tGTP accounted for 
60-70% of the total MeTIN and TGN pool, respectively. MeTIN levels increased further 
after termination of the 6MP infusion, whereas those of TGN remained constant. During 
successive courses MeTIN levels increased further in the intravenous group, but those of 
TGN did not. These data suggest that daily oral administration of low-dose 6MP favors the 
formation of TGN, whereas with high-dose 6MP infusions the formation of TGN becomes 
maximized and the formation of MeTIN is enhanced. MeTIN levels in RBC of patients 
treated with high-dose MTX followed by high-dose 6MP, were much higher when 
compared to those of patients treated with a 6MP infusion alone (see chapter 3). Although 
the number of patients treated with high-dose 6MP alone is small, these data support the 
hypothesis that pretreatment with MTX enhances the anabolic pathway of 6MP in vivo. 
In previous chapters it has been described that methylation of 6MP and its 
metabolites occurs to a large extent during high-dose 6MP infusions. S-adenosyl-L-
methionine is the methyldonor for these reactions. Levels of the metabolites of the 
transmethylation pathway were investigated in the oral and intravenous 6MP group. In RBC 
of both groups, S-adenosyl-L-methionine levels were undetectable. S-adenosyl-L-
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homocysteine levels remained constant during the infusions. In both groups plasma 
homocysteine levels increased and methionine levels decreased during the MTX infusion. 
After termination of it, methionine and homocysteine levels recovered immediately in the 
oral group. There was a delay in the recovery of methionine in the intravenous 6MP group, 
which is probably the result of an increased demand on methylgroups during the 6MP 
infusion. 
Toxicity in the oral and intravenous 6MP groups of the DCLSG-ALL-8 study is 
described in chapter 10. Toxicity was higher in the intravenous group. Treatment had to be 
reduced or delayed more often in this group and vomiting, mucositis, diarrhoea, skin 
lesions, thrombocytopenia and elevation of liver transaminases were more severe in the 
intravenous group than in the oral group. Nonetheless, irreversible or intractable toxicity 
was not encountered in the intravenous 6MP group. 
Whether sequential intravenous administration of high-dose MTX and 6MP results 
in improvement of event-free survival, as compared to conventional high-dose MTX 
infusions in combination with daily oral low-dose 6MP, will be investigated in the future 
by the DCLSG. 
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Future directions 
The present study provides insight into the metabolism of 6MP in vivo. Large 
amounts of 6MP and its metabolites are methylated during high-dose 6MP infusions. It is 
of clinical importance to solve the enigma to what extent thiopurine methylation contributes 
to the cytotoxic action of 6MP and to detoxification of the drug. 
Thiopurine methylation and cytotoxic action of 6MP in vivo 
1. The metabolism of 6MP in lymphoblasts in vivo 
To obtain insight into the contribution of the methylation pathway to the cytotoxic 
action of 6MP, its metabolism should be studied in the target cells, the patients' 
lymphoblasts. There is only an opportunity to do this, which is at diagnosis, when 
lymphoblasts are still present in the peripheral blood and bone marrow. Factors which 
might interfere with the thiopurine metabolism in some patients are allopurinol co-
administration and large tumor burden, as described in chapter 3 and 4. It is worthwhile to 
investigate how much MetIMP is produced, whether formation of MetIMP is correlated 
with TPMT activity, how many TGN are incorporated into DNA [49] and whether adenine 
and guanine nucleotide pools change during the 6MP infusion. These might give an 
impression as to what extent the formation of MetIMP contributes to the cytotoxic action of 
6MP. One should be aware that lymphoblasts which die from 6MP treatment, may evade 
observation. 
2. High-dose 6MP infusions 
The Children's Cancer Group performs a randomized trial with oral or intravenous 
administration of 6MP after standard induction {121}. For three months patients receive 
either daily oral 6MP (75 mg/m2) or weekly high-dose 6MP intravenously (1000 mg/m2). 
No other drugs are administered. TPMT, TGN and MeTIN levels in RBC are being 
measured in this study. It will be interesting to investigate correlations between toxicity and 
TGN and MeTIN levels within each treatment group. 
3. Maintenance chemotherapy with oral 6MP 
Data on correlations between event-free survival and MeTIN levels or TPMT 
activity are still lacking. All data on TGN, MeTIN and TPMT levels should be used to 
elucidate whether or not TGN only are responsible for the therapeutic effect of 6MP. As 
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long as it is unproven that the formation of TGN alone results in cell kill, one should not 
consider a change to oral 6-thioguanine for maintenance treatment. An additional cytotoxic 
effect of 6MP, through inhibition of the purine de novo synthesis or disturbance of the 
transmethylation pathway, may be lost. 
Thiopurine methylation and detoxification of 6MP in vivo 
1. Formation of MeM80HP 
As mentioned before it is unknown from which pathway MeM80HP is produced. 
Methylation of 6MP into MeMP, and further oxidation into MeM80HP, results directly in 
a decreased availability of 6MP. Only 6MP is available for the anabolic pathway leading to 
cytotoxicity. On the other hand, methylation of 6-mercapto-8-hydroxypurine into 
MeM80HP does not directly influence the availability of 6MP for the anabolic pathway. 
Enzyme kinetic studies for xanthine oxidase, aldehyde oxidase or other enzymes with 
thiopurine substrates might help to determine which pathway is most important. 
2. Quantitation of the excreted amount of methylated compounds 
During high-dose 6MP infusions methylated metabolites are present in high 
concentrations in plasma, RBC and mononuclear cells. Little of these metabolites is found 
in urine. The relative absence of these metabolites in urine may be the result of a small 
distribution volume of these compounds. It may also be caused by further metabolism. 
Quantitation of methylthiouric acid may help to explain this. In our experience incubation 
of urine with several glucuronidases did not result in the appearance of MeM80HP. Other 
methods might be developed to detect MeM80HP-glucuronides. 
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De raadselachtige stofwisseling van 6-mercaptopurine: 
toediening van 6-mercaptopunne in het infuus aan kinderen 
met bloedkanker of Iymfeklierkanker 
De meest voorkomende vorm van kanker bij kinderen is bloedkanker Bloedkanker 
is een ziekte waarbij bloedcellen ongeremd groeien Bloedcellen worden gemaakt in het 
beenmerg Er zijn drie typen bloedcellen rode bloedcellen die zuurstof van de longen naar 
de lichaamscellen brengen, witte bloedcellen die een belangrijke rol spelen bij het bestrij-
den van infecties en bloedplaatjes die ervoor zorgen dat het bloed kan stollen. Bij bloedkan-
ker op de kinderleeftijd gaat het meestal om kwaadaardige groei van bepaalde witte 
bloedcellen (acute lymfatische leukemie, kortweg ALL) 
ALL is een ernstige ziekte die zonder behandeling vrijwel altijd ongeneeslijk is. Met 
de huidige behandeling is het genezingspercentage ongeveer 70%. Bij veel vormen van 
kanker is operatie (chirurgie) of bestraling (radiotherapie) de eerste keuze voor behande-
ling Bij ALL heeft behandeling met medicijnen (chemotherapie) de eerste voorkeur In de 
jaren vijftig is men begonnen met de ontwikkeling van deze medicijnen, die ook wel 
chemotherapeutica ot cytostatica genoemd worden. Dit zijn medicijnen die kankercellen 
kunnen doden of die kunnen voorkomen dat de kankercel zich kan vermenigvuldigen. 
6-Mercaptopurine (6MP) is zo'n medicijn Het is een stof die heel sterk lijkt op een 
gewone lichaamsbouwstof. De gelijkenis is zo sterk dat 6MP de kankercel voor de gek kan 
houden. 6MP is dus een 'fopbouwstof. Iedere lichaamscel die zich wil delen in twee 
nieuwe cellen heeft daarvoor bouwstoffen nodig. Kankercellen delen heel snel en hebben 
dus veel bouwstoffen nodig Daarom zullen de kankercellen de fopbouwstof 6MP graag 
opnemen Is 6MP éénmaal in de kankercel dan gaat het pas werken en maakt het de 
kankercel kapot Helaas is het niet zo dat alleen de kankercellen 6MP, of andere chemothe-
rapeutica, opnemen. Ook gewone lichaamscellen, vooral de snel delende cellen, doen dat. 
Zo kunnen bijwerkingen ontstaan als kapot mondslijmvlies of haaruitval. 
Hoe werkt 6MP9 Ondanks het feit dat al in 1953 bekend werd dat 6MP werkt tegen 
bloedkanker, is nog steeds niet duidelijk hoe het nu precies werkt. Onderzoek in laboratoria 
met kankercellen die in flesjes gekweekt worden, heeft het volgende aangetoond 6MP 
wordt pas actief tegen de kankercel als het in de cel in werkzame stoffen (anabole 
producten) is omgezet. Eén van die werkzame stoffen (thioguanine nucleotiden, TGN) kan 
ingebouwd worden in het DNA van de cel Het DNA is het erfelijk materiaal waarin alle 
informatie voor celfuncties opgeslagen ligt. Heeft de kankercel eenmaal TGN ingebouwd in 
het DNA, dan kan deze cel niet meer delen. De kankercel is voor de gek gehouden door de 
fopbouwstof 6MP Dat 6MP via deze weg werkt is al lang bekend 
Er is nog een tweede weg waarlangs 6MP kan werken en die route is minder 
bekend Dit is de methyleringsroute, die leidt tot de vorming van MetlMP. MetIMP is net 
als TGN een werkzame stof of anabool product van 6MP. MetIMP werkt op een andere 
manier dan TGN. MetIMP remt de vorming van nieuwe (gewone) bouwstoffen van het 
DNA. Op deze manier remt MetIMP dus de vorming van nieuw DNA en daarmee remt het 
de celdeling 
Hoe 6MP bij de patiënten werkt is eigenlijk niet goed bekend, omdat het heel 
moeilijk is te onderzoeken. Want zodra er begonnen wordt met de behandeling van ALL 
verdwijnen de kankercellen snel uit het bloed. Er blijven dan nog maar een paar kankercel-
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len over die zich ergens in het lichaam verstoppen. En die zijn nauwelijks meer te bereiken 
voor verder onderzoek. 
Een manier om toch te onderzoeken wat er met 6MP gebeurt in het lichaam van 
patiënten is onderzoek te doen in bloedvocht (plasma), rode of witte bloedcellen. Rode en 
witte bloedcellen zijn in staat om van 6MP de anabole stoffen TGN en MetIMP te maken. 
Maar het effect van TGN en MetIMP in deze cellen is anders dan in de kankercellen. Zo 
hebben rode en witte bloedcellen niet de mogelijkheid om uit zichzelf nieuwe bouwstoffen 
voor het DNA te maken. Daardoor werkt MetIMP niet in deze cellen. Bovendien hebben 
rode bloedcellen geen DNA. Dus kunnen TGN niet ingebouwd worden in het DNA, maar 
stapelen ze zich op in de rode bloedcel. In rode en witte bloedcellen kan dus wel bestu-
deerd worden of 6MP omgezet wordt in werkzame stoffen, maar het effect van 6MP op de 
cel is niet meetbaar. 
Er is nog een medicijn dat veel gebruikt wordt bij de behandeling van ALL. Dit is 
methotrexaat (MTX). MTX werkt voor een deel op dezelfde manier als MetIMP: het remt 
de vorming van nieuwe bouwstoffen van het DNA en daardoor remt het de celdeling. 
Onderzoek in het laboratorium heeft aangetoond dat MTX en 6MP eikaars werking 
versterken. Zou normaal het effect van MTX (stel dit is 3) plus 6MP (ook 3) 6 zijn 
(immers 3+3=6), nu is het effect van MTX en 6MP samen 9 of meer. Deze versterkende 
werking wordt synergisme genoemd. Voorbehandeling met MTX versterkt de werking van 
6MP. Hoe komt dit? Door behandeling met MTX komt er een tekort aan nieuwe (gewone) 
bouwstoffen. Als vervolgens de fopbouwstof 6MP gegeven wordt dan wordt 6MP extra 
graag opgenomen in de cel en kan het omgezet worden in werkzame, anabole producten. 
De achtergrond van het onderzoek dat in dit proefschrift beschreven is, is het 
synergisme tussen MTX en 6MP, dat in het laboratorium gevonden werd. Kinderen met 
ALL werden al jaren behandeld met MTX infusen. Ze kregen daarnaast elke dag een 
tabletje 6MP. Op basis van het synergisme tussen MTX en 6MP zou het mogelijk beter zijn 
om 6MP te geven in een infuus, direct aansluitend aan het MTX infuus. Of deze nieuwe 
behandeling ook beter zou zijn voor de patiënt kan niet van te voren gezegd worden. Om 
eerlijk te kunnen vergelijken tussen de bestaande, 'oude' behandeling met dagelijks een 
tabletje 6MP en de nieuwe behandeling met een 6MP infuus, hebben de patiënten geloot 
voor één van beide behandelingen. Deze loting werd uitgevoerd door de Stichting Neder-
landse Werkgroep Leukemie bij Kinderen (SNWLK), een organisatie in Den Haag die alle 
gegevens van kinderen met bloedkanker en lymfeklierkanker in Nederland registreert en die 
behandelingsprotocollen ontwikkelt. 
In hoofdstuk 1 van dit proefschrift wordt een inleiding gegeven over de achtergrond 
van het onderzoek en over de stofwisseling van 6MP. In hoofdstuk 2 worden de methoden 
beschreven die ontwikkeld zijn om de stofwisselingsproducten van 6MP in plasma, urine, 
rode bloedcellen, witte bloedcellen en bloedkankercellen aan te tonen. 
In hoofdstuk 3 worden de resultaten beschreven van de stofwisseling van 6MP bij 
tien patiënten met lymfeklierkanker die alleen een 6MP infuus kregen (dus niet vooraf 
gegaan door een MTX infuus). De helft van de kinderen kreeg tevens allopurinol, een stof 
die de afbraak van 6MP remt. Het bleek inderdaad aantoonbaar in plasma dat de afbraak-
route van 6MP geremd was. Maar tevens bleek dat de anabole route óók geremd was, iets 
wat niet verwacht was. Dit betekent dat 6MP dus beter niet in combinatie gegeven kan 
worden met allopurinol. Dit stukje onderzoek laat bovendien zien dat metingen in het 
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bloedvocht alléén een verkeerd beeld kunnen geven: de kinderen die met allopunnol 
behandeld waren hadden heel veel 6MP in het bloedvocht, maar juist heel weinig van de 
werkzame, anabole stoffen in de cel. 
In hoofdstuk 4 wordt een patient met lymfekl ierkanker beschreven die eveneens 
alleen een 6MP infuus kreeg. Deze patient had een tumor lysis syndroom gehad. Dit houdt 
in dat de lymfeklierkanker zo groot is dat een deel van de kankercellen vanzelf al dood 
gaat. Daardoor kwamen er veel (gewone) bouwstoffen van de dode kankercellen vrij in het 
bloedvocht van deze patient. Deze bouwstoffen leken een competitie te zijn aangegaan met 
de fopbouwstof 6MP. Bij deze patient werden namelijk nauwelijks werkzame, anabole 
producten van 6MP gevonden. 
In hoofdstuk 5 wordt een overzicht gegeven van het enzym TPMT Een enzym is 
een stof die de omzetting van de ene stof in de ander kan versnellen TPMT versnelt de 
reacties van de methylenngsroute en is op meerdere plaatsen betrokken bij de stofwisseling 
van 6MP De methylenngsroute leidt tot de werkzame, anabole stof MetIMP, maar ook tot 
niet werkzame afbraakproducten van 6MP (catabole producten) Welke rol TPMT speelt in 
enerzijds de werking van 6MP en anderzijds de afbraak van 6MP is niet bekend. Het is wel 
belangrijk dit op te helderen, omdat sommige mensen een hele hoge activiteit van dit 
enzym hebben en anderen een extreem lage activiteit 
In hoofdstuk 6 wordt de ontdekking van een nieuw stofwisselingsproduct van 6MP 
beschreven Het betreft MeM80HP. Er worden hoge concentraties van deze stof gevonden 
in het plasma. Het is waarschijnlijk een afbraakproduct van 6MP De route waarlangs deze 
stof gevormd wordt, alsmede de stoffen waarin het weer verder wordt omgezet is nog niet 
bekend. De rol die TPMT speelt in de vorming van deze stof is evenmin bekend In 
hoofdstuk 7 worden alle stofwisselingsprodukten beschreven die in het plasma aantoonbaar 
zijn van patiënten met bloedkanker die geloot hebben voor de behandeling met MTX en 
6MP infusen. 6MP, thiounnezuur en MeM80HP hebben de hoogste concentraties. In 
hoofdstuk 8 worden de stofwissehngsproducten beschreven die gevonden werden in rode en 
witte bloedcellen van kinderen die met een tabletje 6MP of met een 6MP infuus behandeld 
werden Door dagelijks een tabletje 6MP in te nemen worden met name TGN gevormd, 
terwijl met 6MP infusen de vorming van MetIMP sterk gestimuleerd wordt In hoofdstuk 9 
worden de effecten van MTX en 6MP infusen beschreven op normaal voorkomende 
methylenngsstoffen Het MTX infuus beïnvloedt de spiegels van deze stoffen, maar na 
stoppen van het MTX infuus herstelt dit zich weer. Indien echter direct na het MTX infuus 
een 6MP infuus gegeven wordt dan duurt het langer voordat dit herstel optreedt 
Tenslotte worden in hoofdstuk 10 de bijwerkingen beschreven van een behandeling 
met MTX infusen in combinatie met 6MP tabletjes of met 6MP infusen. Het blijkt dat de 
behandeling met 6MP infusen meer bijwerkingen geeft, zoals misselijkheid, braken, kapot 
mondslijmvhes, diarrhée, huidafwijkingen, daling van bloedplaatjes en stijging van 
bepaalde leverenzymen. Er is geen verschil tussen beide groepen in het optreden van 
infecties of het aantal witte bloedcellen Geen van de bijwerkingen was zo ernstig dat ze 
onbehandelbaar of blijvend waren. 
Of de behandeling met 6MP infusen uiteindelijk leidt tot een verbetering van de 
behandeling van kinderen met ALL zal in de toekomst onderzocht worden door de Stichting 
Nederlandse Werkgroep Leukemie bij Kinderen (SNWLK) 
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